var title_f33_44_34496="Jet or pneumatic nebulizers";
var content_f33_44_34496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumatic (jet) nebulizer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 390px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGGAXkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAoorxH43a7qul+K7WHTtTvbSI2SO0cEzICfMkGcDvwPyppXdiox5nY9uor5QHi/xCMk6/qjZ4x9pfj9aWPxb4kKj/ifannrzcv8A41fs2aexfc+rqK+Vv+Eu8QYyNd1M56/6U/H60n/CWeJN7Ea5qe3P/Py3+NHs2HsX3PqqivlT/hLvEWAx17UvcfaG/wAaevizxFjnXdTBAz/x8vj+dHs2HsX3Pqiivlc+LfECgka9qZx3Nw+B+tR/8Jf4jBGNd1M+v+kt3/GlyMPYvufVlFfLCeLfEG0f8T3Uyen/AB8v1/OkHi3xEOuu6nnpzcP/AI0cgexfc+qKK+Wh4r8RAYOuajuJ4zcv/jTG8WeIQBjXdTwOv+kt/jRyB7F9z6oor5XHi3xFznXNSx/18v8ApzTf+Et8QgZXXtUOen+kP/jRyMPYvufVVFfLA8WeISRnXtT+n2hv8aavi3xEW513U+uMfaX/AMaOQPYvufVNFfKp8XeI1YBtc1Lnj/j5f/GlHi3xEM513UyOn/Hy3+NHIw9i+59U0V8qDxb4jIUf29qeT/08v/jTm8WeIlP/ACHdT6c5uW/xo5GHsX3PqmivlUeLfEfX+3dSIIz/AMfLf40weLfEeSDr2qY9rl8n9aOQPYvufVtFfKn/AAlviMBf+J5qf1+0v/jTf+Eu8R5ONc1T/wACX/xp+zYexfc+raK+VP8AhLPEhIP9u6oP+3l/8aT/AIS7xHzjXdT4z1uWo9mw9i+59WUV8oHxd4j2L/xPtU3d/wDSG4/WhfFviVQoOvamSe5uW/xpcgexfc+r6K+T38W+Jd3y6/qWQen2l+f1pB4t8TLwdf1Mkf8ATywH86ORh7F9z6xor5Jbxh4lCf8AIf1T2Jun/wAaVPGHiU9fEGp8H/n5fn9aOQXsmfWtFY3gqeW58HaHPcSPLPLYwPJI5yzMUBJJ7k1s1BkwooooAKKKKACiiigAooooAKKKKACiiigArwH4/gnxjZ/Ln/QE/wDRkle/V4B+0A5XxlZ84H2BOnX/AFklXDc0pfEeZBRuXdknNWFVVwy4yffpUZI25zk55AHWhSF4UY64rY6gYt1YHrjmpGkJ2jt/Oo9xYjI755PJokK7SS3OMFQaQDmbPQcdyO1NJIX5c4+tGSM4Ixj8zSYY9Bn15oAXeQDjg9c+tKqnqD83U4NIqlgCD06+lKAMNtJ4oAcMhQD9098UoGN2e1KjABe4I60j7snHX1oAFI2k5JPY0HHf0zg9KTpjIIHGOMfWn8ZFAAVyfkKg9aTDDOMnHt0pzOpXA6DqcUwy5J57/nQBKD046dOKibJ2k59SaBIS3O8DqO1L2UhQc+9ACEfMM4b1z60jqCAeTxnFOIO4byPlHrTVJxy3XOaAFUDeAOnt2pwwxB7ngimMFXoRjnoabglucjAzxQA/HOSMZ7e1BTPDHJ7HvTY2IGT0PBJpFkwV4ySevt2NAC7cE5+7jH40i7gDtPJGD3oDbsA8AHLc03BY8cZ4yaAHbsZyQeRikJVxnGO+001k3YII3Drx/n1pTuUsGKn6elAglc7WKj2GeajDk4HcVISGUlT0HpjjFRuFz0wSfXvQMccuzFT36UjAYIU54wSe3vQNwJPQE856/WnuuCGyeDzg9aBEGASg4wPT1pg54Cg57GpCpOeAB6CkctkZBwOevSgR9Z+Av+RH8Pf9g+3/APRa1u1heAhjwP4eH/UPt/8A0Wtbtc7OR7hRRRQIKKKKACiiigAooooAKKKKACiiigAr59/aCJ/4TSzCgZ/s9Dz6eZJX0FXz1+0MM+NLLDYJ09P/AEZJVw3NKXxHmyHcwBGcDOM96AoLKAQSexppOBx24JzyafEuXOTjvjFanSPzjG7BHNOYjHGSD1I71G4KkhiF9DjNC/exkAjmgZKYwcBMHPQegpJGw5BABIpseVIye2RzUshG3PUD+KgAQhiRjjHNGMnPJB96Y3GcdMZwDSnIxgnrQBKmN+RkAdAabkEZBBx+majVslskj1FCHJIA2kcUAPjO/IIOOn4+lIAMsWOc9hzQoAz6Uq7dq7RgAc/40AIuBHnjjsaRupYcE9fUCnAIG+TBB45o3IMjA5JoAbu8ojAIA709dvPYY70pG7hsFSfypDk8kAn6c4oAYTgDv+n509G4yoAIPB7VGwKuoPI7n1prM6sccimBYDgMxIx3P1oKrtUkHbjGfeoi2eiexyacFbb+84G7IoAYyueYznPXPUf40wPgtxz0NTlMg7Rtx39aYcgfMud3GRQA4OHbaBjA44qN3GQR3yASOKHQ9FVsDnPcUow+FzxnvSAZyEIJIb07U7cOEIIA7+9Ky4T75yex71d0rSL3U5ALKItH0aVuFH4/4UAUdvJIIweAenHvWpbaDez6TLfxhTGmW2HIYqOrCuy0nwtY6SvnahILm4xkbl4H0H+NXLnUfMmiiVQkOcEeueKaVyObXQ8pwd/UMQO/Sh+cHPTjHapHiEUkkTZOHZc9gAaYseVygxjjnvQURsJFZj0yPwprHCrhcjrVjyhnJY4+vemSbUJ2tz1waQj6v8Af8iL4d/7B1v8A+i1rerC8BDHgfw8B20+3/wDRa1u1gzke4UUUUhBRRRQAUUUUAFFFFABRRRQAUUUUAFfPv7QSl/GtioxxYIcH/rpJX0FXz7+0IQPGViScf6Cn/oySqhuaUviPMlwGYEYB7mpM5/iHJqDc3QAcHIzzTg7IB3x1+tbHSOO4t98/jzij94MFvXrS7fT6fWkLEOAWH4UBcdGGyu87vX0FP4zyc4wCTTQwY5X7p/WlIHIIJH60AO2ZLKGPSnhVAXPzEjr+NRNx0544NO3sAADx3x1oC4MAWG0heOh708KPLIPGRx7Uz5Swc84PYfzoaTkccnoaAHK+U2kfUn0pxKhc9xxTPvIM/iKGO4kKSTnOPegADA5C4HOaR2DAkc5HXtSAMWw3PtTSjc4Kkg8AdKAAklWxyB6jGaUPhuQAvTINDjjgHrzigRnkEhR/P0/lQA9H+ZVwDkcn2p2/g5BA/LNV0J3gZwOlSYUuAS3XqaYEquu3KgElfzqJjuIOc54AzTShK7UOOSBxRtIO7P4gd/YUBcm3bcDO72pqSHcQ2AgP5GpLKyubo4ijZsng46V1+i+GIVZJLnDtwxTGRketVyu1yXNI5qw029vnK2du8iE5JI+X86tv4c1Zbswi0Lt08xfuEeufSvWLdEjiQfKq7RgDsKZPOsSs23sT/iKi4uc5DSvBkMGJdXkWdu0Y4QfX1rakvobaIQ2SKijgEDAH0FZ2o3zvKys2cHgDpWTc3iQoZLmRY0HdmwKpJLcW5oXN2XZmdyxPcms2W4/eKc9xzXL6p4102DcIHa5ft5S8fnXJXXivVrq6R7aOOOEc+Wwzn6mk5oC5d66r6ncIVIAlYcd+TV2KdZY9wY8jnFclZ6deTzNM65ySWI6ZPNdNp1pJDkyHgDOKiLZabLwV8fMRzgkmkfywR3PfNMBxuBYkD2pqEltwcAdV9qoZ9beBSD4J0Ar0+wQY/wC/a1uVheAsf8IN4e29P7Pt8f8Afta3awe5xvcKKKKQgooooAKKKKACiiigAooooAKKKKACvnv9oY/8VjZgnA+wJ/6Mkr6Er56/aF/5HWyHGP7OQ8/9dJKqG5pT+I8zDENnG4AY4FPHQ5YdOmOtQsGAOcEnoBT4xu+90zgcZxWx0j1ZfLIPByRkCiRl2hcAZAxjtTDuDYHIFNl3HJyWKDPA60APhZi2AcEcfSnByyqCwI6HHemoC56g8Zyads3L1H4etAhwbhiDlR29KapG/wBPcUmxSM857j0p6gFmIYccUAIzl2wu49uPWnFCUJ64/DinooD/ACgc8UrAKoVevpnpzQOxEFbPTgjAJqwFJx8wGOP8BUMROSRxjOPekeQqMP0BwaAJSVyNpHHOKcpBHPcYye3tVZpUVMhQSTgetSQNnjq3Yf0oAlyPL9CAOKTOPvHJGCOOKkW2uZkZ4YGYIdu0dc1dj03YqNctvlP/ACyHI9smnGLewm0igImlkREQu3+yKjuFMDOsoKuOzdq6uHT7pWCCEwcZ27ccU7WvCM95BbPp3mXF0x2tGExgH39qtwUd2Rzt7HEtcf3fm9zTxHJKq4LEtyAo7V1g8J6VpIU+Jtdtre4P/LnAQ8p9j6flVC58RWOkqz6Rpkjtg+VPJKQE91x1Iq4e9pFESkludJ4N0PUjaqbiL7Nbf35jt+hArqwdJsBjzpLqb0T5VzXk+neKrvVLt7i+vZpccTJIchB2df61b1Lxjp9jxExuG/2eB+dE4SWkyE1LY9JfVlu5AEhjhRRgKnpVS6u0VcyNgdz6djXjN/8AEPUDM5sLeONcEBpOce+K5LUda1XVZCby8uJc/wAOcL+Q+tc7aWiNEjf1Pxzq1zPMln5NvGWIUhdz4z1yaxTDeX777qaa4duu4lqi02zleQFkOD0GK7Kxh8mFQAM98ips3uXFGNaeHyVDNhQRg89K2ItNt4UDKmWBzn1q3jggc57UqDKZbhc9KpKxdhiqMFUXHpzTcMWO0Agfez1pzn5iGxzxTcYbdjJPGO9MYzyvvEE5Pb0phTBy4wQOakYlQecEe/8AnNN3gowPXue5oJPrHwDz4G8PdP8AkH2/T/rmtb1YXgIY8D+Hh6afb/8Aota3a52cj3CiiigQUUUUAFFFFABRRRQAUUUUAFFFFABXzz+0OpbxpZ4/6Byfj+8kr6Gr57/aGUHxlZZ4/wCJen/oySqhuaUviPMDgr8/TrU6KANvbg5Heq4jJIBIJJ9egoXPG35c+h/StjoLDY3E7fmPQ05VYjLDA9hUYkk2bxtznAp3mE5LHaOlBQ/CkgKoX096VzsCjIIA5HvUOzkHcMAU4rg5PDHBwP50CHBAV47+h/nTFBBOAMk9enFK64G5ODjv3pI8rlX+h9jmgRIgKsQevf2pzAEg8cdeKT935Z25PPU96nh0+e4MmyMh0UNhuMg9MUBexXDrgkZOOufXFMjjNxL5caM7uPlz0OOtb9noSJKhncFTHlkPZjx+QPFblhpRSNEtoPmtlJBk7ZPr9ePxp27ibOWtNGluTbyS/LAzHercFQO9bOn6RHGsabDNMjl+mD1wM+uD1+tdEthBGxWZ2lJQbEHTcR0z9Mj8Kkluo7dBt2pHt8vC8lhjJOfdTn/gNF0tiWypa6Uw2GZkghkBfB4YHt+vFQxW8NvZyyNEGcHBLHkfT3HBH0pbm83eYFBDL0Zjn/PY1m3Vw80odckt1/z9apNt2Yjo5/FFrFMzXkRu59oCseBkdeK57XPFd7eo8SSG3t2Gxkh+X5T7jnIrD1WWOIiS7nRSeBk5Jx6CuevfEEKKRaQlyP4pOAfwq7U46shpvYy7BfL1OWKVv3o3KS5yW7Hn3FbdrH9qSS1JUEZaMscBa4a5v55NSa4ckzM24FRjn6fSuhsb03IlXaOcCQ45PsPSuzB1OZNJHNWVtWMCi1vQwlQqwIOG4+hNUnTzPmjHJ4JzmtfVHtpGzbKwXbyCMYPfFZSwypPviw8Z+Zl6E+4rTF0XOHMldk0KnLK3QZBpctw2Sp5PUVt2uiRwAbzzjP1q7ptyjpxgAnjjkGranJDEjHI6V5Nj0kkRRKsKhY0GSOoFS7wx5VDng1GMBicg5PQHoKGaMxqCSDnA4oGKGDY6j0IPSl37gVAAA5yKhIyCASAM8jrQD5ajpxwMUATsTkEgf1NRSM4QgEEkf1pWORgdyPwpqsSM4G0nJ/CgYzDMxy2TnIJprE5JOCe/vUpKAlVPNNKjJ3Z9eBQSfWXgE58DeHic5On2/X/rmtb1YXgP/kSPD+P+gfb/APota3a52cj3CiiigQUUUUAFFFFABRRRQAUUUUAFFFFABXz1+0Mf+K0slPQ6enI/66SV9C189ftDg/8ACZWRGAPsCZP/AG0lqobmlL4jy1XwVCqQSSAe1ODZdSRjjqccmkRffOBwB1qUR5GSMk9BWp0CgrtDMCB3NPSRXj+QHGaRVU/KeQB2p8EedwAZmGcKBnNMYw5z8vOD35qZT0DL83b2FWLOxkuWiKr+7mYjevbHf9K07LRlQJJMxBDkleoZeo/rTSbFcw2id2QjcC7BVz0zV+HSLqVHP3XRwu09x656V09ppmxWjjiwpJlDNyPqM9OxFaMVpEpja4YnIO9F6Ak+vs2D+NFktyXLsYVro1uGeIBpRLjYCOfXg+/9K247EiJXuHEMW7awOSSvQkfoasrMLaNVASJ06D73JP8AQgiqb3Q3fuwduPl3nPv+vIp37CH+XbxRsDGWyzEu/Tb/ABAY9Rz+NPlvycCQlsfKQv3RjA/wP4VnSXBLA53/AMuB/VT+lVZriNW8mSVVfBIXOCQO/wCRot3AvTXcu0rvEZVsgJ6k/wCI/Wqby53bBgMMjP5gfzFYN34htoxG0Q3hwfMVuGX3/MZrnb/XZp0XMhIRy47EdcDI+tLmS2HY6q81e2hUvv8ANZG8p1BwR+B9q5zWNfkkhnhhxsLDYwyrbe/1zWETJPuZiWY5O7vmrMWlzykHbtJGfmPXipbbGkV5H84boVK/U1EtjLJ/CfTAretNOjtxuYliO1TSyImdgyOmM0rDtcwf7IjtyHnILdlU1atR+5KxoqKCGVgP85ouj5k6ncegI/z+NaGiW4ub+G34Hm/cH972/pXtYSlGnT5urPNrycp2M+eEAlxz3PYflVKVXDhYzgtymPX0r0nxZ4dg02yjvTIq2GEWS4IPlqzcbc9SehrybxDrMNhcLBZp9qQYcSE7eeh/lVPF0kr3I9lJMvaZdlbpQ+cPwM9Qa6pHDDJYEY+tcPos41m7eOaJLaZz5gKsT839K3Y7qSGfyJR+8QgEevvXl15RlLmid9BtRszZGQvP880xnxlcDJGcCooJt+Wzhh1FO6gneQ3oKxNxXUYBJwAf60xmk5ByBnjHU89KVskr6+ue9IG77fu9zQAscpXO5eDyec4NPWRW2bc59c5qEkhVCg5zkD1pqE7uCCo9B6ikBOrBGAGRztoMqB2BOcjn0pm8cbc8jjt+NBUPnaP9qgR9b+BP+RI8P4/6B8H/AKLWtysLwFk+B/DxIwf7Pt+PT92tbtYM5HuFFFFAgooooAKKKKACiiigAooooAKKKKACvnr9oVAfG1mWOB/Zye3/AC1kr6Fr57/aFDN4yswOn9nJ+fmS1UNzSl8R5esaqAQWyRzzViK2uJDmKKQnsSMD8+lUj5hyMdBgZrs9DtJNQ02C6knVR5nkyAnlSO/0/wAa2STOhuxlWukt8huJUXHVU5P59K1dL0+GK73QxSySnI5P3Qfat+GxtICCFMrDu3Apk94yak0kY2fuxGwiHUDof6Vdl0JuxY9PCq6GVIyuAojGep9PYirSJDES0cahXUAM5yPrj6hh+NUWnIUHIVW5Pc88H+YNVZZ2bO4lmznn1J5/UUndiNOW8QKuN0gXgqDhSo7fiDj8Kqy3j4cFgo6nZ/Fxgn8Rg/hWZNdRpIoeRE8w4QE9T1/lkViXfiOCFP3QzKkmwo/dRkEj6jijRAdI83OSQM5DMx79D+uDVC81WC2EvmOvnRDd5ZO0nuMH8/zri9Q16a6W4jVi0LkERuMlQPSs5pLm8k3vllI5J5IqXPsOx02oeJc7haqBE0eMMOVb6+2cVz897cXAR2kZgg2qWOdoqW10xsI0rcDpjrz61pR2drGB8gaQfxZ61Or3KSMeGznmQ5Jx1ye1Wo9JVf8AWNyeoXvWoNqKQBgexpgclgW3cc57D3ppBYZDbw25/doB2Az2qzJIF+bjGc+x9qiYjBCnJJqIqRhQykd6YyWSRX7AnsO4FU7pgPTn04FTnKE5BC+vWopwQOVzxmgRk3bFZ1cZx2z/ACq5ZzM90llBsM6HzFlYcRg44x/E3fHaq88YbYQOFIPsK2LBLXSLo6m9k12yJmMoRmNj958Hqf5V1LEP2agjmlRTlzHqfw7hsJ9P1bT9fZ54pEDlp2JUL0yAeMgmvCPiX4ZutJ1CWF4j+4bch9YyeD9K9u03VI2hhubdgY3i2ME53I3UVpeNNC07WdKiunkE0sUCQKXA3FD90ZHUjvXLez16lONz5m8O4TWIpS20F+p+ldF4jBDR38XGCEceoPT9f51zviDSb3RtZlsbxSjpyD2dexHtxXQac5vfDt1DP95UOCfbkH9KJBC60JrG4MiZ4KnA/CtbsqjABHSsHQyGiYMCcjjit1GzEuQQ3TpzSRuhRtCb8ZI5GewNBTLBgoz1I9aHLRqfl69qaFIK9MZyMUFAVYrjOCRTGH7vABHbPvT2DBSRjPTNN8wndleOhHqc0WAZtJfgnAHQDrT145xz0HqaeQNrP1x1z1qF84zjBA5A96BH114D/wCRH8Pf9g+3/wDRa1u1g+Af+RG8O/8AYPt//Ra1vVgzje4UUUUCCiiigAooooAKKKKACiiigAooooAK+ev2ht58a2QTB/4l8Zwf+uktfQtfPP7Q3/I62QyP+QfHx6/vJaqG5pS+I8w5GBuBYZP0rovCd2kctxau+EfEnI7jAP8ASucjYBSrD5V9ams5mguo5ByAckZ6jv8ApWy0Og7i41DIIjG73qo00jKTK4jT3OBXLan4ilRmS2jESkYDMMtn+Vc61xcXchMkjszZJLMTTdRLYmx27eIrCK3mCO7FQWVmU7ScYx/KsW88USu0Ri+XKESKRlWY+lZdlp7ysS7ALjnParSaVGqDk8Hv1qLtlWMl7ieWOKIl2RCxVOvXrUsOmzSKevlnnJ7VtRwxW+FjAyMDJH9andwOADnjJz0osFihbaZEF+c5PGO1Xo0VQRjjGAB1NCsDtPO7GBTfmVnIQbc4Ge3vTGPd8NhRzkZ45pWYMfw9OhpgZQzFcmgg88ZPoaYXF/hORhhzjFG4DAQEAc9OtMOSpxyT19e9NYkgE8D09qAuPiwdwcAY7Zp7SLxwMAVEOmcYHr/SpGDBk24APX8PWgAVmVSAR0pApwwO47h0J6Uc5z+Q60EMOSwBJxz0oGVZ7QvjJGAOW6UyATGIRKxAzgfStOOLO0t8wPPWh44wm5WwV6A0J2ZLjcf4Mu0sZ5ILlWP2k7cBvuOPbvkf412c63Nhc23nyMtpOqqfmyFBP7uT254P4elefpcRtcBl2rcJyQeoI6H+n416NChuNFdmjdLy0Tc4bGPKOOCOpwT+VO5m1Y5D452cM0uj6miBJXjaCf13g9T+tcXpTbbSbZyGQqK7/wAXRPqugSRTyK3lqZVc9Ayj/IrzpJGi06LGA8hBA9vWlayFbUdalraTaxwRxitmO5yyFcMemPSuZiUtMHdyTW9ZRMdu0YXHP+FSnc0RolmONw4Pr2phJJAzSCNgDznnPJ9qTG4LzyBVFE5bC4brjApjHABPC/pn1qFWZdoIAznIBpAGDFiVIwBgf1oAkJLHgEjuQKQqq9EABH8XrSM5jX5Rn6DmmF+5U57AigD688Bf8iN4e/7B9v8A+i1rdrB8And4F8PE99Otz/5DWt6udnG9wooooEFFFFABRRRQAUUUUAFFFFABRRRQAV88/tDrnxtYkHB/s9B/5Elr6Gr52/aJbb43s8/9A5Me372SqhuaU/iPNggDIBgrjknmoVIAPQ4PUigscH5fxFIzZk+7kehFbHQLcwpMMtkt1z606GJIc7EGBwSOtMx8o2jjOQO9Ly3AAwfXvSsMtF+GGcZ696YHJCjqBzyc4qvEcBzjlRwCeOtOVjvABwM9xQBMS24/MWz6dqachgeST1pC2PlUHg96UjecMwU5OcmgB2RjjGDgYxTi4CrgMO3PfFMw2AvQdOlKcqmSwI6c0AIuVUljySAccUrHCFRxu6HHSmBgVIPTrinL8rBQC27nBNMQrZUNh+cZGB1oDEsAQGIHJP8AFSFSu3cSR047Uuzcx25A/wA8UAPDE5GOnPWgMA4yoAxnJNRhNoYHg9aGTYCAcseMk0DJguRwcAc0saqoKuwZhzk1Gc5BQn1OP8aQyZb2PBJoAso2BtDfNgEZPWjYzA7uvQ9qiZQfmxyDUuMKPmIJ/WgZmX9l5qkoSsi/dccGuo8E+IJkEhvpRLexbonSXgzxEY6d/T8jWQF5JGTx2NVL23WZQRhZUO5W7j3pbENXOu1XyrZjGyLNbZwfKbAIdcj3OPT61yfiTRpIbOd3RVmt4VmHlpiNV4ymexwQ34GtC6thq2hHBbzYxsk8s9VPRuP7rc/RjXm199vgMtpc3FwdrYZGcnJHqDRKXQi1i/pxGzLAk5rprBSU5JAHbp161zugZkUM/BXgA966oYWJAv3SO/ekkWhcLuLYyPX8aRnBO3aAT1xTY5MABVAA6/T2oLBcgA/NyKooIyCMsuT3ApSy5Hy4PUZ7U3duGMgknHFOmkXaHfdu9x1oARvKLAMBgHAB9ajKp52SBkH5c5pGjGCzfXA9aVW2kMOeeB/WgD628A/8iN4e4x/xL7fj/tmtb1YXgL/kRvD2ev8AZ9v/AOi1rdrnZxvcKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFfOn7Rpx42sOf+Yen/o2SvouvnL9o0sPG9mBnB06Pn/trLVw3NKfxHmBYjjd8o6c4xT1cAkMc/SoHOFXoTjp/jTtocHnI4yRx+VanQO39BHjv0NP3gN1zjjrxTRECoxyOq9s0HHBHQDAwKAFEhCkMctjnFPkbcwO4sp78VGApY57YOO9DYGOAAD3HNAx6ht5LDA79yfenEgMDtypPpyT/k0zaCzNt5HXrjilPC5Y4+g6UhCo/CBxhieOaUli2Nwz6+lM3ZbKjax44pcY4I4A596ABXJBBILYJH0zTyMbdpwfc80zkj5Qd2M8mlUKxfLflTAXbhwd3B7g0+Pf5e4DnsTTBIu8A8dPpUhI2YRhxxn3oGMVgx5JyPanIVAy4wFGfemlfmJxgD8qRs7W3ZII4FAiTcNqsWwBzxTH6qQME5HHTNKMEYY7QBxinBWII9enPFABG5HTrnb1qUykcEFlHT/GoArbn+UfhTVYoAE5z60DLTNlMZOOoxTWOT8o4zVcsxIJ3ZzwcU9WIY7woz2HagCwLie1ikFrt3OOdwzzXLXKNdXMkk5zOx3MzDkmuj8xtxU4GR39Kzb6EmXchBxSaJaK+mW4RxyCueOf0rZyVyygbSPrisuFCWC7RwOK0AHCn5RnoDTGhy5XIHKk/ShtqlsZznqDSZY8ccnuf88UhBwQAAzdW9KABThMKOvekO4ZJIP+0elSAlm3H6D2phyXJbaMdKAAAbQUPOPXp601SNmFz61ITsJbOEz1x2pOWUdefTqfagD638Af8iL4d7/8S63/APRa1vVg+ADnwL4dP/UOt/8A0Wtb1c7OR7hRRRQIKKKKACiiigAooooAKKKKACiiigArgfH/AMNbTxlq8OoXOo3Vq8UAgCxKpBAZmzz/AL36V31FNOw02tjxwfAjTAc/23f9MfcT/Ckj+BGmpnGt35yc/wCrT/CvZKKfMyvaS7njo+BWmgg/23fnHbYmP5UH4E6acH+2r/I/6Zp/hXsVFHMw9pLueOj4E6ZuY/21fZP/AEzTj9KU/AvTi2W1u/Pt5af4V7DRRzMPaS7nj3/Ci9OwR/bd/g9cIn+FL/wozTsYGtX+MY+4n+FewUUczD2ku54+3wL0xsZ1m+46HYn+FA+BmmjdnWr4luvyJ/hXsFFHMw9pLuePL8C9NH/Mavz/AMAT/Cg/AvTScjWr4fSNP8K9hoo5mHPLuePH4FaaSCdavz3/ANWn+FA+BenYIOt3x5z/AKtOP0r2GijmYc8u55D/AMKP0453azfN9Y0/wo/4UbpucjWb7Pb5E4/SvXqKOZh7SXc8gb4G6aems3w/7Zp/hTv+FIaf/wBBq+4GP9Wn+Feu0UczD2ku55D/AMKO03Of7Zvh9EQf0oPwN0ztrF8PT5E4/SvXqKOdh7SXc8hHwP07Of7avumPuJ/hQfgdpxGP7bv/APvhP8K9eoo5mHtJdzyA/AzTSwb+2r/I/wBhP8KVvgbpRzjVr0Z/2E/wr16ijmYc8u546nwJ0xCSNav/APvhP8KePgbpoOf7avz/AMAT/CvX6KOZhzy7nkH/AAo3TeT/AGzfbumfLT/Ck/4UXpm3A1m+B/3E/wAK9goo5mHPLueQD4G6aowus3wHtGn+FH/CjdN3ZGtX2PTy0/wr1+ijmYc8u55B/wAKN07POtXx5zjy0/wpf+FHaduJGs3w9MRp/hXr1FHMw55dyloenrpOjWGnRyNKlpAkAdhgsFULk4+lXaKKkgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACml1DqpYBmzgE8mnV5b4xs9duvHA1+y0xprXw9JBHAS8iyur83ZijCHzQ0UiKMMPmiI5IwAD1Ko1nia4eBZUM6KrvGGG5VYkKSOoBKtg99p9K84gsNavNZtWu7nXUgutWv7e5VJZI0W0XzGhxjGwEomHGCQ2NxBxXOQr4gaZbuaLX08QzaDpcdtKlvMsb3ST3RcTkLswA6lhJgYckDOKAPbVZWB2sCAcHB70teOaovicXEsQfUdP09rrUWjmtrO4kYS/aD5TMkA3MuzldwKNzuydtbFhH4hbW7e8uZtWYnWRbOu10h+yGyyW8voB5v8RyQ3GeooA9LpGZVALMBk4GT3rhfhtb3OkfDKK3W11OTUbOBke1ut8bmZU+5GzjG0kDDLlck4PWuW0V/EM1xJG8eqTWP2nR7hFubO6/dM1xILgBrjLttVIySNqjIIC5yQD2SkRldQyMGU8gg5BrmPh3baimgLda1dajNf3LM0kd5geUA7BQq7RgYx15PHNcHYQeJxoiSbdZt57HR9Mlt7eKN4kNybicTAoAAx2LGGQggAgkdDQB7JVXUZbuK3DWFtHczbgNjy+WMeucGrVcjf6v4utHYnQ/DnlFiI2fXJwzDt8oszg47ZP1oA0vt2v/APQFtP8AwP8A/sKrWWuapfed9isNNuPJkaGXydTD+XIpwyNhOGB4IPIqvFqXjWaNZItA8NMjDII16fn/AMk6+OP7D+I998W/FF94LsNTt786xdebNYSsLdX858qZmCKy5z94DI7DpQB9mTaZe65qts+t2MUFjbwyjy47xm3yMUwcAL0Ct+dW/wDhEtF/582/7/yf/FVhfCyL4gQ6Xt+Itxo8820eW1mpE2f+mhACf98iu6oA5DV/DWlQ3OmrFbOqyTlXAnk+YbGOD83qBU//AAjOj/8APo3/AH/l/wDiq0dd/wCPzSf+vk/+i3qespt3NIrQx/8AhGdH/wCfRv8Av/L/APFUf8Ixo/8Az6N/3/l/+KrYoqLsqyMCy8NaVJrF5E1s5jSCFlXz5MAkyZP3vYflWl/wiWi/8+bf9/5P/iqm03/kPX//AF7wf+hS1r1tHYylucjrGiWuky6bfaXZXReG7UyiB5JG8sqwPy5ORkitE+I0wcabq+e2bGT/AArdoqhHFHXddyf3P/lIuP8A4uj+3dd/54/+Ui4/+LrtaKAOZ0668Q38buj2UO04xcWE0ZP0Bfmrfl+JP+frSP8AwGk/+OVt0UAYnl+JP+frSP8AwGk/+OU1p/ENoQ81tY6hF/ElqTDIPoHJVvxZatPqgW6KCImFZBEXzzuJA6emTWnQBladr9hfTfZxI1veAZa2uFMUo/4Ceo9xkVq1V1HTrPUofKv7aKdByA65Kn1B6g+4rJOk6lp3Oi6gZIR/y63xMi/RZPvD8c0AdBRWAniMWzCPW7K40+Ts5UyxN9HXP6gVJ/wlWjf8/o/79v8A4UAbdFYn/CVaN/z+j/v2/wDhR/wlWjf8/o/79v8A4UAbdFZdlr+mXtylva3PmTPnauxhnAyeo9BWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9QszdGN45PLkjzgkZBB6gj8BVyormdLaB5ZSdijJwMk0ANsrcWtskSsWxklj3JOSfzNT1Vsr1LsuoR43TGVcc4PQ8fQ1aoAydYNwJ49hnEG08wgk7s98fp2rRtDKbWE3AAm2Dfj1xzVS/1E205jSEyFUDv8wGAc9PU8Gr0TrLEkicqwDD6GgDK13/j80n/AK+T/wCi3qeoNd/4/NJ/6+T/AOi3qesp7mkNgoooqCyDTf8AkPX/AP17wf8AoUta9ZGm/wDIev8A/r3g/wDQpa162jsYy3CisPzrz+1Nu6bPm42bfk8vPXp6d89eK3KoQVj6zaXE9wGjiMybNqgPt2Nk8/y59q2KoaneyW0kUUKpvcM2XPAAxx9eaGBcgV0gjWVt0gUBm9Tjk0+oLG4+1Wkc23bvGcdcVPQBWaxtmuRcGJTLnO739frVmiqxvrZbn7OZlEucbff0+tAFmiiuY8f/APCXf2M3/CCf2R/aPOf7R34x/s7eM9evFAGtqGpi0lZPK3rGu+RiwXA9vU8H0q+hV0V1HDDI4r4B+K0XxWOrK/jtNX3GQLEygfZi2RtC+X+7znHvX2qt744CgHw94ayB212cD/0joA6vA9BTTtDAHbk9B61y/wBu8cf9C94b/wDB9P8A/IdfPX7WM/jKa48Hebp8NlMJLn7P/Y9/NdO0mIuv7mMqQM4xnOW6Y5APq/A9BRXzp8Fv+F5Zg/t77L/Y/f8At3P2jb/s7P3mf+ulfRYzjnrQBHHPDK7pFLG7ocMqsCV+vpUleP2PhvVLLT9V15LILdWt5rLwW1tA8N5dCa6m2l5RyU2kOoVSThCOgzWt7XVri702TUW12bTNP8QCWKaO1u0lSB9PlQkLIWmZRM4Usc/ebovAAPaFZXGVYMMkZBzyDg0teL3y+KVDxeZqOm2Zn1N7ea3sbiUrMb+cxu0cAyw8oxsu8FHBJOSRXQRRa9J4gW6ll1fY2t/ZSg3rCLM2eSwToB5vR+oYYB6ggHpFFcd8IbR7D4c6DZXEd/FdWtnDBcRXiOrRypEquq7wMoCCAVyvoTXY0AFFFFABXN/EO7urLwrNLY3EltO1xaxCWPG5Ve4jRsZBGdrEdK6Sq+oWNpqVnJaajawXdrJjfDPGJEbByMqeDyAfwoA4HVvEGq+GdSv7C0uBrQX+zxEb11RoJLm7W32O8a/dIbeMqWG1uoIAvw+Lb+K5mtL62tPtMGtW+ksYmbawktYZmdc88GRgB6LXTWuhaTZ2f2S00uwgtPNWfyYrdFTzFYMr7QMbgyqQeoKg9qJtC0mfVF1KbS7CTUV27bp7dDKMdMPjPHbmgDmPCvizUNX1rSo7iOzWx1Wwur+BI1YSwCGWBArksQxImycBcFcc9arXmv6nb+OL/SrKWLfd3VvbW73QZ4rf/RZZmIUEFifLxjI6k54wdzRPB2naT4hudajd5b6ZZE3NDDGEWR1dx+7jUsSUTlyx+Xryc3tdstB+xXc2vW2l/Y5CjXEl7HH5bFeELluDjOBnpQByFn451Oe80mS6tILLS7l47d7jypJ0lnaZ4SgdSPKBIQozqQ/mAZFa3gTxJqGsz3drrcMVnqMUMVwbNYHUxK5cf6wsUmXKEB0IBwcgcVqDT/DRng1AWmjmazhQxXPlRboIsHZtbHyrgnGMDriqfhC88LD7dH4eg03T5lmnS5t4Y4oZD5Ezws7KvO3cjYY9j70AcX4h8baxbY12E24sLaHWGjsFDBpGtFcDzW3YOWjJwFG3OMmul17xfe2d7qdpp9paTT295Y2kXnSsqsbggEsQCRjOeAattceEPPi1O0ttJvZr+6Fk13aRRSs0jjBDuPbg5PSmRXPgbSNKuJ7T+wILC2uIVm+yRxFYpt4WLcEHDBiME9OvGKAMuLxLrf8AbtxpEf2MX0mrCxMsoZ4YcabDcMUUbWI3MwALZ5zntVK1+IWp32lQ6jb21jDFDDpz3UMgZmka6kCHyyCNqrnIJDbjkcYzXZfbvDsb3OozNp1v5N0pa8mCRhpngQB1kP3iYmRdwPIG3tisbX/DPhe61jSTf3dnaeR5CWliq20YYrIXjCEp5oBZfuo4B2Yx97IB29fNXxu+PWs+H5Z9H0nwre2DvlBfavCUD/7USDhvUEt9RX0rVXU7SyvrOS21S3trm0k4eK4RXRvqG4NAHgv7NXxAnvPBOqah4qn1rUtQn1WRRLb6Zc3YVFihIT9zGyoAWYheOpOK9a/4TzSP+fPxJ/4Tmo//ABirfhbw/wCH/Clpc2vh21ttPtbic3MkMT/J5hVVJAJ+XhV4GBx061tfaIP+e0f/AH0KAOXtfE/h/XNUisxBqy3TZUfatJvLZPXazyRqo9gTznjrXWgYGBwKyTp8c12zx3KmJnErRjBOQQevpkVrUAc9rUzXVzEsTNCLWcHzgA3zEFfunt81Gm2upXen21w+pqrSxq5AtlwCR9a2HsbaS5E7xKZQQc+46GoPD/8AyA7D/rin8qVr7jTaMCR9UW7eIaihC3cdvn7MvRlyT161f1C01K10+6uF1NWaKJ5ADbLgkAn1qvP/AMhOX/sJQ/8AoFbWvf8AID1H/r2k/wDQTS5UHMyHRrKWBpLy5uvPknijB+QIFC7j2/3jV+C4huAxglSQA4O05xUKw/aNKWHcV3whcjtkVDpljLbzNLM0e4oECxggY9f89KYjRqpqly1ra+YgXcWVct0XJxk1bpGUMpVgCD1BpgUtJu3uo5PM2lo22706NVqeCK4ULNGrgHI3DOKciLGoVFCqOgAxTqAEUBVAUAAcADtS0VDeTfZ7WWbaW2KWxQBNWY+lbrpn84iFpPNMe3ndx39OKdpl7LcTPFMIyQocNHnGD2P9PWtGjcAooJAGScAetYs/iXTVkaK1le/uF6xWUZnIPoSvC/8AAiKANllDAhgCD1BpawvtWv3h/wBGsbXTos/fvH82TH/XOM4H/fdP+z+If+glpf8A4Av/APHaANqkKgsCQMjocdKxvs/iH/oI6X/4Av8A/HaPs/iH/oI6X/4Av/8AHaANqisuyh1lLlGvb2wltxnckVq6MeOMEyEDnHatSgDjbLxlKkd02qWOZBqr6VaxWRMjTOqlud20LkKepwO5qOH4h2MmoIjWd1Hpw06TUJ7x8AWwjkdJFkXttKNkgn2z1q9ZeDbW2nWWTUNQuWXU21VRKYgBKyMhX5UHy4c8dcgc9cwjwBpQQxGe9a3kt7q1uYWZCtzDPI0jo/y5ADO2CpU46k0AQQfEjRZbeV/LvfOSSGP7NHGJpW87d5RAjZh8xRxgkEbTuAqta+O7lrvXLm60yeHStOnW1VXWOKQuY0cs0kkqooG8jaQOx3EnaNa08GwQpbrcanqN2Le4huYvNEClWj3bQSka7gd3JOScDmi98F2VzcNcR3l7bXX9onU0mjMbGOUwiEgK6MuNo7gkE5BFABpvjbTtWNl/Y9ve363EEdy7QRqRbxyMyqXyw6lX4XcflJxjBJ4a8caP4j1E2emyOXeFrmBmKETwqyqXUKxIGXThwpO4EAio9I8EW2jSW76XqmqWxSJIZtrRN9pRXd1D7ozggyOMptOD14GLXhjwpbeG3VLC8u2so4vJgtJFi2QJkEKrBBIQAABuZuKAOiooooAKKKKACiiigArl/Hfh+71xNJl0+ZVn0+8+0iJp3gEoMbx48xAxQjfkHaemMc5HUUUAeYS/D+/M2hzW0GmW6aSoYWjXUsy3ZM/mFJXKAlE++h2nEhBwAuGtjwTqsEEbWF1Y218lxrM6z7S+03csjwsVK/Nt3R7gePlwMgCvRKKAPMNP8C62upSXk8trC73VjcENfTXZHkCUOdzovJ3rhQAvB6d6a/D7xBcxXEmoTWEl41nbQlnvZZUnlhuFm3FTGFhRtpG1FIXPevW6KAPPF8J6zBr1zrUMGkzTSXjTrYS3DiFUeytoG+fyiQytA4Hyco56E4FVfh5exaXcWqXFnLIdF0zTIZXypD2000jnodqnem3BJ+XnoCfTaKACoL2ztb6Hyb62huYs7tk0Ydc+uDU9FAGT/wAI1oX/AEBdM/8AAWP/AAo/4RrQv+gLpn/gLH/hWtRQBxfhmK2u9fg1HS9Fh06zS2niaRBEplJkTb8qHOP3bdfWu0rmPh7xoMeAcFnyduBne34k+9Xdb8WeHdBukttc1/SdNuXTzFivLyOF2XJG4BiCRkEZ9jQBtVn+H/8AkB2H/XFP5VjxfEPwXLKkcXi/w68jkKqrqcBLE9ABu61seH/+QHYf9cU/lQBjz/8AITl/7CUP/oFbWvf8gPUf+vaT/wBBNYs//ISl/wCwnD/6BW1r3/ID1H/r2k/9BNAFiy/484P+ua/yptveW9xIyQTI7L1ANLaqHsYlPQxgfpVPT9Me2nR5Jg6xJsjAXHHv+VAGT41ZYrjTp7tdQOlxCZ7k2jSDbhQVLeWQcDn2q5F4d0yaFJYn1Ao6hlP9o3HIPT+Ol8ZY/wCEevskD/R5vck7D0Hc/WtHSP8AkE2X/XBP/QRQByx8M6juO0w7c8Z1G86f990f8IzqXrB/4Mbz/wCLrtKKAOcsrPX7K3WG3Om+WCSPMlmkPP8AtMSf1qfHiT10n/yJW5RQBz8Nvr8AIgTRowTkhFcZP5VJ5HiGYFJLzT7UH+OKFpG/AMQB+v0rcooAwh4Zs5mDarLdao+c4u5Mx/8AftcJ/wCO1tQQx28SxQRpFEowqIoUAewFPooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorK1zXbTRnso7pLmSW8kMUMdvC0rOwQueB/sqTTLTxPot1bafMmp2sa34zapO4ikl5xgI2GznjGM54oA2KK4u/wDiPolpqFxZqJrieK6+wqI5IV8ycKXaMb5FxtVWyzbVyCASeK29O8S6VfWdhcC7it/t7MttFcSLHJKVYqQqk8nI7ZoA2aKKw9e8WaLoU6W1/eqb6QZjsrdGnuZP92JAXI6c4xQBuVHPNFbwvNcSJFCgLO7sFVQO5J6CuSGo+Ldcx/ZelwaBZt/y9aria4I9Vt42wPq8gI7rT7fwHp00yXPiO4u/EV2p3BtTcPCjeqQKBEv127vc0Acn4Y8XTW+pNpPh+z/4SVDE7w3NgTHBxJ/HNJhGA3f8sy2PTmuV+Ovwo8X/ABGsdMvmfR11a2lESWlvuCRQv98vO5Bk2kKeEXjdgEmvZ3UL40tFUAKNOlAAGAP3kdbtAHlHwf8AgloHw9jjvZQup+IMfNeypxFnqIl/hH+19488gHFej+H/APkB2H/XFP5VoV5MvjfXLjUNe0rwZptre2vhy3CTT3LspuJh/wAs0Cjj7rcn0oA7Gf8A5CUv/YTh/wDRdbWvf8gPUf8Ar2k/9BNeXzfELST8O18dhJzIzqv9mhxta7A2hc4z7/THFSTeOdctNR0fR/F+nWdpF4jtSlvcWzswgnYYEcgI9xyPUUAeqWX/AB5wf9c1/lU1R26GOCNDglVAOPpUlAHNeMbuSSC40mzs7q7vLi0lZY4WRFwRtG5mYcZPQZrd0+N4dPtopBh0iVWHuAAayX/5HmL/ALB7f+jBW9QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByXjzw9d65caHNZwWtwtjcyTSw3F3Jbb1aF0GHjRjkFgcY6VyGp/D7xJP4cXSI7y0ktfsbQxRG9mhW0fzpHUZVC06KjRRjeV/1W4gljj1yigDhIvBUy6vZXci2LLFr9xqsnBLNDJazRKv3eWDyqSOmATnPBwI/htqcQRZmtb2Ka0S1nh+3zWyx7J5ZAQVjbeD5oODtwV4Jzx61RQBHcQpcW8sMm7ZIpRtrlTgjBwQQQfcHNZ+g+H9J0CF4tG0+3tA53SNGnzyH1dj8zH3JJrUooAKKKKAMSX/AJHa1/7B8v8A6MjrbrEl/wCR2tf+wfL/AOjI626AM3xJqsWh6DfancBvKtYmkO1Cx4HoK8s/Zkkhk8DareSbjdT6hLLcSMpAJwMAHvxzx0zXsU8UdxBJDMivFIpR1YZDAjBBrDttGsfDXg6TTNIh8iztrdwi5yehJJPck85oA+Q4jKPGiaGVC2a639qEDP8AJ13Bf++SK9x/aalh/wCEH0e/hDrdw30c1s4U4U7ScE9B0H5VUtfh14dOtLrD3GoNrLxS6kIzKvlZRwn3duccjvXM/G/X/iBL4KGlaZ4OE3h+WEeZqKf6W7Ac7gi8xY9WB+tAH0Bpetrq3hO11fT1crcQLKm9CDg99p5x396s6PczTtMsj+dGuNsu3bk9x718xfsl+Jdalm8ZXV1Yax4gum+wxEQzQ7olAuMD99KgCjoAvT0FfQg8UauOngTxJ/3/ANO/+SqALr/8jzF/2D2/9GCt6vO38S6r/wAJlFJ/whPiHf8AYWXy/OsN2PMHP/HzjH459q2v+Eo1f/oRPEn/AH/07/5KoA6qiuV/4SjV/wDoRPEn/f8A07/5Kqay8RancXkMM3g3X7SN2CtPNNYlIx/eYJcs2B7An2oA6SiuO+IEscd54fXVJ2t9Ae5kF8/mGOMnym8tZWBGIy3XJwWCg9cHmNM1LUv7TTTvDGprFol7rEkFldSxm5XyVshI4hJblBKrgHJA+YDIAFAHrFFeKalJc6rrytPcfubGPXrpIGXehkt7qBY2+bJDAOcMMFeduMmr8fjDU49L1OePUoo9VsbRDYaIY1Zr4fZEk8zB/evl2b7hxiMg5OTQB65RXF/DfWr3V01D7VqlhqcEZjaGW3uY5pF3A7lfy1VRyAQMZwec9T2lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGHqpNt4o0W5wNk6zWbH3ZRIv/oph+NblY3i63lm0OaW2XddWrLdwjuXjYNt/EAr+NSx63byiKSFXktpFRhMMYwwBHv0I/OgC/dCRraUQHbKUIQ+hxxXO3MVxHo2rF1mji+yuNsrbiWweRXTnjrWb4lOPD+o/wDXBx+lAHjp1Xy/i3pmmlvkbQLlMf7TSuw/9Ar13wkc+HLD/rmBXlEumWZ+LWl3LW6G4/sG5m3996yEKfqASK9H0C9kg0OxhhjV5GVj8xwAAf8A69AG3HZ6fY3Vzex29rbXFztE86oqNLjO3e3VsZOM9Mn1q2CCAQQQeQRWVcxvqdta3MCpkAny5Dwc8dfb1pZbyy8PaTG+q3tvbRA7Q8rhAzMeEXJ5JzgDqaAK1li68Y6jMAdtpbxWwP8AtMS7foUrerE8IQSLpH2u4XbcX0jXcgPUbzkL+C4H4Vt0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcz8UJ5bb4aeLZ7aV4Z4tIu3jkjYqyMIXIII5BB7101FAHk2r62NInvLnwBd/2pZxafI94q3L3cEEnmxCNwcttYI0zFVPKpkjoTGfGOo/2bFA3iCxMk928dtqEN7bGPasSt5c03lGMOWJIVI9xXHTBJ9dooA8Qn8W33iLR9Bm1LUY7Ceabw9dR6fGEX7YJri2eSQbgXKhmZQFIxsO7Oa9B+IHiK98LLY6jFCbqwfzLaS3RCXa4dc2+COgZ18r6yqe1ddRQB5kfEWt2WtpYX2qQPqlveWNmunrCi/b4pEh8+5UffAUvMRtOAISCDnIwdH8aXOh+HJbZ7y2icWFvNYLPjfPK95cpMFycvtRYsgfdznvXtdFAHmjazrt1r1vDHqxt7e71240cRx28Z8qJLaWYSKWBJkzFtycrhvukjNYQ8deIpRp4e+06yYWccqSXkscEd/L50iSA7lJbhE+WMqwMgPIKivaKKACuesPGvhy9vjZR6vbRX4JH2S6Jt5zg44jkCsR7gV0NVNT02x1W1a21Sytr23brFcRLIh/BgRQBborkD4B02158P3mq6CwGANPu2EQ+kEm6L/wAco+zeNtNB+z3+j67EOiXkTWUx+ske9Cf+2a0AdeeRXKeHrC3tr+90mYMDaP50C7sK8LEleO+07l+gXNc748+JV54T8I6tf6v4c1PTrqGBhbzfu7i2eYjCDejEqNxA+dVry34b/HceJ4rOLWFgtvGNmpSCQnZBqanrGf7khwCB0LAYxkLQB9HaxbS3CwmNBKiEloicbvQ88HHvVLVYZLfwlcxSkb/LK4BzjJ4H4ZxXKW/iPxDcW8U1veadLE+JlfyGBf8A6ZkZ4HUbuvtVbUPEmvS2rpeLprWokQy+UTuKs6/KPQrzyfvcdK09lLsK6KM3/JUtJ9/Ddyf/ACJXf+FraC60GJLiJJAjvjcOnNefud3xN0Nv73heZvzINaeg+KNTgtNtnpcMltHI+8PPteXJ/g7DH+1UqLlsNsv/ABRTxmNPSPwE9lDchPl+0I5H0XaCN3TG4bf6fJV9onj8/F/w0vxDg1C5u5NTtFD3Mu+Eq0ygBXTciqT/AHRx6V9Z6l4qvbGzhubU/ablmHm2sgxuY/8ALNCP4ieB1Hc11Ph7T5YEnvdRAOo3pDzDqI1x8sY9lH5nJpWa3EmZi3vjdQAvh3w0AOABr0/H/knS/bvHH/QveG//AAfT/wDyHXVUUhnK/bvHH/QveG//AAfT/wDyHW5o0upzWhbWrOytLrcQI7S6a4Tbxg7mjjOevG38avUUAcj8VGnHhALaE+bLqWmwhRM0IcPfQKULqCVDAlSQDwTwelcQniLVdG0sWJuf7PmOrTRXYuboN/ZsewtEgmmVgUk2hldlxhigAOAPZaKAPIk8a61DqelLdX9leyTwRLHZ6RLDL58hD5Z1YeYUbC4eM7VGSQQCar6X408RXOiNOmraVJdTy6bHt3JNJaST3cUMitCoQqgWQgK53gqQWPb2WigDz7+3Nfs/FcfhiSRby8d471LoQBA1ksZEgI+6H85AnXgTIe3POxeL9Su9Fjc6lFqDSwWNxeKiCP8As+4e6hRrc7MMOGf5Xyw2HJOcV7HRQBy/gS91TVINSvtSvIpYf7QvbS3gjgCeUkN3NECWydxKoOw+nUnqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwvGfhLRPGmkLpniWzN5YrKswiE0kXzgEAkoyk9TxnH5CuH/4Z8+GH/Qs/+T91/wDHK9VooA851LwifDlvu8PQ3E2l7cS2nmvNLGf+ekbOSzH1UnJ6jng5erXa6lo8ElssJiQogaHnd86ZzxxjHQ8ivWq53XfC2m3xnu1WW0vWUlri1fy2fj+Ifdb/AIEDWkZ2tzdCWjgGH/FzdAH/AFKsn/stN0qdLLTgZw+6WZhDGq7nmJ6BF6sf8nAqXGPiloC9f+KXkHP1Wu78HaBYabYW93Ejy3ssSh7mdt8mP7oP8K+wAFEJ8lxtXKvhfw7Klymqayii8UH7PbBty2wPU56GQ9z0HQdyetooqG23djCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUN8cWU59I2/lU1V9RVmsLlUUs5jYADqTigDkLbwuJtZ0vxIbogwaMbL7Pt4O4A7s/hU0Hjfw1o8ejaVqWtWUWp3bRW0NoH3ytI5CqCi5IBJHJAHvR4u8IN4q8IQaY2r6xo7rAFL6dP5TMdoG1+PmHHTjvXzlo/wCzp4p0Hxn4a1mwvYL2xg1G2uJ2/wBTcwIsqszbHypIAJ6knHTtQB9fUVyv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLQB1VFcr/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi0AdVRXK/8Ivq//Q9+JP8Avxp3/wAi0qeGNWV1J8c+I2AOSpg0/B9uLWgDqax/+El0b+1P7OGoQG78zySoJIEnXyy33Q/+znPtWxXD+HbfW9H0Z9AGlT+aJrjy9USWEw4kkd1lYF/M3/MCRs+9nkjmgDuKK8itvCesvpiwQ6TPp0Z/sqO8hN2hN1JFeRvcThlc5/dB8s2HfOCMgCraeErzS7qC8s7EW6wateMXjkUeXp7Ws+xFGeI/OaMiMdDzgYJoA9SorxPw94d1XVvCunTWOn3lhbXdro32kG6VJLxkuYpJ59ySEg+Tu+YkO2cY+Va2G8H6lbeMpJ0g1FrSO5hexuLSSDEFusSqYWeRvNVchyVUMG3A9ScAHqlFeL2vg/WI9Dmsn0e7NtFcW8sKtHaNPdMscqubtPO8qdfmQ7tyOzckfICbcPhbxFJq+m3WrWtwHjisfJbTHgKWRjC+bHmV96qWBJ2b9ysVOcDIB6o19bLqUentKBeSQtOsWDkorKpb04LKPxqzXmnw/wDDmpab4h0671HSWt7mHSZLTUL9pIm+23RkiJl+VixDbXYFgCBgYHAr0ugAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4m38drJOjy2UUGnTwXdxbXUt0F3LbsFYyAriMHcCDk8dcdK7auGtvh7atrV3dajLFcWEsV1DHYRJKkapcOrPkNK6g/KOY1jGSxx0wAUj8S2SyuGl0kx3FvcpBK8kksdrGjRGRZWlaEMqHaVz5eNxHODmul13xJ/Znhm31eG1+1LP5WBHJuiQPj52kQN+7AOSwB47U1PBejRibyxqKyTOryzDVLoSuVUqMyeZuIwcYzjp6CtGTQ7BtHttLjjkt7G2VEhS1nkgMaoMKFaNgwAAxjPSgDl38fr9ma6gsobmztbSK8v54LxXSKORnUGIgfvceWzHO3jHU/KLh8cWwgjl+xzYebUYcbhwbOSRGP/AvLJH1q2PBWgD7MFsnVYEWMKtzKBKquzgSgNiXDs7fPu5Zj1Jyv/CGaF9tmu/skpllM5Km6mMambPmlY921S+STtAyTnrzQBnad4w1HU5baCz8PstzLarfPFcXiLst2OEOVDAuxDYXgDacsOMr4a8cx69rf2O30+dbSTzhDdAOQfLbad4KBVDclcM2QOdp4rXuvC+k3LWbNBPG9pD9nieC6lhbyuPkYowLrwOGyKk07w5punXz3VlHcQszvJ5S3UvkBnJLMId3lgkknIUcknuaANeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A jet flow of driving gas creates an area of low pressure above the medication reservoir, generating an aerosol. The baffle helps ensure the formation of respirable particles, and prevents inhalation of oversized droplets of medication. Most nebulizers require a flow rate of 6 to 8 liters per minute for optimum performance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34496=[""].join("\n");
var outline_f33_44_34496=null;
var title_f33_44_34497="Immunostaining for EBV LMP";
var content_f33_44_34497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunostaining for Epstein-Barr virus (EBV) latent membrane protein (LMP) in a case of EBV-associated Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 196px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunostaining for Epstein-Barr virus (EBV) latent membrane protein (LMP) demonstrates strong cytoplasmic staining, with paranuclear accentuation in the Hodgkin cells. EBV-positive small lymphocytes do not stain for LMP in Hodgkin lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al, Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34497=[""].join("\n");
var outline_f33_44_34497=null;
var title_f33_44_34498="Heaney retractor";
var content_f33_44_34498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Heaney retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This retractor is especially designed for vaginal exposure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34498=[""].join("\n");
var outline_f33_44_34498=null;
var title_f33_44_34499="Neomycin, colistin, hydrocortisone, and thonzonium: Patient drug information";
var content_f33_44_34499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Neomycin, colistin, hydrocortisone, and thonzonium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/39/38514?source=see_link\">",
"     see \"Neomycin, colistin, hydrocortisone, and thonzonium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coly-Mycin&reg; S;",
"     </li>",
"     <li>",
"      Cortisporin&reg;-TC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to neomycin, colistin, hydrocortisone, thonzonium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10899 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34499=[""].join("\n");
var outline_f33_44_34499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200612\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024896\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024895\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024900\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024901\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024903\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024898\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024899\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024904\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024905\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/39/38514?source=related_link\">",
"      Neomycin, colistin, hydrocortisone, and thonzonium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_44_34500="Duodenal ulcer with visible vessel";
var content_f33_44_34500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duodenal ulcer with visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a duodenal ulcer with a nonbleeding visible vessel in a large circumferential ulcer&nbsp;(Forrest classification IIa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34500=[""].join("\n");
var outline_f33_44_34500=null;
var title_f33_44_34501="Trazodone: Patient drug information";
var content_f33_44_34501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trazodone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     see \"Trazodone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/744?source=see_link\">",
"     see \"Trazodone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10515304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oleptro&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trazodone D&reg;;",
"     </li>",
"     <li>",
"      Apo-Trazodone&reg;;",
"     </li>",
"     <li>",
"      Dom-Trazodone;",
"     </li>",
"     <li>",
"      Mylan-Trazodone;",
"     </li>",
"     <li>",
"      Novo-Trazodone;",
"     </li>",
"     <li>",
"      Nu-Trazodone;",
"     </li>",
"     <li>",
"      Nu-Trazodone D;",
"     </li>",
"     <li>",
"      Oleptro&trade;;",
"     </li>",
"     <li>",
"      PHL-Trazodone;",
"     </li>",
"     <li>",
"      PMS-Trazodone;",
"     </li>",
"     <li>",
"      ratio-Trazodone;",
"     </li>",
"     <li>",
"      Teva-Trazodone;",
"     </li>",
"     <li>",
"      Trazorel&reg;;",
"     </li>",
"     <li>",
"      ZYM-Trazodone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703068",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trazodone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Long-acting products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablets may be broken in half.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11115 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-518C2F532B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34501=[""].join("\n");
var outline_f33_44_34501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10515304\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230281\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022121\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022123\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022122\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022127\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022128\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022130\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022125\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022126\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022131\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022132\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=related_link\">",
"      Trazodone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/744?source=related_link\">",
"      Trazodone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_44_34502="Periungual Bowen";
var content_f33_44_34502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periungual Bowen disease (squamous cell carcinoma in situ)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34502=[""].join("\n");
var outline_f33_44_34502=null;
var title_f33_44_34503="Surgery for ventricular tachyarrhythmias";
var content_f33_44_34503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgery for ventricular tachyarrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Mark E Josephson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34503/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/44/34503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of sustained ventricular tachycardia (VT) is approximately 3 percent in patients who survive an acute myocardial infarction (MI), usually occurring 48 hours to six weeks after the event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of such patients have had a large MI, typically associated with a substantial reduction in left ventricular ejection fraction and often with a left ventricular aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advances in early revascularization for acute MI as well as increasing use of beta blockers and angiotensin-converting enzyme (ACE) inhibitors post-MI have led to a reduction in the frequency of these complications. For left ventricular aneurysm, for example, the incidence following an MI in which Q waves develop has fallen from 30 to 35 percent to 8 to 15 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=see_link\">",
"     \"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery was once a prominent component of the treatment of post-MI VT. However, because of proven efficacy and ease of implantation, an implantable cardioverter-defibrillator (ICD) is currently the most common strategy for treating serious ventricular arrhythmias in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although an ICD can treat VT and usually prevent the consequences of untreated sustained VT (ie, syncope, sudden death), surgery remains an important procedure since it offers the potential for cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/5\">",
"     5",
"    </a>",
"    ]. Catheter mapping of the arrhythmia plays an integral role in localizing all potential tachycardias circuits and planning the surgical approach. Arrhythmia surgery is particularly useful when surgical revascularization (coronary bypass grafting) is also necessary, since it offers added hemodynamic benefits, including improvement in left ventricular ejection fraction and alleviation of symptoms of heart failure.",
"   </p>",
"   <p>",
"    Another method for potential control or cure of VT is catheter ablation of myocardial tissue using a radiofrequency source of energy; other modes of ablation, such as thermal (hot or cold), light (laser), mechanical (ultrasound), and chemical methods have been developed and are being investigated. Radiofrequency ablation is highly effective for many supraventricular tachycardias and has replaced surgery as a first-line therapy in their management. It has not advanced sufficiently to be a primary therapy for VT associated with coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONDIRECTED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of VT has gone through several phases. It began with sympathectomy, which was followed by other nondirected modalities such as aneurysm resection, with and without accompanying coronary revascularization, and encircling endocardial ventriculotomy. None of these procedures has produced more than limited success. With the advent of programmed stimulation and mapping techniques, directed, map-guided VT surgery became the most important surgical approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aneurysmectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of VT with left ventricular aneurysms has been noted since the 1930s. In reports published in the late 1970s and 1980, nondirected aneurysmectomy produced limited success, with a reported efficacy for prevention of VT recurrence that ranged from 0 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As an example, one series of 56 patients undergoing aneurysmectomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bypass grafting observed an operative mortality of almost 20 percent, with an additional late mortality of 18 percent; the mortality among those with a recent MI was 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/8\">",
"     8",
"    </a>",
"    ]. Among 35 long-term survivors followed for a mean of 41 months, 20 remained on antiarrhythmic drugs because of recurrent ventricular arrhythmia. In another series of 19 patients undergoing aneurysmectomy, the operative mortality was 42 percent and 79 percent had recurrent VT postoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited success of nondirected aneurysmectomy alone is presumably due to the fact that most VTs arise from the border of the aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/10\">",
"     10",
"    </a>",
"    ], an area rarely excised during surgery. In contrast, long-term control of malignant ventricular arrhythmias has been excellent when aneurysmectomy is combined with left ventricular reconstruction and nonguided endocardial resection, with or without cryoablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one large series, 2 percent of patients experienced recurrence of clinically significant arrhythmia, although arrhythmia could still be induced in the electrophysiology laboratory in 8 to 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/11\">",
"     11",
"    </a>",
"    ]. The operative mortality was 7.5 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Coronary artery bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical revascularization with coronary artery bypass grafting has been used as a treatment for VT or ventricular fibrillation associated with coronary heart disease. The results have been unpredictable and the recurrence rate is generally high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The poor results are a probable reflection of the general lack of importance of active and reversible ischemia in the pathogenesis of the arrhythmia. Experimental studies suggest that fixed myocardial scar or aneurysm, with the interdigitation of viable myocardium, provides the substrate for reentry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Endocardial mapping'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathectomy to denervate the heart involves bilateral thoracotomies and results in bilateral Horner's syndrome. Initial successful reports were published in the 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A review of this procedure as a treatment of ventricular premature beats, nonsustained VT, and arrhythmias associated with ischemia found that the operative mortality was 10 percent and the success rate 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sympathectomy has not been adequately studied for the treatment of VT due to prior MI. As a result, its relative efficacy for this indication is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Encircling endocardial ventriculotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encircling endocardial ventriculotomy (EEV) is a nonguided technique, which involves creating a transmural ventriculotomy, perpendicular to the wall and encircling an endocardial scar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/22\">",
"     22",
"    </a>",
"    ]. This technique disconnects the VT circuit from the rest of the myocardium, inhibiting the spread of abnormal electrical activity and eliminating myocardial activation. However, EEV was subsequently abandoned because of extensive damage to viable myocardium and the development of postoperative heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These complications led to the development of modified techniques, including partial EEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/24\">",
"     24",
"    </a>",
"    ] and shallower, nontransmural incisions. In addition, EEV can be combined with cryoablation, laser ablation, and thermocoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIRECTED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial experience with a directed approach used intraoperative epicardial electrophysiologic mapping. However, subsequent data suggested that endocardial mapping was more accurate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/25\">",
"     25",
"    </a>",
"    ]. Although accurate mapping was initially limited to patients with inducible sustained VT, the availability of newer mapping techniques has allowed for mapping even in the absence of sustained VT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocardial mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of programmed electrical stimulation and endocardial mapping to study VT after a healed myocardial infarction led to the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VT after MI usually originated from areas of the subendocardium adjacent to an aneurysm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electrograms recorded from these areas often showed low amplitude and fragmentation, suggesting inhomogeneous conduction and the potential for reentry, the most frequent mechanism for sustained monomorphic VT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologic analysis of the subendocardial tissue removed from patients with postinfarction VT showed viable Purkinje fibers and muscle bundles, trapped in fibrous tissues and displaying an abnormal geometric pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings led to the hypothesis that the genesis of VT in patients with a myocardial infarction associated with a scar or aneurysm was reentry occurring within adjacent or interdigitating isolated bundles of surviving subendocardial tissues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrophysiologic study permits reproducible induction of sustained monomorphic VT in 90 percent of patients with a history of spontaneous VT. The ability to map the electrical outputs of the myocardium, localize the origin of focal VT, and define critical sites required for maintenance of macroreentrant VT allowed further development of surgical and catheter-based procedures that could destroy the site of origin, ablate the critical pathways associated with reentrant excitation, or isolate arrhythmogenic areas from the remainder of the heart and render them incapable of generating sustained arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Surgical subendocardial resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The realization that the origin of VT was, in the majority of cases, subendocardial or intraseptal and at the border of a ventricular aneurysm or infarct scar led to the development of surgical subendocardial resection (SER), guided by activation or pace mapping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. SER involves preoperative identification of the earliest site of left ventricular activation by electrophysiologic study, followed by intraoperative mapping of the left ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/29\">",
"     29",
"    </a>",
"    ]. This was initially accomplished with a hand held stick or roving probe but the subsequent development of endocavitary balloon electrodes and computerized acquisition systems permit the simultaneous recording from multiple sites of activation.",
"   </p>",
"   <p>",
"    Removal of scar and sites of abnormal electrograms, including septal segments of the aneurysm, probably explains the superiority of this technique over nonguided aneurysmectomy and EEV. In SER, only the subendocardium in the area of the VT focus is removed; as a result, there is no significant postoperative worsening of ventricular function as is seen with EEV. In one study, for example, 65 patients with VT were treated with either SER or simple left ventricular aneurysmectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/28\">",
"     28",
"    </a>",
"    ]. SER was associated with a lower rate of VT recurrence (17 versus 50 percent at three months) and, among those who died, a lower rate of death from ventricular tachyarrhythmias (three of 12 versus 12 of 17 with aneurysmectomy; 25 versus 71 percent).",
"   </p>",
"   <p>",
"    However, since SER does not remove the risk of arrhythmia recurrence or arrhythmic death, other modalities have been evaluated in conjunction with SER or alone, including cryoablation, laser ablation, and thermocoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In addition, some patients have received an ICD after SER. The potential efficacy of this approach was illustrated in a study of 28 patients, all of whom had had previous myocardial infarctions and between one and five cardiac arrests; an ICD was implanted in conjunction with SER [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/33\">",
"     33",
"    </a>",
"    ]. There were three perioperative deaths. At a median follow-up of 25 months, four of the survivors (16 percent) had recurrences of hypotensive VT, which were automatically terminated by the ICD. There was one sudden death in a patient whose ICD was not functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epicardial mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that compared endocardial with epicardial mapping found that endocardial activation precedes epicardial activation in approximately 70 percent of VTs, with less than 10 percent representing complete epicardial reentry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/34\">",
"     34",
"    </a>",
"    ]. An epicardially-based circuit is suggested if endocardial mapping is performed adequately, but does not identify abnormal sites of VT origin, ie, there are no sites in which activation occurs more than 50 msec prior to the onset of the surface QRS complex. An epicardial circuit is more common in patients without a discrete aneurysm or those with a prior inferior MI. These circuits may require deep or epicardial mapping for identification; deep or transmural ablation may be necessary for their ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ARRHYTHMIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our opinion that surgery should be considered for patients with VT related by coronary heart disease in the following situations (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with VT resistant to antiarrhythmic drug therapy",
"     </li>",
"     <li>",
"      Patients with a history of cardiac arrest in whom monomorphic VT is induced, especially if surgical revascularization is being considered",
"     </li>",
"     <li>",
"      Patients with VT in whom aneurysm resection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral valve surgery is being considered to control ventricular dysfunction",
"     </li>",
"     <li>",
"      Patients with VT and disorders associated with an identifiable pathophysiological substrate, such as postoperative tetralogy of Fallot",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability to induce sustained monomorphic VT implies the presence of a fixed substrate; revascularization alone has not been shown to alter this substrate or prevent recurrent VT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An attempt should be made to map and localize the origin of all induced sustained monomorphic VT morphologies, since failure to eradicate these sites is associated with recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. An effective modification of SER in patients with multiple morphologies is the use of sequential SER, guided by intraoperative mapping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/39\">",
"     39",
"    </a>",
"    ]. Use of this sequential surgical procedure renders 90 percent of patients free of inducible VT, although approximately 10 percent still require antiarrhythmic drugs. In one report, for example, the actuarial incidence of freedom from a serious arrhythmic event was 76 percent at 42 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported operative mortality with arrhythmia surgery has usually ranged from 8 to 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35,38,40,41\">",
"     35,38,40,41",
"    </a>",
"    ]. Rates as high as 20 percent have been described; the higher values typically come from series that included patients with poor preoperative status. In retrospective data of the first 100 patients undergoing SER for VT, there was a 9 percent perioperative mortality, a significant proportion of which were due to heart failure rather than a direct complication of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35\">",
"     35",
"    </a>",
"    ]. Risk factors for increased postoperative mortality include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left ventricular ejection fraction &lt;20 percent",
"     </li>",
"     <li>",
"      History of prior cardiac surgery",
"     </li>",
"     <li>",
"      The presence of infarctions in the anterior and inferior walls",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of mapping and the importance of eradicating inducible arrhythmia were illustrated in a report of 105 patients treated with a variety of surgical techniques; the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The operative mortality was 16 percent (including 6 percent from heart failure and 4 percent from VT).",
"     </li>",
"     <li>",
"      At postoperative electrophysiologic study performed in 79 patients, VT was induced much less often in those who had map-guided compared to visually-guided operations (25 versus 64 percent, p = 0.001). The results of this study predicted VT recurrence (22 versus 50 percent at two years in those without and with inducible VT).",
"     </li>",
"     <li>",
"      At two years, VT recurrence was much less likely in patients with map-guided operations (29 versus 63 percent, p = 0.004).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another series of 289 patients who underwent SER for refractory VT due to coronary disease, the operative mortality rate was 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/40\">",
"     40",
"    </a>",
"    ]. Approximately 93 percent of patients who survived the procedure remained free of clinical VT; 60 to 70 percent of patients did not require suppressive antiarrhythmic therapy.",
"   </p>",
"   <p>",
"    Surgery is also effective for patients with VT soon after an MI. In a retrospective study of 87 patients with sustained VT between three and 90 days after an acute MI, those who had frequent (&ge;3) episodes of early postinfarction VT had significantly better survival with surgery compared with medical therapy guided by electrophysiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/2\">",
"     2",
"    </a>",
"    ]. Given the high mortality (both from arrhythmia and reinfarction) and morbidity (heart failure) in these patients, early operative intervention may be the therapy of choice. Surgery was uniformly successful in patients with fewer episodes of VT, but these patients did as well with medical therapy.",
"   </p>",
"   <p>",
"    In comparison to these findings, surgical treatment has a lower success rate in patients whose primary substrate for VT is",
"    <strong>",
"     not",
"    </strong>",
"    coronary disease. In those with cardiomyopathy, for example, the underlying myocardial disease is diffuse, and discrete scar or aneurysm are not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Success rates with surgery of only 55 percent (versus 95 percent in patients with ischemic heart disease) have been reported in those with a nonischemic etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/43\">",
"     43",
"    </a>",
"    ]. However, a more contemporary study reported successful reduction in VT in six of eight non-ischemic cardiomyopathy patients (75 percent) treated with surgical cryoablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Predictors of recurrent arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent variables that predict a high rate of recurrent VT, some of which have already been mentioned, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disparate sites of origin of VT (particularly if greater than 5 mm between the mapped sites or origin) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35,37,45\">",
"       35,37,45",
"      </a>",
"      ]. In one series, the failure rate in such patients was 64 percent compared to 30 percent in those without this finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Visually-guided rather than map-guided surgery (63 versus 29 percent failure rate at two years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/38\">",
"       38",
"      </a>",
"      ] or lack of a completed intraoperative map [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of a discrete left ventricular aneurysm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low left ventricular ejection fraction.",
"     </li>",
"     <li>",
"      Inducible VT after the procedure (22 versus 50 percent at two years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An inferior site of origin of the arrhythmia or VT with a right bundle branch block morphology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35,45\">",
"       35,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cryoablative techniques, particularly when applied to the periannular ventricular muscle between the mitral valve annulus and infarct border, has improved results in patients with inferior infarctions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had an MI and have episodes of sustained VT have typically had a large MI, usually associated with a substantial reduction in left ventricular ejection fraction and often with a left ventricular aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In such patients, SER guided by endocardial mapping results in a lesser likelihood of death from ventricular tachyarrhythmia than simple aneurysmectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/28\">",
"     28",
"    </a>",
"    ]. Surgery also produces a better long-term survival than medical therapy in patients with frequent (&ge;3) episodes of VT occurring between three and 90 days after an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one center, overall five-year survival after surgery was 50 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34503/abstract/48\">",
"     48",
"    </a>",
"    ]. The sudden death rate was less than that following implantation of an ICD, and clinical recurrence of VT occurred in approximately 5 percent at a mean follow-up of 5.5 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advances in early revascularization for acute myocardial infarction (MI) as well as increasing use of beta blockers and angiotensin-converting enzyme (ACE) inhibitors post-MI have led to a reduction in the incidence of both sustained ventricular tachycardia (VT) and ventricular aneurysms. While surgery was once a prominent component of the treatment of post-MI VT, an implantable cardioverter-defibrillator (ICD) is currently the most common strategy for treating serious ventricular arrhythmias in these patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical management of VT has evolved, beginning with sympathectomy, which was followed by other nondirected modalities such as aneurysm resection with and without accompanying coronary revascularization and encircling endocardial ventriculotomy. With the advent of programmed stimulation and mapping techniques, however, more directed and map-guided VT surgery became the most important surgical approach. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nondirected procedures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Directed procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery or catheter ablation should be considered for patients with VT related to coronary heart disease, in patients with VT resistant to antiarrhythmic therapy, patients in whom aneurysm resection is being considered, and in patients with prior cardiac arrest with inducible monomorphic VT. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications for arrhythmic surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/1\">",
"      Wellens HJ, B&auml;r FW, Vanagt EJ, Brugada P. Medical treatment of ventricular tachycardia: considerations in the selection of patients for surgical treatment. Am J Cardiol 1982; 49:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/2\">",
"      Kleiman RB, Miller JM, Buxton AE, et al. Prognosis following sustained ventricular tachycardia occurring early after myocardial infarction. Am J Cardiol 1988; 62:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/3\">",
"      DiMarco JP, Lerman BB, Kron IL, Sellers TD. Sustained ventricular tachyarrhythmias within 2 months of acute myocardial infarction: results of medical and surgical therapy in patients resuscitated from the initial episode. J Am Coll Cardiol 1985; 6:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/4\">",
"      Volpi A, Cavalli A, Turato R, et al. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-3) Data Base. Am Heart J 2001; 142:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/5\">",
"      Krishnan SC, Josephson ME. Surgery for postinfarction ventricular tachycardia: is it obsolete? Pacing Clin Electrophysiol 2000; 23:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/6\">",
"      Sami M, Chaitman BR, Bourassa MG, et al. Long term follow-up of aneurysmectomy for recurrent ventricular tachycardia or fibrillation. Am Heart J 1978; 96:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/7\">",
"      de Soyza N, Murphy ML, Bissett JK, et al. Ventricular arrhythmias in chronic stable angina pectoris with surgical or medical treatment. Ann Intern Med 1978; 89:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/8\">",
"      Buda AJ, Stinson EB, Harrison DC. Surgery for life-threatening ventricular tachyarrhythmias. Am J Cardiol 1979; 44:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/9\">",
"      Harken AH, Horowitz LN, Josephson ME. Comparison of standard aneurysmectomy and aneurysmectomy with directed endocardial resection for the treatment of recurrent sustained ventricular tachycardia. J Thorac Cardiovasc Surg 1980; 80:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/10\">",
"      Josephson ME, Horowitz LN, Farshidi A, et al. Recurrent sustained ventricular tachycardia. 2. Endocardial mapping. Circulation 1978; 57:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/11\">",
"      Dor V, Sabatier M, Montiglio F, et al. Results of nonguided subtotal endocardiectomy associated with left ventricular reconstruction in patients with ischemic ventricular arrhythmias. J Thorac Cardiovasc Surg 1994; 107:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/12\">",
"      Sosa E, Jatene A, Kaeriyama JV, et al. Recurrent ventricular tachycardia associated with postinfarction aneurysm. Results of left ventricular reconstruction. J Thorac Cardiovasc Surg 1992; 103:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/13\">",
"      Garan H, Ruskin JN, DiMarco JP, et al. Electrophysiologic studies before and after myocardial revascularization in patients with life-threatening ventricular arrhythmias. Am J Cardiol 1983; 51:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/14\">",
"      Manolis AS, Rastegar H, Estes NA 3rd. Effects of coronary artery bypass grafting on ventricular arrhythmias: results with electrophysiological testing and long-term follow-up. Pacing Clin Electrophysiol 1993; 16:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/15\">",
"      Kron IL, Lerman BB, Haines DE, et al. Coronary artery bypass grafting in patients with ventricular fibrillation. Ann Thorac Surg 1989; 48:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/16\">",
"      El-Sherif N, Smith RA, Evans K. Canine ventricular arrhythmias in the late myocardial infarction period. 8. Epicardial mapping of reentrant circuits. Circ Res 1981; 49:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/17\">",
"      Wit AL, Allessie MA, Bonke FI, et al. Electrophysiologic mapping to determine the mechanism of experimental ventricular tachycardia initiated by premature impulses. Experimental approach and initial results demonstrating reentrant excitation. Am J Cardiol 1982; 49:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/18\">",
"      Fenoglio JJ Jr, Pham TD, Harken AH, et al. Recurrent sustained ventricular tachycardia: structure and ultrastructure of subendocardial regions in which tachycardia originates. Circulation 1983; 68:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/19\">",
"      ESTES EH Jr, IZLAR HL Jr. Recurrent ventricular tachycardia. A case successfully treated by bilateral cardiac sympathectomy. Am J Med 1961; 31:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/20\">",
"      Zipes DP, Festoff B, Schaal SF, et al. Treatment of ventricular arrhythmia by permanent atrial pacemaker and cardiac sympathectomy. Ann Intern Med 1968; 68:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/21\">",
"      Kadowaki MH, Levett JM. Sympathectomy in the treatment of angina and arrhythmias. Ann Thorac Surg 1986; 41:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/22\">",
"      Guiraudon G, Fontaine G, Frank R, et al. Encircling endocardial ventriculotomy: a new surgical treatment for life-threatening ventricular tachycardias resistant to medical treatment following myocardial infarction. Ann Thorac Surg 1978; 26:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/23\">",
"      Ungerleider RM, Holman WL, Calcagno D, et al. Encircling endocardial ventriculotomy for refractory ischemic ventricular tachycardia. III. Effects on regional left ventricular function. J Thorac Cardiovasc Surg 1982; 83:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/24\">",
"      Ostermeyer J, Breithardt G, Borggrefe M, et al. Surgical treatment of ventricular tachycardias. Complete versus partial encircling endocardial ventriculotomy. J Thorac Cardiovasc Surg 1984; 87:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/25\">",
"      Wittig JH, Boineau JP. Surgical treatment of ventricular arrhythmias using epicardial, transmural, and endocardial mapping. Ann Thorac Surg 1975; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/26\">",
"      Horowitz LN, Harken AH, Kastor JA, Josephson ME. Ventricular resection guided by epicardial and endocardial mapping for treatment of recurrent ventricular tachycardia. N Engl J Med 1980; 302:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/27\">",
"      Josephson ME, Waxman HL, Cain ME, et al. Ventricular activation during ventricular endocardial pacing. II. Role of pace-mapping to localize origin of ventricular tachycardia. Am J Cardiol 1982; 50:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/28\">",
"      Mason JW, Stinson EB, Winkle RA, et al. Surgery for ventricular tachycardia: efficacy of left ventricular aneurysm resection compared with operation guided by electrical activation mapping. Circulation 1982; 65:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/29\">",
"      Josephson ME, Harken AH, Horowitz LN. Endocardial excision: a new surgical technique for the treatment of recurrent ventricular tachycardia. Circulation 1979; 60:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/30\">",
"      Manolis AS, Rastegar H, Payne D, et al. Surgical therapy for drug-refractory ventricular tachycardia: results with mapping-guided subendocardial resection. J Am Coll Cardiol 1989; 14:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/31\">",
"      Svenson RH, Littmann L, Gallagher JJ, et al. Termination of ventricular tachycardia with epicardial laser photocoagulation: a clinical comparison with patients undergoing successful endocardial photocoagulation alone. J Am Coll Cardiol 1990; 15:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/32\">",
"      C&aacute;ceres J, Werner P, Jazayeri M, et al. Efficacy of cryosurgery alone for refractory monomorphic sustained ventricular tachycardia due to inferior wall infarction. J Am Coll Cardiol 1988; 11:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/33\">",
"      Platia EV, Griffith LS, Watkins L Jr, et al. Treatment of malignant ventricular arrhythmias with endocardial resection and implantation of the automatic cardioverter-defibrillator. N Engl J Med 1986; 314:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/34\">",
"      Kaltenbrunner W, Cardinal R, Dubuc M, et al. Epicardial and endocardial mapping of ventricular tachycardia in patients with myocardial infarction. Is the origin of the tachycardia always subendocardially localized? Circulation 1991; 84:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/35\">",
"      Miller JM, Kienzle MG, Harken AH, Josephson ME. Subendocardial resection for ventricular tachycardia: predictors of surgical success. Circulation 1984; 70:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/36\">",
"      Krafchek J, Lawrie GM, Wyndham CR. Cryoablation of arrhythmias from the interventricular septum: initial experience with a new biventricular approach. J Thorac Cardiovasc Surg 1986; 91:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/37\">",
"      Waspe LE, Brodman R, Kim SG, et al. Activation mapping in patients with coronary artery disease with multiple ventricular tachycardia configurations: occurrence and therapeutic implications of widely separate apparent sites of origin. J Am Coll Cardiol 1985; 5:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/38\">",
"      Swerdlow CD, Mason JW, Stinson EB, et al. Results of operations for ventricular tachycardia in 105 patients. J Thorac Cardiovasc Surg 1986; 92:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/39\">",
"      Haines DE, Lerman BB, Kron IL, DiMarco JP. Surgical ablation of ventricular tachycardia with sequential map-guided subendocardial resection: electrophysiologic assessment and long-term follow-up. Circulation 1988; 77:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/40\">",
"      Hargrove WC, Miller JM. Risk stratification and management of patients with recurrent ventricular tachycardia and other malignant ventricular arrhythmias. Circulation 1989; 79:I178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/41\">",
"      Lee R, Mitchell JD, Garan H, et al. Operation for recurrent ventricular tachycardia. Predictors of short- and long-term efficacy. J Thorac Cardiovasc Surg 1994; 107:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/42\">",
"      Guiraudon G, Fontaine G, Frank R, et al. Surgical treatment of ventricular tachycardia guided by ventricular mapping in 23 patients without coronary artery disease. Ann Thorac Surg 1981; 32:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/43\">",
"      Frank G, Lowes D, Baumgart D, et al. Surgical alternatives in the treatment of life-threatening ventricular arrhythmias. Eur J Cardiothorac Surg 1988; 2:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/44\">",
"      Anter E, Hutchinson MD, Deo R, et al. Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol 2011; 4:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/45\">",
"      Miller JM, Kienzle MG, Harken AH, Josephson ME. Morphologically distinct sustained ventricular tachycardias in coronary artery disease: significance and surgical results. J Am Coll Cardiol 1984; 4:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/46\">",
"      Lacroix D, Warembourg H, Klug D, et al. Intraoperative computerized mapping of ventricular tachycardia: differences between anterior and inferior myocardial infarctions. J Cardiovasc Electrophysiol 1999; 10:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34503/abstract/47\">",
"      Ivey TD, Brady GH, Misbach GA, Greene HL. Surgical management of refractory ventricular arrhythmias in patients with prior inferior myocardial infarction. A preliminary report. J Thorac Cardiovasc Surg 1985; 89:369.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, Williams &amp; Wilkins, Philadelphia 1993.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1039 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34503=[""].join("\n");
var outline_f33_44_34503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONDIRECTED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aneurysmectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Coronary artery bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Encircling endocardial ventriculotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIRECTED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocardial mapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Surgical subendocardial resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epicardial mapping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDICATIONS FOR ARRHYTHMIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Predictors of recurrent arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/4/25673?source=related_link\">",
"      Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_44_34504="Awareness with recall following general anesthesia";
var content_f33_44_34504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Awareness with recall following general anesthesia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     Michael Avidan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     George A Mashour, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34504/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/44/34504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phrase \"awareness with recall\" (AWR) refers to both intraoperative consciousness and explicit recall of intraoperative events. Other terms, such as \"intraoperative awareness during general anesthesia\", \"anesthesia awareness\", or simply \"awareness\", are used as synonyms.",
"   </p>",
"   <p>",
"    AWR is a real and potentially psychologically devastating complication requiring the attention of the entire perioperative team. An explicit query about awareness events both postoperatively and at surgical follow-up evaluation should be performed to identify this problem and initiate psychological support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is important to note that patients tend not to talk to their physicians about awareness events unless specifically asked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most important contributing factor for AWR is underdosing of anesthesia relative to a given patient's specific requirements. With relatively minor but cost-effective modifications to anesthesia care, the incidence of AWR can potentially be reduced. However, as AWR is not likely to be eradicated completely, especially in the context of individual variability, the patient needs to be informed about this complication in situations of high risk.",
"   </p>",
"   <p>",
"    Patients frequently do not understand the difference between sedation and general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/5\">",
"     5",
"    </a>",
"    ], and may report prior episodes of AWR with psychologic sequelae when a procedure was performed under sedation (with or without local or regional anesthesia) rather than general anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEMORY AND RECALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is unclear how often a patient may reach some meaningful level of consciousness during surgery, the main outcome of interest is postoperative recall for the event. Two main forms of memory are described, implicit and explicit memory. Implicit memory, also known as procedural memory, is an unconscious memory aiding in the performance of a task without any recollection of prior experiences facilitating that task. Explicit memory is the conscious recollection of previous experiences (explicit recall) or factual information (semantic memory) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/7\">",
"     7",
"    </a>",
"    ]. The discrimination between these two types of memory is illustrated in the famous case of \"H.M.\", who developed anterograde amnesia following bilateral temporal lobectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/8\">",
"     8",
"    </a>",
"    ]. He was unable to remember meeting someone (defective explicit memory), but was able to normally perform technical tasks (intact implicit memory).",
"   </p>",
"   <p>",
"    Intraoperative awareness and postoperative recall, like implicit and explicit memory, are dissociated from each other. As an example, in one study of intubated patients under a light plane of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    anesthesia prior to surgery, a tourniquet was used to exclude one of the patient's arms from the effects of neuromuscular blockers (ie, isolated forearm technique) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/9\">",
"     9",
"    </a>",
"    ]. Unequivocal responses to commands to move the isolated limb were seen in 66 percent of patients. Of the patients who demonstrated intraoperative awareness, only one in four had explicit recall of the event postoperatively. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Total intravenous anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of large, prospective, multi-center studies of AWR in both the United States and Europe, the exact incidence of AWR is debated because of methodological differences in postoperative assessment of awareness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/10\">",
"     10",
"    </a>",
"    ], and differences in anesthetic practice.",
"   </p>",
"   <p>",
"    Awareness experiences range from isolated auditory perceptions to reports of a patient being fully awake, immobilized, and in pain. The incidence of AWR in various population studies ranges from 0.0068 percent to 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/1,2,10-14\">",
"     1,2,10-14",
"    </a>",
"    ]. While this incidence is low, AWR may affect as many as 60,000 adults each year in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/11\">",
"     11",
"    </a>",
"    ]. A National Audit Project in the United Kingdom reported an incidence of approximately 1 in 15,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/15\">",
"     15",
"    </a>",
"    ], but this likely represents a significant underestimate due to the lack of patient interviews to assess AWR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pediatric population appears to fall into a higher risk category for AWR. The incidence of awareness in pediatric anaesthesia ranges from 0.2 to 1.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/17\">",
"     17",
"    </a>",
"    ]. A combined sample from five cohort studies involving 4486 anesthetics found 33 cases of awareness. Multivariate regression analysis found significant factors associated with awareness in children were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    maintenance (odds ratio [OR] 2.4, 95% CI 1.08-5.32), and use of a tracheal tube (OR 3.0, 95% CI 1.20-7.56). Assessing the presence of AWR in children, however, poses a number of challenges related to developmental factors and the accuracy of postoperative interviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRIBUTING FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anesthetic underdosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important contributing factor for AWR is underdosing of anesthesia relative to a given patient's specific requirements.",
"   </p>",
"   <p>",
"    This can occur for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is a mistake or failure in the delivery of anesthesia",
"     </li>",
"     <li>",
"      The anesthetic technique results in inadequate anesthesia",
"     </li>",
"     <li>",
"      It is judged unsafe to administer sufficient anesthesia",
"     </li>",
"     <li>",
"      A specific patient's needs are underappreciated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Technical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment malfunction and human error can be a cause of AWR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/1\">",
"     1",
"    </a>",
"    ]. Difficult intubations may also lead to AWR, presumably due to insufficient anesthesia during prolonged intubation attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/20\">",
"     20",
"    </a>",
"    ]. For total intravenous anesthesia, infiltration of intravenous catheters or dosage miscalculations may result in inadequate anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Total intravenous anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total intravenous anesthesia (TIVA) is associated with a higher risk for AWR compared with inhalational anesthesia. Observational studies and a single randomized trial support mounting evidence of an increased risk of AWR with TIVA compared with inhalational agent-based anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    In contrast to inhalational anesthesia for which the exhaled concentration of anesthetic gases allows real-time dose adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], blood concentrations of intravenous agents are not easily obtained during TIVA, which may lead to underdosing. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Minimum alveolar concentration monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Newer tests may allow the prediction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    concentrations in serum by determining the propofol concentration in exhaled air; however, these methods are still experimental [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, TIVA has traditionally relied on patient response to noxious stimuli as an indication of insufficient anesthetic dosing. When neuromuscular blockade is needed, movement as an indicator of insufficient anesthesia is prevented. Brain monitoring may improve the ability to gauge the depth of anesthesia in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Brain monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The increased risk of AWR with TIVA and potential benefit of brain monitoring are illustrated in the following studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study from Japan found that a preponderance of patients with AWR had undergone anesthesia with TIVA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/23\">",
"       23",
"      </a>",
"      ]. A survey involving 21 anesthesiologists and 85,156 anesthetic cases identified 24 patients with definite (n = 10) or possible (n = 14) awareness for an incidence of 0.028 percent. TIVA was used in 21 of the 24 cases (88 percent).",
"     </li>",
"     <li>",
"      A trial from China involving 5228 patients also found a high incidence of AWR with TIVA, and suggested that a monitoring protocol decreased AWR in patients receiving TIVA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/24\">",
"       24",
"      </a>",
"      ]. Adult patients undergoing TIVA were randomly assigned to receive bispectral index (BIS)-guided monitoring (BIS 40 to 60) or BIS monitoring where the results were not available to the anesthesiologist (control group). The incidence of awareness was significantly higher in the control group (0.65 versus 0.14 percent) compared with the BIS-guided group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Resistance to anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthetic-induced sedation, immobility, hypnosis, and amnesia are mediated by specific receptors at various anatomic sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/27\">",
"     27",
"    </a>",
"    ]. Different doses of anesthetic agent are required to achieve the various anesthetic effects. For example, amnesia typically occurs at lower doses of anesthetic compared with hypnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Genetic or acquired alterations in the receptors or enzymes that mediate anesthetic and analgesic effects, or in the metabolism of these agents, can alter vulnerability to AWR.",
"   </p>",
"   <p>",
"    Patients who have a history of AWR are thought to be at higher risk for subsequent episodes of AWR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/20\">",
"     20",
"    </a>",
"    ]. This susceptibility may, in some instances, be related to genetic factors. Individuals with mutations of the melanocortin-1 receptor gene, associated with the red hair phenotype, might have increased inhalational anesthesia requirements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/31\">",
"     31",
"    </a>",
"    ]. It is likely there are several uncharacterized genetic polymorphisms that result in resistance to various anesthetic agents.",
"   </p>",
"   <p>",
"    The inhalational agents, benzodiazepines, and opioids are metabolized by the cytochrome P450 family of enzymes. Some medications induce cytochrome P450, whereas others may be potent inhibitors, thus complicating anesthetic dosing. It is important to know all of the patient's routine medications and supplements to identify potential anesthetic and analgesic interactions.",
"   </p>",
"   <p>",
"    Alcohol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    induce cytochrome P450 2E1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/32\">",
"     32",
"    </a>",
"    ]; therefore, patients with habitual alcohol intake may require increased inhalational anesthetic doses. Acute alcohol intoxication, however, is associated with a decreased inhalational anesthesia requirement.",
"   </p>",
"   <p>",
"    Patients who frequently use benzodiazepines or opioids can develop tolerance and may have an increased requirement for hypnotic or analgesic agents. Cytochrome P450 3A, which is involved in the metabolism of opioids, is induced by numerous drugs including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , barbiturates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , rifampicin, and St. John's wort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients who regularly take any of these drugs may require increased opioid doses to maintain adequate analgesia. Inadequate analgesia can result in higher levels of cortical stimulation due to pain and may result in heightened awareness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anesthesia-related medical risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeries that are classically considered higher risk for AWR include trauma surgery, cardiac surgery, and cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/13,20,21\">",
"     13,20,21",
"    </a>",
"    ]. Underdosing of general anesthetic agents during these surgeries is not infrequent in order to maintain adequate blood pressure and limit the adverse medical consequences of hemodynamic compromise. With life-saving surgeries, a short interval between anesthetic induction and surgical incision (eg, emergent hemorrhage control) is also a contributing factor.",
"   </p>",
"   <p>",
"    Monitoring end-tidal anesthetic concentrations and the use of newer inhalational agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    , which have a faster onset of anesthetic action may help to decrease the risk of AWR in these patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Depth of anesthesia monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neuromuscular blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of paralyzing agents is associated with both increased risk and severity of AWR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/1,20\">",
"     1,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Muscle paralysis removes one of the physiologic signs of patient awareness (ie, purposeful movement) and is not necessary for many surgeries. The use of muscle relaxants negatively affects the experience of unintended intraoperative awareness and may increase the potential for long-term psychological sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While immobilization of the heart is usually required for cardiac surgery, paralysis of skeletal muscles is not necessary. Some degree of muscle relaxation, however, facilitates both thoracic and abdominal surgery. Partial skeletal muscle paralysis (assessed by peripheral nerve stimulation) can be used to improve operating conditions for the surgeon, and still allow some purposeful movement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SEQUELAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequelae of AWR are psychological. Many cases of AWR involve a fleeting recollection of intraoperative events and do not cause significant psychological anxiety or stress. Other experiences can be vivid and traumatic. These more significant experiences appear more likely when muscle relaxants have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. An early emotional response by the patient after the awareness event is also a risk factor for the development of post-AWR psychological disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/4\">",
"     4",
"    </a>",
"    ]. The most serious is posttraumatic stress disorder (PTSD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported incidence of psychological symptoms following an awareness event ranges from 33 to 69 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/3,4,37-40\">",
"     3,4,37-40",
"    </a>",
"    ]. Methodological issues are also a problem in the study of the sequelae of AWR. Prospective studies are preferred, but the low incidence of AWR and even lower incidence of PTSD associated with AWR complicates such investigation. Retrospective studies that recruit patients based on referral, advertising, or closed legal claims may result in selection bias.",
"   </p>",
"   <p>",
"    Patients who have experienced AWR are treated in a supportive manner following the event and should be offered psychiatric counseling. The psychological effects of an AWR experience often present in a delayed fashion. Therefore, both surgeon and primary care physician should be vigilant in identifying potential early signs of a psychological disturbance (eg, intrusive thoughts, flashbacks, recurrent dreams or nightmares, avoidance of stimuli associated with the trauma, sleep disturbance, exaggerated startle response, hypervigilance).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STRATEGIES FOR PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplying sufficient intravenous or inhalational anesthetic throughout the operative experience is the first line of AWR prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Depth of anesthesia monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring strategies are aimed at recognizing when the administered level of anesthesia is insufficient. The first public demonstration of surgery under general anesthesia took place in 1846. The \"monitor\" reflecting anesthetic depth was the general response of the patient to the administered agents. Later, depth of anesthesia was stratified based upon the qualitative physiologic effects of anesthesia (eg, respiratory pattern, muscle tone, eye movements); comparisons between various anesthetic agents could not be made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous reports have demonstrated that hemodynamic parameters are not reliable in the assessment of anesthetic depth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/3\">",
"     3",
"    </a>",
"    ]. Physiologic changes during surgery (eg, tachycardia, hypertension) may reflect insufficient anesthesia; however, some patients, such as those who are hypovolemic or under beta-adrenergic blockade, may not have the anticipated physiologic response to a noxious stimulus. Conversely, sympathetic activation leading to increased heart rate and blood pressure may occur even in the presence of adequate anesthesia. Moreover, the use of neuromuscular blocking agents complicates the assessment of the physiologic effects of anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Neuromuscular blockade'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The unreliability of physiologic parameters and inability to recognize consciousness in the paralyzed patient motivated interest in other methods to assess anesthetic depth including monitoring exhaled anesthetic gas concentrations (ie, minimum alveolar concentration [MAC], and brain activity monitoring with the electroencephalogram [EEG]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Minimum alveolar concentration monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum alveolar concentration (MAC) of an anesthetic agent is the exhaled concentration of the anesthetic agent at which 50 percent of patients do not respond with movement to a noxious stimulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/44\">",
"     44",
"    </a>",
"    ]. The MAC for movement suppression (mediated at the level of the spinal cord) is usually higher than the MAC for suppression of consciousness or memory (ie, MAC-awake), thereby providing a margin of safety (assumes adequate analgesia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different inhalational agents can be compared using MAC. As an example, the MAC of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    is approximately 1.2 percent, while the MAC of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    is 6 percent, indicating that isoflurane is more potent than desflurane because it achieves the same effect at a lower concentration.",
"   </p>",
"   <p>",
"    While an exhaled concentration of anesthetic agent that decreases below 0.7 MAC has been proposed as an appropriate alarm threshold level, it is not guaranteed that hypnosis and amnesia will be achieved at concentrations above 0.7 MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/22,46\">",
"     22,46",
"    </a>",
"    ]. Other important limitations of MAC as a monitor of anesthetic depth include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MAC relates to movement responses, which are obscured by neuromuscular blockers. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neuromuscular blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC is variable among patients and is dependent on age, pharmacogenetics, temperature, and other factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/31,47,48\">",
"       31,47,48",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MAC is not applicable to intravenous agents. Commonly used medications such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      have analogous concepts (ie, Cp50, plasma concentration); however, these are not routinely measured intraoperatively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Total intravenous anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Brain monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain monitoring (eg, unprocessed electroencephalography, processed electroencephalography, evoked potentials) provides useful information during anesthesia and might improve anesthetic delivery and recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/50\">",
"     50",
"    </a>",
"    ]. The raw, unprocessed EEG reflects the effects of general anesthetics on the brain, but is less practical for intraoperative monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Efficacy of preventive strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Processed EEG refers to the translation of the raw EEG signal (delta, theta, alpha, beta, gamma [in ascending order of frequency]) from the time domain to the frequency domain via fast Fourier transform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/52\">",
"     52",
"    </a>",
"    ]. The analysis of the contribution of each frequency band results in a frequency spectrum. A variety of characteristics of this spectrum are then analyzed to assess the depth of anesthesia. The stimulus-response technique of evoked potentials (usually auditory evoked responses) is also used to assess anesthetic depth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of commercially available devices have been studied as potential depth of anesthesia monitors, including bispectral index (BIS), auditory evoked potentials, entropy, and cerebral state monitors (",
"    <a class=\"graphic graphic_table graphicRef81084 \" href=\"mobipreview.htm?21/31/22014\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Threshold alarms are set according to the device manufacturer's specifications. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Efficacy of preventive strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adjunctive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of adjunctive agents (ie, sedative agents, analgesics) during periods of suboptimal anesthesia, and minimizing or avoiding muscle relaxants, may limit the traumatic effect of an intraoperative awareness event, thereby diminishing the likelihood of subsequent distress.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzodiazepines - Benzodiazepines are given for their amnestic effects. Agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      are typically given preoperatively. Re-dosing the benzodiazepine intraoperatively might facilitate amnesia if providing adequate anesthesia becomes challenging.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"       Scopolamine",
"      </a>",
"      - Scopolamine is an anticholinergic agent associated with amnesia and can also be used if anesthesia is inadequate. Scopolamine does not depress cardiovascular function but may cause tachycardia.",
"     </li>",
"     <li>",
"      Opioids - Opioids diminish responses to noxious stimuli and when adequately dosed, ensure the patient is pain-free should an awareness event occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/58-60\">",
"       58-60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Efficacy of preventive strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although brain monitoring with bispectral index (BIS) might improve anesthetic delivery and recovery from anesthesia, the use of a specific monitoring protocol (MAC or processed EEG) to prevent AWR is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/50,61-63\">",
"     50,61-63",
"    </a>",
"    ]. Patients at high risk for awareness (eg, cardiac, trauma, obstetric surgery) are most often included in trials, whereas surgical patients who are not at high risk have not been adequately studied. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Contributing factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefits of monitoring for the prevention of AWR in the subset of high-risk patients was suggested by a metaanalysis of four trials, two comparing BIS versus clinical monitoring (2493 patients) including the B-Aware trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/46\">",
"     46",
"    </a>",
"    ], and two comparing BIS versus end-tidal anesthetic concentration monitoring (1981 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/50\">",
"     50",
"    </a>",
"    ]. The risk of awareness was significantly decreased (odds ratio [OR] 0.33, 95% CI 0.13-0.94) using BIS monitoring. In the larger of the studies that compared BIS with end-tidal anesthetic concentration monitoring (the B-Unaware trial), no significant differences in the incidence of AWR were found among 1941 patients (total intravenous anesthesia [TIVA] excluded) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/22\">",
"     22",
"    </a>",
"    ]. Some speculated that the reduction in AWR and attributed to a specific monitoring protocol may be predominantly due to increased overall clinical vigilance.",
"   </p>",
"   <p>",
"    The BIS or Anesthesia Gas to Reduce Explicit Recall (BAG-RECALL) trial enrolled three times as many patients as the B-Unaware trial to provide a more precise estimate of any benefit that might be associated with BIS monitoring. The BAG-RECALL trial randomly assigned 2861 patients to a BIS-guided protocol (with an audible alert if the BIS value was &lt;40 or &gt;60) (",
"    <a class=\"graphic graphic_table graphicRef81084 \" href=\"mobipreview.htm?21/31/22014\">",
"     table 1",
"    </a>",
"    ), or a BIS-blinded, end-tidal anesthetic concentration-guided (ETAC) protocol (with an audible alert if the ETAC was &lt;0.7 or &gt;1.3 minimum alveolar concentration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/64\">",
"     64",
"    </a>",
"    ]. Unexpectedly, more patients experienced awareness events in the BIS-monitored group (definite awareness: 7 versus 2, possible awareness: 19 versus 8) compared with the end-tidal monitoring group. There were no differences between the groups in the amount of anesthesia administered or the incidence of other postoperative adverse outcomes.",
"   </p>",
"   <p>",
"    Using data obtained from the B-Unaware Trial, a general relationship between ETAC and BIS was able to be derived; however, BIS frequently correlated poorly with anesthetic concentration, was often insensitive to changes in anesthetic concentration, and there was wide interindividual variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/65\">",
"     65",
"    </a>",
"    ]. One interpretation of these results is that BIS is limited in guiding anesthetic maintenance. However, similar limitations probably apply to other depth-of-anesthesia indices. &nbsp;",
"   </p>",
"   <p>",
"    Although the B-Unaware and BAG-RECALL trials do not establish the superiority of the BIS over ETAC monitoring, a lower than expected incidence of AWR (compared with historical incidence) occurred with either form of monitoring in both studies, suggesting an efficacy of either monitoring protocol in high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/22,64\">",
"     22,64",
"    </a>",
"    ]. The Michigan Awareness Control Study, which assessed AWR in surgical patients not pre-selected for risk of awareness, was also unable to detect a difference between BIS and ETAC alert protocols in preventing AWR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/66\">",
"     66",
"    </a>",
"    ]. By post hoc analysis, the BIS appeared to be superior to routine care (without alert protocols); a similar analysis was not done for ETAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006, the American Society of Anesthesiologists (ASA) reviewed the available data and concluded that the utility of routine brain monitoring, and preemptive use of benzodiazepines, are not sufficiently established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34504/abstract/21\">",
"     21",
"    </a>",
"    ]. The ASA advises:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify risk factors for AWR. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Utilize a checklist protocol for anesthesia machines and equipment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Anesthetic underdosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use a brain monitor only in selected patients, but do not allow the maintenance of monitor parameters to conflict with other important anesthesia objectives. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Depth of anesthesia monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administer benzodiazepines intraoperatively at the detection of an awareness event on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Adjunctive medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2012, the",
"    <a class=\"external\" href=\"file://publications.nice.org.uk/depth-of-anaesthesia-monitors-bispectral-index-bis-e-entropy-and-narcotrend-compact-m-dg6\">",
"     National Institute for Health and Clinical Excellence (NICE)",
"    </a>",
"    , in the United Kingdom, issued recommendations on the use of electroencephalography (EEG)-based depth of anesthesia monitors. They recommended an EEG-based monitor be considered as an option for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher risk of AWR (eg, high opiate or alcohol use history, airway problems, prior AWR, concomitant use of muscle relaxants)",
"     </li>",
"     <li>",
"      Tendency toward hemodynamic instability at typical anesthetic doses (eg, older patients, those with comorbidities, those having certain types of surgery)",
"     </li>",
"     <li>",
"      Higher risk from deep levels of anesthesia (eg, older patients, those with liver disease, high body mass index, poor cardiovascular function)",
"     </li>",
"     <li>",
"      Receiving total intravenous anesthesia (TIVA), based on inability to measure end-tidal anesthetic concentration, and on cost-effectiveness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Awareness with recall (AWR) refers to both intraoperative consciousness and explicit recall of intraoperative events. An explicit query about awareness events both postoperatively and at follow-up surgical evaluation should be performed to identify this problem and initiate support. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraoperative awareness events occur more frequently than the postoperative recall of these events. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Memory and recall'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One-third to two-thirds of patients with AWR develop psychological sequelae. Early recognition of AWR is important in order to provide supportive psychological counseling. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Sequelae'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anesthetic underdosing is a major factor increasing the risk for AWR and can be due to technical, surgical, or patient-related factors. The use of total intravenous anesthesia or neuromuscular blockade also increases AWR risk. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient-related factors increasing the incidence of AWR include both genetic and acquired resistance to anesthesia. When these specific risk factors are identified, the anesthetic dose should be increased. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although neuromuscular blockade is often preferred to maintain a quiet operative field, we avoid the use of neuromuscular blocking agents whenever possible. These agents interfere with the ability to detect awakening and may increase the risk of long-term psychological sequelae when an awareness event has occurred. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neuromuscular blockade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients, whenever possible, we suggest minimum alveolar concentration (ie, MAC) monitoring with alarms for low concentration (eg, 0.7 MAC) to prevent premature emergence from anesthesia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Minimum alveolar concentration monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a prior episode of AWR, we suggest brain monitoring (unprocessed or processed EEG monitoring) in addition to MAC monitoring (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients",
"      <strong>",
"       at high risk for AWR",
"      </strong>",
"      (eg, cardiac, trauma, or obstetric surgery) undergoing inhalational anesthesia, we suggest setting a suitable low alarm (eg, 0.7 MAC) for exhaled anesthetic gas",
"      <strong>",
"       or",
"      </strong>",
"      using a brain monitor with an appropriately set audible alarm limit (eg, BIS&gt;60) over no monitoring (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Efficacy of preventive strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing total intravenous anesthesia (TIVA) with administration of neuromuscular blockers, we suggest brain monitoring (eg, with unprocessed EEG or processed EEG), over no monitoring as a strategy to prevent AWR (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contributing factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Efficacy of preventive strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/1\">",
"      Sandin RH, Enlund G, Samuelsson P, Lennmarken C. Awareness during anaesthesia: a prospective case study. Lancet 2000; 355:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/2\">",
"      Sebel PS, Bowdle TA, Ghoneim MM, et al. The incidence of awareness during anesthesia: a multicenter United States study. Anesth Analg 2004; 99:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/3\">",
"      Moerman N, Bonke B, Oosting J. Awareness and recall during general anesthesia. Facts and feelings. Anesthesiology 1993; 79:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/4\">",
"      Samuelsson P, Brudin L, Sandin RH. Late psychological symptoms after awareness among consecutively included surgical patients. Anesthesiology 2007; 106:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/5\">",
"      Esaki RK, Mashour GA. Levels of consciousness during regional anesthesia and monitored anesthesia care: patient expectations and experiences. Anesth Analg 2009; 108:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/6\">",
"      Kent CD, Mashour GA, Metzger NA, et al. Psychological impact of unexpected explicit recall of events occurring during surgery performed under sedation, regional anaesthesia, and general anaesthesia: data from the Anesthesia Awareness Registry. Br J Anaesth 2013; 110:381.",
"     </a>",
"    </li>",
"    <li>",
"     Kelz MB, Mashour GA, Abel T, Maze M. Sleep, memory, and consciousness. In: Miller's Anesthesia, 7th ed, Miller RD, Fleisher LA, Wiener-Kronish JP, Young WL (Eds), Elsevier, 2009. p.237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/8\">",
"      Milner B. The medial temporal-lobe amnesic syndrome. Psychiatr Clin North Am 2005; 28:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/9\">",
"      Kerssens C, Klein J, Bonke B. Awareness: Monitoring versus remembering what happened. Anesthesiology 2003; 99:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/10\">",
"      Mashour GA, Wang LY, Turner CR, et al. A retrospective study of intraoperative awareness with methodological implications. Anesth Analg 2009; 108:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/11\">",
"      Orser BA, Mazer CD, Baker AJ. Awareness during anesthesia. CMAJ 2008; 178:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/12\">",
"      Pollard RJ, Coyle JP, Gilbert RL, Beck JE. Intraoperative awareness in a regional medical system: a review of 3 years' data. Anesthesiology 2007; 106:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/13\">",
"      Errando CL, Sigl JC, Robles M, et al. Awareness with recall during general anaesthesia: a prospective observational evaluation of 4001 patients. Br J Anaesth 2008; 101:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/14\">",
"      Xu L, Wu AS, Yue Y. The incidence of intra-operative awareness during general anesthesia in China: a multi-center observational study. Acta Anaesthesiol Scand 2009; 53:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/15\">",
"      Pandit JJ, Cook TM, Jonker WR, et al. A national survey of anaesthetists (NAP5 Baseline) to estimate an annual incidence of accidental awareness during general anaesthesia in the UK. Br J Anaesth 2013; 110:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/16\">",
"      Mashour GA, Kent C, Picton P, et al. Brief report: assessment of intraoperative awareness with explicit recall: a comparison of 2 methods. Anesth Analg 2013; 116:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/17\">",
"      Davidson AJ, Smith KR, Bluss&eacute; van Oud-Alblas HJ, et al. Awareness in children: a secondary analysis of five cohort studies. Anaesthesia 2011; 66:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/18\">",
"      Davidson AJ, Huang GH, Czarnecki C, et al. Awareness during anesthesia in children: a prospective cohort study. Anesth Analg 2005; 100:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/19\">",
"      Bluss&eacute; van Oud-Alblas HJ, van Dijk M, Liu C, et al. Intraoperative awareness during paediatric anaesthesia. Br J Anaesth 2009; 102:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/20\">",
"      Ghoneim MM, Block RI, Haffarnan M, Mathews MJ. Awareness during anesthesia: risk factors, causes and sequelae: a review of reported cases in the literature. Anesth Analg 2009; 108:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/21\">",
"      American Society of Anesthesiologists Task Force on Intraoperative Awareness. Practice advisory for intraoperative awareness and brain function monitoring: a report by the american society of anesthesiologists task force on intraoperative awareness. Anesthesiology 2006; 104:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/22\">",
"      Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the bispectral index. N Engl J Med 2008; 358:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/23\">",
"      Morimoto Y, Nogami Y, Harada K, et al. Awareness during anesthesia: the results of a questionnaire survey in Japan. J Anesth 2011; 25:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/24\">",
"      Zhang C, Xu L, Ma YQ, et al. Bispectral index monitoring prevent awareness during total intravenous anesthesia: a prospective, randomized, double-blinded, multi-center controlled trial. Chin Med J (Engl) 2011; 124:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/25\">",
"      Perl T, Carstens E, Hirn A, et al. Determination of serum propofol concentrations by breath analysis using ion mobility spectrometry. Br J Anaesth 2009; 103:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/26\">",
"      Soehle M, Kuech M, Grube M, et al. Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. Br J Anaesth 2010; 105:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/27\">",
"      Grasshoff C, Rudolph U, Antkowiak B. Molecular and systemic mechanisms of general anaesthesia: the 'multi-site and multiple mechanisms' concept. Curr Opin Anaesthesiol 2005; 18:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/28\">",
"      Barr G, Anderson RE, Owall A, Jakobsson JG. Being awake intermittently during propofol-induced hypnosis: a study of BIS, explicit and implicit memory. Acta Anaesthesiol Scand 2001; 45:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/29\">",
"      Alkire MT, Gorski LA. Relative amnesic potency of five inhalational anesthetics follows the Meyer-Overton rule. Anesthesiology 2004; 101:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/30\">",
"      Cheng VY, Martin LJ, Elliott EM, et al. Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci 2006; 26:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/31\">",
"      Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004; 101:279.",
"     </a>",
"    </li>",
"    <li>",
"     Flockhart D. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine 2007. file://medicine.iupui.edu/clinpharm/ddis/table.asp (Accessed on July 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/33\">",
"      Chin KJ, Yeo SW. Bispectral index values at sevoflurane concentrations of 1% and 1.5% in lower segment cesarean delivery. Anesth Analg 2004; 98:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/34\">",
"      Chin KJ, Yeo SW. A BIS-guided study of sevoflurane requirements for adequate depth of anaesthesia in Caesarean section. Anaesthesia 2004; 59:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/35\">",
"      Paech MJ, Scott KL, Clavisi O, et al. A prospective study of awareness and recall associated with general anaesthesia for caesarean section. Int J Obstet Anesth 2008; 17:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/36\">",
"      Lennmarken C, Sydsjo G. Psychological consequences of awareness and their treatment. Best Pract Res Clin Anaesthesiol 2007; 21:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/37\">",
"      Osterman JE, Hopper J, Heran WJ, et al. Awareness under anesthesia and the development of posttraumatic stress disorder. Gen Hosp Psychiatry 2001; 23:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/38\">",
"      Domino KB, Posner KL, Caplan RA, Cheney FW. Awareness during anesthesia: a closed claims analysis. Anesthesiology 1999; 90:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/39\">",
"      Schwender D, Kunze-Kronawitter H, Dietrich P, et al. Conscious awareness during general anaesthesia: patients' perceptions, emotions, cognition and reactions. Br J Anaesth 1998; 80:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/40\">",
"      Lennmarken C, Bildfors K, Enlund G, et al. Victims of awareness. Acta Anaesthesiol Scand 2002; 46:229.",
"     </a>",
"    </li>",
"    <li>",
"     Snow JD. On the inhalation of the vapour of ether in surgical operations, 1st ed, John Churchill (Ed), London 1847.",
"    </li>",
"    <li>",
"     Guedel A. Inhalation Anaesthesia: A Fundamental Guide, Macmillan, New York 1937.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/43\">",
"      Griffith HR, Johnson GE. The Use of Curare in General Anesthesia. Anesthesiology 1942; 3:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/44\">",
"      Eger EI 2nd, Saidman LJ, Brandstater B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 1965; 26:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/45\">",
"      Antognini JF, Schwartz K. Exaggerated anesthetic requirements in the preferentially anesthetized brain. Anesthesiology 1993; 79:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/46\">",
"      Myles PS, Leslie K, McNeil J, et al. Bispectral index monitoring to prevent awareness during anaesthesia: the B-Aware randomised controlled trial. Lancet 2004; 363:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/47\">",
"      Eger EI 2nd. Age, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awake. Anesth Analg 2001; 93:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/48\">",
"      Nickalls RW, Mapleson WW. Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. Br J Anaesth 2003; 91:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/49\">",
"      Smith C, McEwan AI, Jhaveri R, et al. The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. Anesthesiology 1994; 81:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/50\">",
"      Punjasawadwong Y, Boonjeungmonkol N, Phongchiewboon A. Bispectral index for improving anaesthetic delivery and postoperative recovery. Cochrane Database Syst Rev 2007; :CD003843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/51\">",
"      Bennett C, Voss LJ, Barnard JP, Sleigh JW. Practical use of the raw electroencephalogram waveform during general anesthesia: the art and science. Anesth Analg 2009; 109:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/52\">",
"      Rampil IJ. A primer for EEG signal processing in anesthesia. Anesthesiology 1998; 89:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/53\">",
"      Scheller B, Schneider G, Daunderer M, et al. High-frequency components of auditory evoked potentials are detected in responsive but not in unconscious patients. Anesthesiology 2005; 103:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/54\">",
"      Schneider G, Hollweck R, Ningler M, et al. Detection of consciousness by electroencephalogram and auditory evoked potentials. Anesthesiology 2005; 103:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/55\">",
"      Bruhn J, Myles PS, Sneyd R, Struys MM. Depth of anaesthesia monitoring: what's available, what's validated and what's next? Br J Anaesth 2006; 97:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/56\">",
"      Bowdle TA. Depth of anesthesia monitoring. Anesthesiol Clin 2006; 24:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/57\">",
"      Voss L, Sleigh J. Monitoring consciousness: the current status of EEG-based depth of anaesthesia monitors. Best Pract Res Clin Anaesthesiol 2007; 21:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/58\">",
"      Ghouri AF, White PF. Effect of fentanyl and nitrous oxide on the desflurane anesthetic requirement. Anesth Analg 1991; 72:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/59\">",
"      McEwan AI, Smith C, Dyar O, et al. Isoflurane minimum alveolar concentration reduction by fentanyl. Anesthesiology 1993; 78:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/60\">",
"      Katoh T, Kobayashi S, Suzuki A, et al. The effect of fentanyl on sevoflurane requirements for somatic and sympathetic responses to surgical incision. Anesthesiology 1999; 90:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/61\">",
"      Puri GD, Murthy SS. Bispectral index monitoring in patients undergoing cardiac surgery under cardiopulmonary bypass. Eur J Anaesthesiol 2003; 20:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/62\">",
"      Ekman A, Lindholm ML, Lennmarken C, Sandin R. Reduction in the incidence of awareness using BIS monitoring. Acta Anaesthesiol Scand 2004; 48:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/63\">",
"      Liu SS. Effects of Bispectral Index monitoring on ambulatory anesthesia: a meta-analysis of randomized controlled trials and a cost analysis. Anesthesiology 2004; 101:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/64\">",
"      Avidan MS, Jacobsohn E, Glick D, et al. Prevention of intraoperative awareness in a high-risk surgical population. N Engl J Med 2011; 365:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/65\">",
"      Whitlock EL, Villafranca AJ, Lin N, et al. Relationship between bispectral index values and volatile anesthetic concentrations during the maintenance phase of anesthesia in the B-Unaware trial. Anesthesiology 2011; 115:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34504/abstract/66\">",
"      Mashour GA, Shanks A, Tremper KK, et al. Prevention of intraoperative awareness with explicit recall in an unselected surgical population: a randomized comparative effectiveness trial. Anesthesiology 2012; 117:717.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 400 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-84F5313BFF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34504=[""].join("\n");
var outline_f33_44_34504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEMORY AND RECALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anesthetic underdosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Technical issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Total intravenous anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Resistance to anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anesthesia-related medical risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neuromuscular blockade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STRATEGIES FOR PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Depth of anesthesia monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Minimum alveolar concentration monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Brain monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adjunctive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Efficacy of preventive strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/31/22014\" title=\"table 1\">",
"      Processed EEG brain monitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_44_34505="Treatment of Chlamydia trachomatis infection";
var content_f33_44_34505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Chlamydia trachomatis infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34505/contributors\">",
"     Jeanne Marrazzo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34505/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34505/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/44/34505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydia trachomatis, a small gram-negative bacterium, is the most common cause of bacterial sexually transmitted disease (STD) in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/1\">",
"     1",
"    </a>",
"    ]. A significant proportion of patients are asymptomatic, thereby providing an ongoing reservoir for infection. The most frequent clinical manifestation of chlamydial infection in men is urethritis, while the most common finding in women is cervicitis.",
"   </p>",
"   <p>",
"    The treatment of urethritis, cervicitis, proctitis, and epididymitis secondary to C. trachomatis infection will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of these diseases, as well as other types of C. trachomatis-related diseases, such as pelvic inflammatory disease, reactive arthritis, lymphogranuloma venereum, and endemic trachoma (an ocular infection seen commonly in the developing world), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8409?source=see_link\">",
"     \"Epidemiology, diagnosis, and management of trachoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevent complicated infections related to chlamydia and their sequelae (eg, pelvic inflammatory disease, infertility, ectopic pregnancy, epididymitis).",
"     </li>",
"     <li>",
"      Decrease the risk of transmission to others; this includes sexual partners and infants at delivery, the latter group at risk of acquiring ocular chlamydial infection from an infected mother. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27992?source=see_link\">",
"       \"Chlamydia trachomatis infections in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attain resolution of symptoms; between 83 and 86 percent of symptomatic patients with cervicitis or urethritis improve clinically within two weeks of starting treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H230641\">",
"    <span class=\"h2\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete care of the patient presenting with a chlamydial infection should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active antimicrobial therapy (see",
"      <a class=\"local\" href=\"#H5623059\">",
"       'Available agents for chlamydia'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Directed or empiric therapy for concomitant gonococcal infection, if appropriate (see",
"      <a class=\"local\" href=\"#H60698042\">",
"       'Coinfection with gonorrhea'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H5622636\">",
"       'Indications for empiric therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Counseling for HIV testing (see",
"      <a class=\"local\" href=\"#H343045\">",
"       'HIV counseling and testing'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Counseling to return for persistent or recurrent symptoms (see",
"      <a class=\"local\" href=\"#H342755\">",
"       'Persistent or recurrent symptoms'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Retesting to evaluate for recurrent infection (see",
"      <a class=\"local\" href=\"#H8751131\">",
"       'Retesting'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Evaluation and treatment of sexual partners (see",
"      <a class=\"local\" href=\"#H43\">",
"       'Management of sex partners'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5622559\">",
"    <span class=\"h1\">",
"     TREATMENT OF UNCOMPLICATED GENITAL CHLAMYDIA INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncomplicated genital chlamydial infections include urethritis in men and urethritis and cervicitis in women. The majority of uncomplicated genital chlamydial infections are asymptomatic in men and women; these infections may only be found after screening, but should be treated promptly as suggested below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We typically suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram single-dose therapy) with observed therapy when possible. If cost is an issue, then we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) in the nonpregnant patient for seven days with patient counseling on the need for adherence for optimal outcome. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60697861\">",
"    <span class=\"h2\">",
"     Impact of life cycle on antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of C. trachomatis infection requires special consideration, largely due to its rather unique life cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infectious form of the organism, the extracellular elementary body, is metabolically inert and resistant to killing. Thus, antibiotics must target the sequestered intracellular and intravacuolar phases of the life cycle of this pathogen. For this reason, antibiotics with good intracellular penetration must be used.",
"   </p>",
"   <p>",
"    In addition, antibiotic concentrations must be present throughout the entire 36- to 48-hour life cycle of the organism. Thus, either a prolonged course of therapy or selection of an antibiotic with a long half-life is required to ensure adequate levels of the antibiotic agent.",
"   </p>",
"   <p>",
"    Antibiotic resistance appears to be exceedingly rare. The intracellular nature of the pathogen eliminates the opportunity for rapid evolution of cell surface components that could contribute to drug resistance. Furthermore, the elementary body is relatively inert, which limits opportunities for replication and the generation of antibiotic-resistant mutations. These features may also explain the paucity of inflammatory responses and the asymptomatic nature of most chlamydial infections. (See",
"    <a class=\"local\" href=\"#H342789\">",
"     'Drug resistance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623059\">",
"    <span class=\"h2\">",
"     Available agents for chlamydia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623486\">",
"    <span class=\"h3\">",
"     Antibiotic efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To be considered effective for a sexually transmitted disease, an antibiotic agent should achieve a microbiologic cure in more than 95 percent of treated patients. Microbial cure is a more reliable parameter for drug efficacy than clinical cure for 2 reasons: 1) a significant proportion of patients may have other coinfections that will not respond to the administered drug and 2) most patients have no clinical manifestations at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623067\">",
"    <span class=\"h3\">",
"     First-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, C. trachomatis is highly susceptible to tetracyclines and macrolides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/3\">",
"     3",
"    </a>",
"    ]. Within these two classes, first-line agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , respectively.",
"   </p>",
"   <p>",
"    A meta-analysis of twelve randomized trials including 1543 patients compared the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    for the treatment of uncomplicated genital chlamydial infections in men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/4\">",
"     4",
"    </a>",
"    ]. Microbial cure rates were similar between both agents (97 and 98 percent for azithromycin and doxycycline, respectively). It should be noted that microbiological cure in these earlier studies was documented with culture or enzyme immunoassay testing rather than the more sensitive nucleic acid amplification technique (NAAT) assay, which is preferred today.",
"   </p>",
"   <p>",
"    Adverse events occurred in approximately one-quarter of the patient population in both treatment arms. The most frequently reported adverse events were gastrointestinal in nature and included diarrhea, abdominal pain, nausea and vomiting, and dyspepsia; no serious adverse events were reported.",
"   </p>",
"   <p>",
"    Based on these data, the Centers for Disease Control and Prevention (CDC) recommend either agent as first-line therapy for the treatment of chlamydial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ]. When cost is not a factor, we prefer the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram single-dose therapy) with observed therapy when possible. If cost is an issue, then we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) for seven days with patient counseling on the need for adherence for optimal outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623074\">",
"    <span class=\"h4\">",
"     Advantages of azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    has excellent intracellular and tissue penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/6\">",
"     6",
"    </a>",
"    ]. Due to its half-life of five to seven days, azithromycin can be administered as single-dose therapy (1 gram orally) under direct observation. It can be used in pregnant women (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Pregnant women'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Providing single-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    on-site at the time of diagnosis, if possible, is strongly recommended to ensure compliance and to decrease the risk of complicated infection, such as pelvic inflammatory disease. This is particularly important when asymptomatic chlamydial infection is detected as part of routine screening, since it is unclear how long the patient may have been infected. In one study of 4158 women with positive screening tests for C. trachomatis, only 24 percent were treated presumptively on the day of their visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/7\">",
"     7",
"    </a>",
"    ]. Treatment was ultimately administered in 96 percent of the remaining patients but at a median interval of 21 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623081\">",
"    <span class=\"h4\">",
"     Advantages of doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is its lower cost per treatment course compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . Whether patients will be compliant with seven full days of twice-daily dosing is a relevant concern (see",
"    <a class=\"local\" href=\"#H343008\">",
"     'Patient counseling'",
"    </a>",
"    below). However, whether seven full days of twice-daily dosing is required for clinical cure is unclear since microbiologic cures have been attained in patients with suboptimal adherence to a seven-day regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623088\">",
"    <span class=\"h3\">",
"     Alternative therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623096\">",
"    <span class=\"h4\">",
"     Quinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quinolones",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    are both highly effective against C. trachomatis but require a full week of therapy and are considerably more costly than either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . Furthermore, these drugs cannot be used in pregnancy or lactation and should not be administered to adolescents younger than 18 years of age due to concerns regarding bone abnormalities. Other quinolones, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , are either less effective or have not been tested against C. trachomatis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    are recognized as alternative therapies in the fluoroquinolone class by the CDC; dose is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"       Ofloxacin",
"      </a>",
"      300 mg orally twice daily for seven days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      500 mg orally once daily for seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We rarely use quinolones to treat C. trachomatis, but they are alternative options for the nonpregnant patient who cannot tolerate one of the first-line therapies. These medications played a more important therapeutic role in the past when they were used to provide concomitant coverage for both gonococcal and chlamydial infections, which can coexist. However, due to the emergence of quinolone drug resistance, these drugs can no longer be considered adequate coverage for Neisseria gonorrhoeae. (See",
"    <a class=\"local\" href=\"#H60698042\">",
"     'Coinfection with gonorrhea'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623103\">",
"    <span class=\"h4\">",
"     Erythromycins and penicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;These alternative regimens are notably inferior in their ability to affect microbial cure, with cure rates in the range of 85 to 89 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Their primary use is in pregnant women who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . When these agents are used, test of cure should be performed to ensure microbiologic eradication. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Test of cure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623110\">",
"    <span class=\"h3\">",
"     Agents with limited activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfonamides and cephalosporins have limited activity and should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60698042\">",
"    <span class=\"h2\">",
"     Coinfection with gonorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydial and gonococcal infections may coexist in a significant percentage of community patients, which has a direct impact on treatment since first-line agents for C. trachomatis, in the dosage forms recommended, do not have adequate activity against gonococci. A single injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg) cures the majority of uncomplicated gonococcal urogenital, anorectal, and pharyngeal infections. Ceftriaxone can also be used during pregnancy. Other treatment options for gonorrhea are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In certain high-risk populations, such as adolescents entering juvenile detention centers, coinfection rates as high as 50 percent have been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, in a study of more than 14,000 young adults aged 18 to 26 years in the general community, the overall prevalence of chlamydia was 4.1 percent; the rates of concomitant gonococcal infection among those with chlamydia were 7.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, while it is important to confirm if Neisseria gonorrhoeae may coexist in patients with a diagnosis of chlamydial infection, presumptive therapy for gonorrhea is not routinely indicated for all patients.",
"   </p>",
"   <p>",
"    Additional treatment for gonorrhea should be based on the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In men, treatment should be initiated if the clinician detects intracellular Gram-negative diplococci on a Gram stain of urethral discharge, which have a high degree of sensitivity and specificity for gonococci.",
"     </li>",
"     <li>",
"      The Gram stain is less helpful in women since nonpathogenic Neisseria species may be present in vaginal flora. The decision to empirically treat N. gonorrhoeae in women should be based upon significant concern for gonococcal infection based on individual risk (eg, partner with new diagnosis of gonorrhea) or high local prevalence rates of gonorrhea (eg, greater than 5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"       5",
"      </a>",
"      ]. This type of information is obtained by calling your local public health department.",
"     </li>",
"     <li>",
"      If Neisseria gonorrhoeae infection is subsequently documented on NAAT, additional directed therapy for gonococcal infection must be given as well, even if the patient is asymptomatic. If diagnostic testing with a NAAT is negative, no additional therapy is necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5622636\">",
"    <span class=\"h2\">",
"     Indications for empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for chlamydial infection should be offered to persons who present with symptoms suggestive of infection (cervicitis, pelvic inflammatory disease, urethritis) if follow-up cannot be ensured and if relatively insensitive diagnostic testing is being used (eg, culture rather than nucleic acid amplification testing). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link&amp;anchor=H22688671#H22688671\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Diagnosis of chlamydial infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H2014238#H2014238\">",
"     \"Acute cervicitis\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a recent known or possible sexual exposure to chlamydia should also be offered empiric therapy. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Management of sex partners'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link&amp;anchor=H4057931#H4057931\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Patients with recent exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, empiric therapy for chlamydia should be given to patients with documented gonococcal infection, unless nucleic acid amplification testing is negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=see_link&amp;anchor=H23#H23\">",
"     \"Disseminated gonococcal infection\", section on 'Concurrent treatment for Chlamydial infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=see_link&amp;anchor=H1115841#H1115841\">",
"     \"Treatment of uncomplicated gonococcal infections\", section on 'Approach to treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF OTHER CHLAMYDIAL INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chlamydial proctitis, defined as inflammation of the distal rectal mucosa that can cause anorectal pain, rectal discharge, or tenesmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/12\">",
"     12",
"    </a>",
"    ], is relatively uncommon and occurs almost exclusively in men who have sex with men (MSM) who have had receptive rectal intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Chlamydial proctitis may be caused by either the common genital strains of C. trachomatis (serovars D-K) that typically cause uncomplicated genital infection in men and women or the lymphogranuloma venereum (LGV) strains (serovars L1, L2, L3), which can cause severe disease (eg, abundant bloody or mucopurulent discharge, severe pain with defecation, fever) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=see_link\">",
"     \"Lymphogranuloma venereum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link&amp;anchor=H22688649#H22688649\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Proctitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data regarding the best treatment approach for acute proctitis. In the largest trial, published in 1988, 129 MSM were randomly assigned to either empiric therapy for both chlamydia and gonorrhea or directed treatment after laboratory testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients assigned to the empiric therapy arm had more rapid resolution of symptoms; however, the findings of the study were limited by patient attrition and the use of antibiotics that are not currently administered for these indications due to high rates of drug resistance.",
"   </p>",
"   <p>",
"    Another issue is that sensitive nucleic acid amplification testing (NAAT) testing is not widely used on rectal specimens, although some laboratories have validated this method; other methods are less sensitive and may lead to underdiagnosis of both C. trachomatis and N. gonorrhoeae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link&amp;anchor=H22688671#H22688671\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Diagnosis of chlamydial infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, empiric therapy for both chlamydia and gonorrhea is indicated for the treatment of patients with acute proctitis. An empiric regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) plus a single intramuscular dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg) are recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ]. The duration of doxycycline therapy will depend on the severity of symptoms. For patients with mild proctitis, seven days of therapy is adequate. Patients with severe proctitis may have lymphogranuloma venereum infection, which requires a full three-week course of doxycycline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Epididymitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. gonorrhoeae or C. trachomatis are the most frequent pathogens in epididymitis among sexually active men &lt;35 years of age. Symptoms include unilateral testicular pain; signs include tenderness and palpable swelling of the epididymis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link&amp;anchor=H22688635#H22688635\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Epididymitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because symptoms of epididymitis are often severe and improve rapidly with timely antibiotic treatment, empiric therapy for both gonococcal and chlamydial infection is indicated before diagnostic studies are available. The Centers for Disease control and Prevention (CDC) guidelines recommend the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (250 mg intramuscular as a single dose) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice daily) for 10 days for the treatment of acute epididymitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     Ofloxacin",
"    </a>",
"    (300 mg orally twice daily for 10 days) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg daily for 10 days) should be administered for patients with epididymitis who are allergic to cephalosporins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tetracyclines. Outpatient treatment is usually sufficient except for patients who appear toxic with a high fever or in those in whom severe pain necessitates the exclusion of another diagnosis such as testicular torsion or infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623758\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cervical infection is untreated, C. trachomatis ascends to the upper genital tract at least 20 percent of the time, which may manifest as either silent infection (\"subclinical\" pelvic inflammatory disease [PID], or silent endometritis) or overt PID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Therefore, women with cervicitis should undergo a physical examination to exclude signs of upper tract disease (eg, cervical motion, uterine, or adnexal tenderness). Apart from direct involvement of the pelvic organs, PID can also include peritonitis and inflammation of the liver capsule (Fitzhugh-Curtis syndrome). Treatment for PID should provide broad coverage for the wide array of implicated pathogens, including antibiotics active against C. trachomatis, most commonly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . The management of PID is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5623402\">",
"    <span class=\"h2\">",
"     Oropharyngeal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of oropharyngeal chlamydia and the transmissibility of this infection are unclear. The optimal treatment regimen is also unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ]. In the absence of available data, most experts recommend that a positive test result be treated with a regimen active against genital chlamydial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5624097\">",
"    <span class=\"h1\">",
"     TREATMENT IN SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of chlamydia during pregnancy prevents transmission of C. trachomatis to infants through the birth canal. The recommended regimens for treatment of the pregnant female are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (1 gram orally given as a single dose) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg orally three times daily for seven days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who cannot tolerate either of these regimens should be treated with one of four",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    regimens, as follows. In general, erythromycins are associated with a high degree of gastrointestinal complaints (primarily nausea). The lower dose 14-day regimens may be helpful for women who cannot tolerate higher doses of erythromycin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      base 500 mg orally four times daily for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      base 250 mg orally four times daily for 14 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      ethylsuccinate 800 mg orally four times daily for 7 days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      ethylsuccinate 400 mg orally four times daily for 14 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women who present in labor and were not treated for a prior positive chlamydial screening test should be treated immediately with one of the above regimens. However, this may not substantially decrease the risk of transmission of chlamydia to the newborn. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27992?source=see_link&amp;anchor=H4#H4\">",
"     \"Chlamydia trachomatis infections in the newborn\", section on 'Risk of transmission'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27992?source=see_link&amp;anchor=H21#H21\">",
"     \"Chlamydia trachomatis infections in the newborn\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    estolate are contraindicated in pregnancy and lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5348136\">",
"    <span class=\"h3\">",
"     Test of cure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cure rates of chlamydia in women who are pregnant are generally lower than in nonpregnant females, particularly with the alternative agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    . For this reason, a test of cure is recommended for all pregnant women and should be performed no earlier than three weeks after treatment is initiated. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Patient follow-up: Test of cure versus retesting'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HIV-infected patients with chlamydial infections is the same as in HIV-seronegative patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343008\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343031\">",
"    <span class=\"h2\">",
"     Medication adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to educate the patient regarding treatment adherence, particularly if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is prescribed. One study of men and women with uncomplicated genital chlamydial infection evaluated medication compliance with doxycycline by administering medications through an electronic medication system where all pill box openings were electronically recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/18\">",
"     18",
"    </a>",
"    ]. Eighty percent of 223 patients returned their pill bottles for assessment. Patients were considered strictly compliant if they had opened their bottles for at least 12 of 14 doses; only 25 percent of the patients demonstrated this level of adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343038\">",
"    <span class=\"h2\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled to avoid sexual activity until seven days after initiating treatment; they may subsequently resume having sex provided that their symptoms have resolved and their sex partners have been treated. Persistence of symptoms may indicate infection with an additional pathogen (eg, Trichomonas vaginalis), reinfection, or incomplete adherence to the therapeutic regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343045\">",
"    <span class=\"h2\">",
"     HIV counseling and testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sexually transmitted diseases are at increased risk of acquiring HIV infection and should be offered HIV testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343072\">",
"    <span class=\"h2\">",
"     Pregnancy testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with chlamydial infection should undergo pregnancy testing. This is particularly important if treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP: TEST OF CURE VERSUS RETESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two different strategies for testing for chlamydia after treatment, including &ldquo;test of cure&rdquo;, which is performed no earlier than three weeks after treatment, or &ldquo;retesting&rdquo;, which is performed approximately three months after treatment of infection, or if this is not possible, at the first visit thereafter within 12 months of treatment.",
"   </p>",
"   <p>",
"    A test of cure should be obtained in pregnant women, patients with persistent symptoms, and patients who were treated with suboptimal antibiotic regimens, whereas retesting should be performed routinely on all patients with documented chlamydial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8751131\">",
"    <span class=\"h2\">",
"     Retesting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retesting is performed on all patients with documented chlamydial infection for the express purpose of evaluating whether a patient has been reinfected. Epidemiologic studies have documented that persons with chlamydial infection often have a history of recent treated infection in the preceding months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. A systematic review of 38 studies of women with C. trachomatis reported a median reinfection rate of 14 percent (range, 0 to 32 percent); higher rates were associated with younger age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/22\">",
"     22",
"    </a>",
"    ]. Similarly, in a study of over 144,000 positive chlamydia tests performed at a single large laboratory in the United States, the rates of repeat positive tests were 16, 14, and 15 percent among men, nonpregnant and pregnant women, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/23\">",
"     23",
"    </a>",
"    ]. Retesting is particularly important in the pregnant woman since recurrent infection could put the infant at risk of C. trachomatis ocular infection at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of recurrent chlamydial infections result from resumption of unprotected sex with an untreated sex partner, though some do result from sex with a new sex partner. In women, repeat infections confer an increased risk of developing complicated genital infections, such as pelvic inflammatory disease. Thus, recently infected persons should have repeat testing for C. trachomatis infection approximately three to six months after treatment, regardless of whether patients believe their sex partners were treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Test of cure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A &ldquo;test of cure&rdquo; is defined as diagnostic testing performed for the express purpose of assessing whether the administered antibiotic regimen eradicated the pathogen. Since cure rates of lower genital tract infection are generally high (&gt;95 percent) in compliant, nonpregnant patients who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , a test of cure is not indicated for these patients.",
"   </p>",
"   <p>",
"    Indications for test of cure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Persistent symptoms",
"     </li>",
"     <li>",
"      Use of a regimen with inferior cure rates, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these situations, test of cure should be performed no earlier than three weeks after treatment is completed. This is especially important when nucleic acid amplification tests (NAAT) are used, as they may be positive in the presence of dead organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342755\">",
"    <span class=\"h1\">",
"     PERSISTENT OR RECURRENT SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that patients be counseled to monitor for symptom resolution and return for evaluation of persistent or recurrent symptoms. Persistent symptoms in patients with confirmed chlamydial infection after appropriate therapy with good adherence are usually not due to primary treatment failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A detailed prospective evaluation of 20 women with culture-proven and polymerase chain reaction (PCR)-proven C. trachomatis urogenital infections was performed to assess the incidence of persistent infection after treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/24\">",
"       24",
"      </a>",
"      ]. After five months of serial sampling with PCR, culture, and serial measurements of local and systemic antibody to C. trachomatis, no evidence of persistent infection was documented.",
"     </li>",
"     <li>",
"      One longitudinal prospective study of adolescent females with chlamydia used DNA genotyping and behavioral histories to assess whether repeated chlamydial infections may be related to reinfection versus treatment failure with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/25\">",
"       25",
"      </a>",
"      ]. Of 79 matched-paired samples, 10 were classified as \"probable\" treatment failures. Antibiotic efficacy was estimated to be 92 percent; although this is somewhat lower than the 95 percent target for sexually transmitted disease (STD) eradication, the study illustrates that the vast majority of patients respond to treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent symptoms related to chlamydial infection may be due to reinfection or to infection with another pathogen not optimally treated with the initial antibiotic regimen. Other etiologic agents to consider include Ureaplasma, Mycoplasma genitalium, and genital herpes.",
"   </p>",
"   <p>",
"    In a double-blind trial that randomized 452 men to single-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or a seven-day course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for empiric treatment of nongonococcal urethritis (NGU), cultures were performed for N. gonorrhoeae, C. trachomatis, and U. urealyticum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/26\">",
"     26",
"    </a>",
"    ]. U. urealyticum was found in 127 of 410 patients tested (28 percent); the clinical cure rates were comparable between the azithromycin and doxycycline groups (90 versus 89 percent) regardless of whether C. trachomatis or U. urealyticum were isolated. However, NGU may also be caused by Mycoplasma genitalium, which appears to respond better to azithromycin than doxycycline, although overall clinical eradication rates with azithromycin are low (66 to 89 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with persistent or recurrent symptoms, clinicians should inquire about possible reinfection, including whether sex partners were treated (see",
"    <a class=\"local\" href=\"#H43\">",
"     'Management of sex partners'",
"    </a>",
"    below). The medical history should also assess whether the patient is using vaginal douches or other chemical irritants; such products can provoke a local inflammatory response with subsequent vaginal symptoms that can be confused with infection. Males with chronic prostatitis may also have evidence of chronic urethral inflammation (ie, &gt;5 WBCs per high-powered field), which may be confused with NGU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342782\">",
"    <span class=\"h2\">",
"     Recurrence of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of symptoms after initial resolution should lead to a repeat evaluation for chlamydia and other sexually transmitted diseases that cause urethritis or cervicitis, including gonorrhea, bacterial vaginosis, and other pathogens. Objective signs of urethritis should be present before consideration of re-initiation of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ]. Retreatment should be considered if the patient was not adherent to the course of antibiotics or was re-exposed to an untreated partner. A repeat diagnosis of chlamydia in a previously treated patient usually indicates reinfection, as noted above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link&amp;anchor=H22688720#H22688720\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\", section on 'Recurrence of symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient has been adherent, and has no history of re-exposure, persistent urethritis after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    may indicate infection with a pathogen that is resistant to doxycycline (eg, Ureaplasma urealyticum or Mycoplasma genitalium). Trichomonas vaginalis can occasionally cause urethritis in males and females. While awaiting a diagnostic work-up, the 2010 Centers for Disease Control and Prevention sexually transmitted disease guidelines recommend [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      2 grams orally in a single dose",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"       Tinidazole",
"      </a>",
"      2 gram orally in a single dose",
"      <br/>",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      1 gram orally in a single dose (if not used for the initial episode)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342789\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistence or recurrence of symptoms should not be attributed to C. trachomatis drug resistance; drug resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    has not been demonstrated to date.",
"   </p>",
"   <p>",
"    Although the swine pathogen, Chlamydia suis, is commonly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    resistant, there are no examples of stable tetracycline resistance in clinical strains of C. trachomatis. One in vitro study was able to demonstrate that a clinical strain of C. trachomatis was able to acquire a resistance element from a C. suis strain within coculture experiments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SEX PARTNERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Issues of reinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex partners are typically asymptomatic and, unless treated, will reinfect the index patient or spread infection to other partners. In fact, rates of reinfection among index cases of women with C. trachomatis range from 15 to 30 percent, and are typically associated with resumption of sex with previously established partners (not new partners) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Low rates of partner assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, sex partners of persons with chlamydial infection should be examined, tested for C. trachomatis and N. gonorrhoeae, treated, and counseled on prevention. Unfortunately, this approach is infrequently successful. The alternative traditional approach of using public health field workers to notify exposed sex partners can be useful, but is costly and is not available in most areas. In lieu of public health advocacy, patients are asked to notify their partners of the need for medical evaluation and treatment. This approach has been deemed a public health failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Expedited partner therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strategy termed \"expedited partner therapy\" (EPT) has been proposed as an alternative way to increase the proportion of sex partners receiving treatment and to decrease rates of reinfection in the index patient. With EPT, treatment (without examination) is facilitated by giving an antibiotic or a prescription to the index patient or by calling in a prescription directly for the partner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. EPT for chlamydia can be accomplished with single-dose oral therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients and sexual partners should be counseled to abstain from sexual activity until the therapeutic course of antibiotics is completed, or in the case of azithromycin, for seven days after the single-dose treatment was administered.",
"   </p>",
"   <p>",
"    In one randomized controlled trial, 2751 patients (23 percent male) with diagnosed gonococcal infection, chlamydial infection, or both were assigned either to an \"expedited treatment group\" or a standard referral group. Patients in the expedited treatment group were given \"partner packets\" of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    to distribute to their partners, without requiring a formal medical evaluation of the partners. In the standard referral arm, patients simply notified their sex partners of the need for evaluation and treatment. Patients assigned to expedited treatment of sexual partners were significantly more likely to report that all of their partners had been treated compared with those assigned to the standard referral arm (61 versus 49 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/33\">",
"     33",
"    </a>",
"    ]. The trial also demonstrated a significant benefit in lowering the number of recurrent infections among those assigned to expedited treatment (relative risk of reinfection 0.75, 95% CI 0.56 to 0.97).",
"   </p>",
"   <p>",
"    The limitations of this approach include lost opportunities for screening and counseling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/34\">",
"     34",
"    </a>",
"    ] and a risk of adverse events related to antibiotic administration. However, the Centers for Disease Control and Prevention consensus is that EPT offers a valuable means to control sexually transmitted diseases and is an option for partner management, although ongoing evaluation of this approach is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34505/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Legal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should routinely employ EPT for the partners of persons with chlamydial infection, to the extent permitted by regional laws and regulations where they are practicing, when follow-up is in question. The legal status of EPT is state specific, although surveys indicate that many clinicians frequently pursue the practice in managing their patients with sexually transmitted infections. The legal status of EPT options can be found at",
"    <a class=\"external\" href=\"file://www.cdc.gov/std/ept\">",
"     www.cdc.gov/std/ept",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SCREENING FOR CHLAMYDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for C. trachomatis is a critically important tool in the control of this infection, and is discussed in a separate section. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=see_link\">",
"     \"Screening for Chlamydia trachomatis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/52/23362?source=see_link\">",
"       \"Patient information: Chlamydia and gonorrhea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"       \"Patient information: Chlamydia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of treatment are to prevent complicated infections related to chlamydia (eg, pelvic inflammatory disease, infertility, ectopic pregnancy), decrease the risk of transmission to others, and attain resolution of symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimicrobial agents that have excellent activity against C. trachomatis include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (a macrolide). (See",
"      <a class=\"local\" href=\"#H5623059\">",
"       'Available agents for chlamydia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uncomplicated genital chlamydial infections include urethritis in men and urethritis and cervicitis in women. We recommend single-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (1 gram) for patients with uncomplicated genital chlamydial infections. Observed therapy is preferred when possible. (See",
"      <a class=\"local\" href=\"#H5622559\">",
"       'Treatment of uncomplicated genital chlamydia infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When cost is a factor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily) for seven days is an equally effective alternative. Patients who are prescribed doxycycline should be counseled on treatment adherence. Women should also have pregnancy testing since doxycycline is not recommended for pregnant women. (See",
"      <a class=\"local\" href=\"#H5622559\">",
"       'Treatment of uncomplicated genital chlamydia infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chlamydial and gonococcal infections may coexist in a significant percentage of community patients, which has a direct impact on treatment since first-line agents for chlamydia do not have activity against gonococci. Additional empiric therapy for gonorrhea should be based on a high suspicion of infection (eg, a positive Gram stain in men, a sexual partner recently diagnosed with gonorrhea). (See",
"      <a class=\"local\" href=\"#H60698042\">",
"       'Coinfection with gonorrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric therapy for chlamydial infection should be offered to persons who present with symptoms suggestive of infection (cervicitis, pelvic inflammatory disease, urethritis). This is especially true if follow-up cannot be ensured and if relatively insensitive diagnostic testing is being used (eg, culture rather than nucleic acid amplification testing). (See",
"      <a class=\"local\" href=\"#H5622636\">",
"       'Indications for empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinical symptoms of proctitis (eg, tenesmus), we recommend empiric therapy for both chlamydia and gonorrhea. An empiric regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      100 mg twice daily plus a single intramuscular dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (250 mg) have excellent activity against chlamydia and gonorrhea, respectively. The duration of therapy for mild proctitis is doxycycline for seven days; patients with severe proctitis should be treated for 21 days. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Proctitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In men with epididymitis, we recommend empiric therapy for both chlamydial and gonococcal infections with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg orally twice daily) for 10 days plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (250 mg intramuscular as a single dose). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Epididymitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      is contraindicated during pregnancy; the preferred agent is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of HIV-infected patients with chlamydial infection is the same as in HIV-seronegative patients. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A &ldquo;test of cure&rdquo; for assessing the adequacy of the prescribed antibiotic regimen is not routinely done except in the pregnant female or among those with persistent symptoms. In these circumstances, a test of cure can be performed at least three weeks after treatment. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Patient follow-up: Test of cure versus retesting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recently infected persons should have repeat testing for chlamydia approximately three to six months after treatment, regardless of whether patients believe their sex partners were treated, to rule out the possibility of reinfection. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Patient follow-up: Test of cure versus retesting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Stamm WE. Chlamydia trachomatis infections of the adult. In: Sexually Transmitted Diseases, 4th Edition, Holmes KK, Sparling PF, Mardh PA, et al (Eds), McGraw-Hill, New York 2008. p.575.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/2\">",
"      Thorpe EM Jr, Stamm WE, Hook EW 3rd, et al. Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. Genitourin Med 1996; 72:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/3\">",
"      Geisler WM. Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: evidence reviewed for the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007; 44 Suppl 3:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/4\">",
"      Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29:497.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/6\">",
"      Stamm WE. Azithromycin in the treatment of uncomplicated genital chlamydial infections. Am J Med 1991; 91:19S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/7\">",
"      Foglia G, Rhodes P, Goldberg M, St Louis ME. Completeness of and duration of time before treatment after screening women for Chlamydia trachomatis infections. Sex Transm Dis 1999; 26:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/8\">",
"      Bachmann LH, Stephens J, Richey CM, Hook EW 3rd. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/9\">",
"      Kahn RH, Mosure DJ, Blank S, et al. Chlamydia trachomatis and Neisseria gonorrhoeae prevalence and coinfection in adolescents entering selected US juvenile detention centers, 1997-2002. Sex Transm Dis 2005; 32:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/10\">",
"      Nsuami M, Cammarata CL, Brooks BN, et al. Chlamydia and gonorrhea co-occurrence in a high school population. Sex Transm Dis 2004; 31:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/11\">",
"      Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/12\">",
"      Rompalo AM, Roberts P, Johnson K, Stamm WE. Empirical therapy for the management of acute proctitis in homosexual men. JAMA 1988; 260:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/13\">",
"      Geisler WM, Morrison SG, Bachmann LH. Absence of lymphogranuloma venereum strains among rectal Chlamydia trachomatis outer membrane protein A genotypes infecting women and men who have sex with men in Birmingham, Alabama. Sex Transm Dis 2008; 35:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/14\">",
"      Manavi K, McMillan A, Young H. The prevalence of rectal chlamydial infection amongst men who have sex with men attending the genitourinary medicine clinic in Edinburgh. Int J STD AIDS 2004; 15:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/15\">",
"      Ward H, Alexander S, Carder C, et al. The prevalence of lymphogranuloma venereum infection in men who have sex with men: results of a multicentre case finding study. Sex Transm Infect 2009; 85:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/16\">",
"      Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/17\">",
"      Wiesenfeld HC, Sweet RL, Ness RB, et al. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 2005; 32:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/18\">",
"      Augenbraun M, Bachmann L, Wallace T, et al. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis 1998; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/20\">",
"      Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001; 28:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/21\">",
"      Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007; 83:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/22\">",
"      Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009; 36:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/23\">",
"      Hoover KW, Tao G, Nye MB, Body BA. Suboptimal adherence to repeat testing recommendations for men and women with positive Chlamydia tests in the United States, 2008-2010. Clin Infect Dis 2013; 56:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/24\">",
"      Workowski KA, Lampe MF, Wong KG, et al. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection. JAMA 1993; 270:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/25\">",
"      Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010; 201:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/26\">",
"      Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. JAMA 1995; 274:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/27\">",
"      Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis 2009; 48:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/28\">",
"      Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis 2011; 52:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/29\">",
"      Suchland RJ, Sandoz KM, Jeffrey BM, et al. Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. Antimicrob Agents Chemother 2009; 53:4604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/30\">",
"      Gaydos CA, Wright C, Wood BJ, et al. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex Transm Dis 2008; 35:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/31\">",
"      Murphy TV, Slade BA, Broder KR, et al. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/32\">",
"      Hogben M. Partner notification for sexually transmitted diseases. Clin Infect Dis 2007; 44 Suppl 3:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/33\">",
"      Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34505/abstract/34\">",
"      Khan A, Fortenberry JD, Juliar BE, et al. The prevalence of chlamydia, gonorrhea, and trichomonas in sexual partnerships: implications for partner notification and treatment. Sex Transm Dis 2005; 32:260.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases. US Department of Health and Human Services; Atlanta, GA 2006.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7579 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-8A237B75EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34505=[""].join("\n");
var outline_f33_44_34505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H230641\">",
"      Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5622559\">",
"      TREATMENT OF UNCOMPLICATED GENITAL CHLAMYDIA INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60697861\">",
"      Impact of life cycle on antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5623059\">",
"      Available agents for chlamydia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5623486\">",
"      - Antibiotic efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5623067\">",
"      - First-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5623074\">",
"      Advantages of azithromycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5623081\">",
"      Advantages of doxycycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5623088\">",
"      - Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5623096\">",
"      Quinolones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5623103\">",
"      Erythromycins and penicillins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5623110\">",
"      - Agents with limited activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60698042\">",
"      Coinfection with gonorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5622636\">",
"      Indications for empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF OTHER CHLAMYDIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Epididymitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5623758\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5623402\">",
"      Oropharyngeal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5624097\">",
"      TREATMENT IN SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5348136\">",
"      - Test of cure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H343008\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343031\">",
"      Medication adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343038\">",
"      Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343045\">",
"      HIV counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343072\">",
"      Pregnancy testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PATIENT FOLLOW-UP: TEST OF CURE VERSUS RETESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8751131\">",
"      Retesting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Test of cure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H342755\">",
"      PERSISTENT OR RECURRENT SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H342782\">",
"      Recurrence of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H342789\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      MANAGEMENT OF SEX PARTNERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Issues of reinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Low rates of partner assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Expedited partner therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Legal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SCREENING FOR CHLAMYDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=related_link\">",
"      Clinical manifestations and diagnosis of Chlamydia trachomatis infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_44_34506="Adjuvant therapy for resected stage III (node-positive) colon cancer";
var content_f33_44_34506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant therapy for resected stage III (node-positive) colon cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Jeffrey W Clark, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Hanna K Sanoff, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/44/34506/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/44/34506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 102,480 new cases of colon cancer are diagnosed annually in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/1\">",
"     1",
"    </a>",
"    ]. Data on global incidence are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     Globocan database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Surgical resection is the only curative treatment for locoregional colon cancer. Outcome is most closely related to the extent of disease at presentation (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). Five-year survival rates according to tumor stage at diagnosis (using the older 2002 AJCC staging criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/2\">",
"     2",
"    </a>",
"    ]) for 119,363 patients with colon cancer reported to the SEER (Surveillance, Epidemiology and End Results) database between 1991 and 2000 were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I (T1-2 N0) &mdash; 93 percent",
"     </li>",
"     <li>",
"      Stage IIA (T3N0) &mdash; 85 percent",
"     </li>",
"     <li>",
"      Stage IIB (T4N0) &mdash; 72 percent",
"     </li>",
"     <li>",
"      Stage IIIA (T1-2 N1) &mdash; 83 percent",
"     </li>",
"     <li>",
"      Stage IIIB (T3-4 N1) &mdash; 64 percent",
"     </li>",
"     <li>",
"      Stage IIIC (N2 disease) &mdash; 44 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year survival rates using the newer 2010 AJCC staging criteria for colon cancer, derived from a smaller subset of colon cancers reported to the SEER database between 1975 and 2000, are depicted in the table (",
"    <a class=\"graphic graphic_figure graphicRef81414 \" href=\"mobipreview.htm?40/54/41824\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/4\">",
"     4",
"    </a>",
"    ]. The differences between the 2002 and 2010 TNM staging criteria are outlined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'TNM staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have undergone potentially curative resection, disease recurrence is thought to arise from clinically occult micrometastases that are present at the time of surgery. The goal of postoperative (adjuvant) therapy is to eradicate these micrometastases, thereby increasing the cure rate.",
"   </p>",
"   <p>",
"    The benefits of adjuvant chemotherapy have been most clearly demonstrated in stage III (node-positive) disease, whereas benefit in stage II disease remains controversial. This topic review will cover adjuvant therapy for patients with resected stage III colon cancer. Adjuvant therapy for stage II (node-negative) colon cancer, adjuvant therapy for colon cancer in elderly patients, surgical management and prognosis of colon cancer, chemotherapy after resection of colorectal cancer liver metastases, a compilation of protocols for treatment of colon cancer, and recommendations for posttreatment follow-up are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=see_link\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) monotherapy failed to show a survival benefit relative to resection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/5\">",
"     5",
"    </a>",
"    ]. Interest in adjuvant chemotherapy was revived in the late 1980s with reports that suggested a survival benefit from 5-FU-based combination regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and by the discovery of modulators of 5-FU activity, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV), and levamisole, an immunomodulatory agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first large-scale trial to demonstrate a survival benefit for adjuvant chemotherapy in colon cancer, the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-01, randomly assigned 1166 patients with Dukes' B or C colon cancer (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ) to surgery alone, nonspecific immunotherapy with BCG, or MOF (semustine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ) chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/6\">",
"       6",
"      </a>",
"      ]. MOF was associated with a significant improvement in five-year overall survival compared to surgery alone or BCG, a benefit that was no longer apparent at 8 or 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benefit for adjuvant 5-FU plus levamisole was initially shown in a North Central Cancer Treatment Group (NCCTG) trial in which 401 patients with Dukes' B or C colon cancer were randomly assigned to observation or one year of levamisole with or without 5-FU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Successive trials demonstrating the inferiority of",
"      <span class=\"nowrap\">",
"       5-FU/levamisole",
"      </span>",
"      compared to 5-FU plus LV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/11,12\">",
"       11,12",
"      </a>",
"      ], and reports implicating this regimen in the development of a multifocal cerebral demyelinating syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/13-15\">",
"       13-15",
"      </a>",
"      ] markedly diminished the use of levamisole for adjuvant therapy. Levamisole is no longer commercially available.",
"      <br/>",
"      <br/>",
"      The era of modern adjuvant chemotherapy was ushered in by trials showing a survival benefit for 5-FU plus LV over surgery alone, the superiority of",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      over MOF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/16\">",
"       16",
"      </a>",
"      ], and more recently, the benefit of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      to a",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      backbone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENDPOINTS TO DEFINE BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the gold standard to define benefit from adjuvant therapy has been improvement in overall survival. However, disease-free survival (DFS, defined as the time from randomization to any event, irrespective of cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/17\">",
"     17",
"    </a>",
"    ]) at two or three years appears to be an acceptable surrogate for five-year overall survival, especially for stage III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, three-year DFS is an appropriate endpoint to define benefit from adjuvant therapy in colon cancer.",
"   </p>",
"   <p>",
"    However, the duration of follow-up that is required to see DFS benefits translating into prolonged overall survival may be longer because of the prolongation in median survival that is associated with newer treatments for metastatic disease (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonetheless, two- or three-year DFS is now accepted as a legitimate endpoint for treatment benefit, at least for stage III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/21\">",
"     21",
"    </a>",
"    ]. Significant improvements in three-year DFS formed the basis for the approval of adjuvant FOLFOX in the US. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Oxaliplatin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H405297564\">",
"    <span class=\"h1\">",
"     TIMING OF ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy is typically started only after recovery from surgery. There is no agreement as to the optimal time to initiate adjuvant chemotherapy. Guidelines from ASCO and the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    do not explicitly state a time interval within which chemotherapy should commence. Adjuvant colon cancer trials typically mandate initiation of chemotherapy within six to eight weeks of resection, and this has become an accepted approach",
"   </p>",
"   <p>",
"    In clinical practice, the interval between surgery and initiation of chemotherapy is often longer than eight weeks; the reason for delay in treatment commencement have not been well documented, but the dominant reason is delayed recovery from surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. &nbsp;Alternatively, delays may occur because of inefficiencies in the healthcare system or shortages of resources to deliver care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/25\">",
"     25",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Whether a delay in the administration of adjuvant therapy compromises outcomes is controversial. There are no randomized trials addressing this issue in patients with resected colon cancer. Several retrospective studies are available, most of which consist predominantly or exclusively of patients with stage III disease, and none of which included patients receiving an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen. In general, the data are conflicting, with two reports suggesting a worse overall and event free survival (EFS) with a delay beyond eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], one a worse overall survival with delay beyond 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/25\">",
"     25",
"    </a>",
"    ], another suggesting worse overall survival but no impact on EFS with a delay beyond 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/28\">",
"     28",
"    </a>",
"    ], and another, no impact on either disease-free or overall survival from a delay beyond 45 or 56 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/29\">",
"     29",
"    </a>",
"    ]. In adjuvant therapy trials in which time between surgery and initiation of chemotherapy has been examined as a prognostic factor for outcome, delay beyond six to eight weeks has not been associated with inferior outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse impact of delaying chemotherapy beyond eight weeks has been addressed in two meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One meta-analysis consisted of eight studies that compared outcomes among patients with colon or rectal cancer who had delayed chemotherapy compared to those who started within eight weeks of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/33\">",
"       33",
"      </a>",
"      ]. Delay of chemotherapy beyond eight weeks was associated with a significantly higher risk of death (relative risk 1.20, 95% CI 1.15 to 1.26), although relapse-free survival (RFS) was not significantly affected. This suggests that most of the mortality was from surgery-related complications and not cancer related.",
"     </li>",
"     <li>",
"      The second meta-analysis included ten studies (one randomized trial, and nine",
"      <span class=\"nowrap\">",
"       cohort/population-based",
"      </span>",
"      studies) totaling over 15,000 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/34\">",
"       34",
"      </a>",
"      ]. A four week delay in the time to administer adjuvant chemotherapy beyond 8 weeks was associated with a significant increase in mortality (hazard ratio [HR] for death 1.14, 95% CI 1.10-1.17) and disease relapse (HR 1.14, 95% CI 1.10 to 1.18).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the conclusion that adjuvant chemotherapy should be started within eight weeks of surgery, if at all possible. Delay beyond two months may compromise the effectiveness of chemotherapy, but it is unknown whether there is any cutoff point beyond which the benefits of adjuvant chemotherapy are lost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22984319\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY DOSING IN OBESE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cancer patients with a large body surface area (BSA), chemotherapy drug doses are often reduced, because of concern for excess toxicity. However, there is no evidence that fully-dosed obese patients experience greater toxicity from chemotherapy for colorectal cancer; furthermore, obese patients who are given reduced doses may have inferior outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/35\">",
"     35",
"    </a>",
"    ]. Although limited, the available data do not support the policy of routine dose reduction (or capping the maximal BSA to 2.0 m",
"    <sup>",
"     2",
"    </sup>",
"    ) for obese patients with colon cancer. Guidelines from ASCO recommend that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     5-FU-BASED THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bolus 5-FU plus LV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preclinical data indicating a synergistic interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV) and 5-FU prompted several trials of adjuvant",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/6,16,37-41\">",
"     6,16,37-41",
"    </a>",
"    ]. Both drugs together form a stable ternary complex with thymidylate synthetase (TS), and this permits prolonged inhibition of the enzyme by 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most American patients receive a racemic mixture of d,l-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (leucovorin calcium), and this is the version that has been used in most reported clinical trials. However, the l-isomer is the biologically active moiety, and an intravenous preparation of l-leucovorin is now commercially available in the US (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    , Fusilev). It is dosed at one-half that of d,l leucovorin.",
"   </p>",
"   <p>",
"    Three seminal trials established bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    as a standard adjuvant regimen for resected stage III colon cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NSABP C-03 trial established the superiority of 5-FU plus high-dose LV over MOF chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar degree of benefit with lower doses of LV was seen in an NCCTG study in which 317 patients with high-risk stage II or III colon cancer were randomly assigned to observation or six cycles of 5-FU (425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus LV (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      each given days 1 to 5, every four to five weeks (the \"Mayo regimen\") [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The IMPACT (International Multicentre Pooled Analysis of Colon Cancer Trials) report consisted of pooled data from 1526 patients with resected Dukes' B or C (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ) colon cancer who were enrolled in three independent trials in Italy, Canada, and France [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In all cases, patients were randomly assigned to observation or six cycles of monthly 5-FU (375 to 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) plus high-dose LV (200 mg daily), both administered on days 1 to 5. Treatment was associated with a significant 22 percent reduction in death (three-year overall survival 83 versus 78 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/38\">",
"       38",
"      </a>",
"      ]. In subgroup analysis, benefit was almost entirely limited to node-positive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent studies have focused on the optimal LV dose, duration of therapy (6 versus 12 months) and infusional versus bolus 5-FU schedules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dose of LV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The equivalence of low-dose versus high-dose LV in combination with 5-FU has been shown in multiple studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/41,43-45\">",
"     41,43-45",
"    </a>",
"    ]. In the largest, US Intergroup study (INT) 0089, 3759 patients with resected stage II or III colon cancer were randomly assigned to one of the following four regimens: 12 months of",
"    <span class=\"nowrap\">",
"     5-FU/levamisole;",
"    </span>",
"    six to eight months of the Mayo regimen (5-FU 425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus low dose LV 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, each on days 1 to 5, every four to five weeks); four cycles of weekly 5-FU plus high-dose LV (both 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week for six of each eight weeks, the \"Roswell Park [RPMI] regimen\"); or",
"    <span class=\"nowrap\">",
"     5-FU/levamisole",
"    </span>",
"    plus low-dose LV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/43\">",
"     43",
"    </a>",
"    ]. There were no significant DFS or overall survival differences among any of the trial arms (",
"    <a class=\"graphic graphic_table graphicRef62211 \" href=\"mobipreview.htm?29/42/30379\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, this trial and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/44\">",
"     44",
"    </a>",
"    ] document a different pattern of toxicity in patients treated with the low-dose Mayo regimen compared to the RPMI regimen. The five day bolus regimen appears to be more toxic (particularly with regard to diarrhea) in women compared to men and in older as compared to younger patients. As a result, the RPMI regimen has been adopted by many as the preferred regimen when bolus 5-FU and LV is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three randomized trials show no added benefit from 12 as compared to six to eight months of",
"    <span class=\"nowrap\">",
"     5-FU/LV-containing",
"    </span>",
"    adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/41,43,45\">",
"     41,43,45",
"    </a>",
"    ]. A Cochrane review concluded that shorter duration of chemotherapy (three to six months) compared with longer duration of chemotherapy (9 to 12 months) was not associated with inferior relapse-free or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/46\">",
"     46",
"    </a>",
"    ]. However, there were no data upon which to base a recommendation for six months versus a shorter duration. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest six months of adjuvant therapy. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infusional versus bolus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lack of superiority but more favorable side effect profile for continuous infusion 5-FU over bolus 5-FU plus LV has been shown in at least three trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/30,47,48\">",
"     30,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small trial directly compared 24 weeks of the Mayo regimen (low-dose bolus 5-FU plus LV) versus 12 weeks of protracted 5-FU alone (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/30\">",
"     30",
"    </a>",
"    ]. Infusional 5-FU was associated with a trend towards better five-year recurrence-free survival (73 versus 67 percent, p = 0.1) and overall survival (76 versus 72 percent, p = 0.08), and it caused less diarrhea, mucositis, nausea, vomiting, and neutropenia. However, no trial has compared infusional 5-FU versus the better-tolerated RPMI regimen of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Dose of LV'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Short-term infusional 5-FU/LV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of metastatic disease, short-term infusional regimens of 5-FU plus LV (the so called de Gramont schedule) are associated with superior outcomes when compared to monthly bolus schedules of",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    These are the",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    schedules that have been used in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Oxaliplatin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The better tolerability of the de Gramont schedule (the original protocol included LV 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours followed by 5-FU 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    bolus and then 600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 22 hours, on two consecutive days every two weeks) versus monthly bolus 5-FU plus high-dose LV (LV 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    followed by a 15-minute bolus injection of 5-FU 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    both on days 1 to 5, every four weeks) was shown in a randomized trial of 905 patients with resected stage II (43 percent) or III colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/31\">",
"     31",
"    </a>",
"    ]. At a median follow-up of six years, there was no statistically significant difference in either DFS or overall survival, but neutropenia, diarrhea and mucositis were all significantly less with the de Gramont schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with protracted infusional 5-FU, these regimens require central venous access, and it is unclear whether the added inconvenience and cost is justified in patients who are to receive",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    alone without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . Nevertheless, the more favorable toxicity profile of the de Gramont schedule over bolus 5-FU plus LV makes it an attractive option, particularly for individuals with significant comorbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orally active fluoropyrimidines such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and UFT offer increased convenience and the possibility of an improved therapeutic ratio (at least with capecitabine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is absorbed intact through the intestinal wall and then converted to 5-FU in three sequential enzymatic reactions. The final requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor compared to normal tissue, forming the basis for enhanced selectivity for tumor cells and better tolerability.",
"   </p>",
"   <p>",
"    UFT is a 4:1 molar combination of ftorafur with uracil. Uracil competitively inhibits the degradation of 5-FU, resulting in sustained concentrations in both plasma and the tumor.",
"   </p>",
"   <p>",
"    The benefit of oral fluoropyrimidines was addressed in a meta-analysis of individual data from five Japanese trials involving 5232 patients with resected stage I, II, or III colon cancer who were randomly assigned to adjuvant oral fluoropyrimidines (5-FU, UFT, or hexacarbamoyl-5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ) versus observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/51\">",
"     51",
"    </a>",
"    ]. In the aggregate, oral therapy reduced the risk of recurrence and death by 11 and 15 percent, respectively. However, the absolute survival benefit for patients with stage III disease was only 2.5 percent, a value that seems inferior to that achievable with modern parenteral 5-FU-based regimens.",
"   </p>",
"   <p>",
"    More recent trials suggest that the magnitude of benefit with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or UFT is at least equivalent to that of IV bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV:",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     European/Canadian",
"    </span>",
"    X-ACT study randomly assigned 1987 patients with resected stage III colon cancer to six months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    alone (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days) or monthly bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (the Mayo regimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/52\">",
"     52",
"    </a>",
"    ]. The trial was statistically powered to demonstrate therapeutic equivalence, with DFS as the primary endpoint.",
"   </p>",
"   <p>",
"    At a median 3.8-year follow-up,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    was at least as effective as",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    and there was some suggestion of superiority in terms of three-year DFS (64 versus 61 percent, p = 0.05) and overall survival (81 versus 78 percent, p = 0.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/52\">",
"     52",
"    </a>",
"    ]. Despite the fact that one-half of all patients receiving capecitabine required dose reduction, the incidence of adverse effects was lower than with",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    with the exception of hand-foot syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Largely based upon these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    was approved for adjuvant therapy of colon cancer in the US. However, capecitabine should be used cautiously in elderly patients, particularly those with diminished creatinine clearance. Furthermore, a dose of 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily is often poorly tolerated in American patients, although Europeans and Asians seem to be better able to tolerate this dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=see_link\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H8#H8\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, patients may be considered for crossover from a",
"    <span class=\"nowrap\">",
"     5-FU/LV-based",
"    </span>",
"    adjuvant regimen to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    . However, at least some data suggest that both the incidence and severity of capecitabine-associated toxicity are substantially higher when it is given after",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/54\">",
"     54",
"    </a>",
"    ]. The mechanism underlying this sequence-specific exacerbation of toxicity is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     UFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative efficacy of UFT compared to parenteral",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was shown in NSABP trial C-06, in which 1608 patients with resected stage II or III colon cancer were randomly assigned to bolus weekly 5-FU with high-dose LV (for 24 rather than the usual 32 weeks) or UFT plus oral LV (five 35-day cycles) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/55\">",
"     55",
"    </a>",
"    ]. There were no significant differences in the five-year rates of DFS (68 versus 67 percent for UFT and",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    respectively) or overall survival (79 percent in both groups).",
"   </p>",
"   <p>",
"    Although UFT is widely available in Europe and Asia, it is not available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Summary and choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with resected colon cancer who are going to receive 5-FU-based adjuvant chemotherapy (ie, without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ), the best adjuvant regimen is not conclusively established. Although most of the trials demonstrating the benefit of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    used the Mayo regimen (daily treatment for five days once per month), the more favorable toxicity profile of the weekly RPMI regimen (four courses of 5-FU 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus LV 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    both given for six of every eight weeks) has led many to consider this the preferred regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protracted infusion 5-FU alone (three courses of 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for 56 of every 63 days) and short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (a modified de Gramont regimen is depicted in the table (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"     table 3",
"    </a>",
"    )) both provide oncologic outcomes that are at least as good and less toxic as compared to bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    However, it is unclear whether the added inconvenience and cost of a central venous line and ambulatory infusion pump is justified in patients who are to receive a nonoxaliplatin-based regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The oral fluoropyrimidines",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and UFT are at least as effective as bolus 5-FU plus LV. However, reimbursement policies for oral cytotoxic agents such as capecitabine vary greatly between countries and even regionally within the US. The higher out of pocket costs for capecitabine (particularly among patients covered by the US Medicare program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/56\">",
"     56",
"    </a>",
"    ]) compared with IV 5-FU-based regimens (which are typically covered by the third-party payer) must often be considered in choosing the best treatment for individual patients. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Oral fluoropyrimidines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OXALIPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is the only platinum-type drug with activity in colorectal cancer; it is used only in combination with a fluoropyrimidine. The survival benefit of adding oxaliplatin to adjuvant fluoropyrimidine-based therapy after resection of node-positive colon cancer has been demonstrated in randomized trials (which have typically enrolled younger, healthier, and less racially diverse patients) and is supported by a large analysis of five observational cohorts of patients treated at the community level in diverse practice settings, including older and minority patients, and those with higher levels of comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=see_link&amp;anchor=H17#H17\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\", section on 'Oxaliplatin-based regimens'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     MOSAIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit for adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was first suggested in the MOSAIC trial, which randomly assigned 2246 patients with resected stage II (40 percent) or III colon cancer to a six month course of one of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The original de Gramont regimen (LV 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      as a two-hour infusion, followed by bolus 5-FU 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and then a 22-hour infusion of 5-FU 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      every two weeks)",
"     </li>",
"     <li>",
"      The same regimen of",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1 every 14 days, a regimen termed FOLFOX4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a median follow-up of 82 months, five-year DFS (the primary endpoint) was significantly higher with FOLFOX (73 versus 67 percent, hazard ratio [HR] 0.80) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, six-year overall survival rates were also significantly higher, both in the entire group (79 versus 76 percent, HR 0.84, p = 0.046), and in those with stage III (73 versus 69 percent, HR 0.80, p = 0.023), but not stage II disease.",
"   </p>",
"   <p>",
"    Among patients with stage III disease, the probability of remaining free from a DFS event (relapse or death) at five years was significantly higher with FOLFOX (66 versus 59 percent, HR 0.78, p=0.05), while it was not significantly different in those with stage II disease (84 versus 80 percent, HR 0.84, p = 0.258). In an exploratory analysis, there was a larger absolute difference in DFS that favored FOLFOX in the subgroup of stage II patients with high-risk tumors, but it was not statistically significant (82 versus 75 percent, HR 0.72) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530323#H589530323\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Benefit of fluoropyrimidine-based chemotherapy'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Febrile neutropenia (1.8 versus 0.2 percent) and grade 3 or 4 diarrhea (10.8 versus 6.6 percent) were more common with FOLFOX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/58\">",
"     58",
"    </a>",
"    ]. Although some form of peripheral neuropathy developed in 92 percent of patients receiving FOLFOX, it was severe (grade 3) in only 13 percent and generally reversible. By 48 months, grade 1, 2, or 3 neuropathy was observed in 12, 3, and 0.7 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H15#H15\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based largely upon the MOSAIC trial results,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    was approved, in combination with infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    for adjuvant therapy of completely resected stage III colon cancer in the US. While FOLFOX4 was the regimen used in the adjuvant registration trial, many American oncologists use modified FOLFOX6 (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    ) because it does not require a day 2 bolus of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . Modified FOLFOX7 (",
"    <a class=\"graphic graphic_table graphicRef55829 \" href=\"mobipreview.htm?10/19/10558\">",
"     table 5",
"    </a>",
"    ) eliminates bolus 5-FU completely and is less myelosuppressive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     NSABP C-07 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Better outcomes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    were also reported in NSABP C-07, which randomly assigned 2407 patients with stage II (29 percent) or III colon cancer to three cycles of bolus weekly",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (the RPMI regimen) with or without oxaliplatin (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on weeks 1, 3, and 5 of every eight week cycle, FLOX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/60\">",
"     60",
"    </a>",
"    ]. With eight years of median follow-up, five-year DFS significantly favored FLOX (69 versus 64 percent, HR 0.82) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/61\">",
"     61",
"    </a>",
"    ], but the difference in overall survival was not statistically significant (five-year survival 80 versus 78 percent, HR 0.88).",
"   </p>",
"   <p>",
"    Toxicity was prominent in both groups. Hospitalization for diarrhea or dehydration was required in 51 patients receiving FLOX and 28 of the control group (5.5 versus 3 percent, p = 0.08) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/61\">",
"     61",
"    </a>",
"    ]. While the risk of death within 60 days of starting treatment was 1.2 percent overall and similar in both groups, five deaths in the FLOX group were directly attributed to chemotherapy-induced enteropathy, versus one in the control group. Grade 3 or 4 vomiting (13 versus 9 percent) and grade 3 neurosensory toxicity (8.2 versus 0.2 percent) were also significantly more common with FLOX.",
"   </p>",
"   <p>",
"    In our view,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus bolus weekly",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    appears more toxic than combinations of oxaliplatin with infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (eg, FOLFOX). Furthermore, in the setting of metastatic disease, bolus regimens that are similar to FLOX have proven to be inferior to FOLFOX (eg, in the TREE trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/62\">",
"     62",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H29#H29\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'First-line oxaliplatin plus 5-FU/LV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, we prefer FOLFOX as long as ambulatory infusional therapy is feasible. Guidelines for adjuvant treatment of stage III colon cancer from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    consider either regimen as preferred over",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Capecitabine plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, orally active fluoropyrimidines such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    offer increased convenience. The combination of capecitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 day cycle plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV on day 1), a regimen termed XELOX, was directly compared to standard IV bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    in a phase III trial involving 1886 patients with stage III colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/63\">",
"     63",
"    </a>",
"    ]. The control arm of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was either the Mayo (425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    5-FU and 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    LV daily on days 1 to 5, once per month) or RPMI regimen (5-FU and LV, each 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    weekly for six of every eight weeks) at the discretion of each center.",
"   </p>",
"   <p>",
"    In the latest report, after a median followup of 74 months, DFS was significantly superior with XELOX than with bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (HR for DFS 0.80, 95% CI 0.69 to 0.93, seven year DFS of 63 versus 56 percent) as was overall survival (HR 0.83, 95% CI 0.70-0.99, seven year overall survival 73 versus 67 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, XELOX was associated with less grade 3 or 4 neutropenia (9 versus 16 percent), febrile neutropenia (&lt;1 versus 4 percent), stomatitis (&lt;1 versus 9 percent), and alopecia (4 versus 20 percent) but more neurotoxicity (78 [11 percent grade 3 or 4] versus 8 [&lt;1 percent grade 3 or 4] percent), grade 3 hand-foot syndrome (5 versus &lt;1 percent) and grade 3 or 4 thrombocytopenia (5 versus &lt;1 percent) than bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. Rates of grade 3 or 4 diarrhea and dehydration with XELOX were significantly higher in patients over the age of 65.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to adjuvant fluoropyrimidines in patients with resected stage III colon cancer has been shown in multiple randomized trials, and benefit appears to be evident across diverse practice settings and patient subgroups. The use of oxaliplatin for stage II disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=see_link&amp;anchor=H589530323#H589530323\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Benefit of fluoropyrimidine-based chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    plus short-term infusional FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX, (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    )) is a widely accepted standard regimen for resected stage III colon cancer. Both FLOX (oxaliplatin plus bolus FU and leucovorin) and XELOX (oxaliplatin plus oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"     table 6",
"    </a>",
"    )) are more toxic but could be considered if an ambulatory infusion pump is not feasible. Furthermore, the decision to use FLOX or XELOX does not eliminate the need for a central line. A significant number of patients report local pain when oxaliplatin is infused via peripheral vein, and many centers routinely infuse the drug via central line. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     IRINOTECAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing chemotherapy cannot be considered a standard approach for patients requiring adjuvant chemotherapy for resected colon cancer. This conclusion is based upon negative results from three separate trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The earliest trial (CALGB 89803) randomly assigned 1264 patients with resected stage III colon cancer to weekly bolus LV plus 5-FU without or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (the IFL regimen) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/66\">",
"       66",
"      </a>",
"      ]. Neither failure free survival nor overall survival were better with IFL, and there were significantly higher rates of grade 3 or 4 neutropenia (43 versus 5 percent), febrile neutropenia, and treatment-related death (2.8 versus 1 percent).",
"     </li>",
"     <li>",
"      The FOLFIRI regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      plus short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"       table 7",
"      </a>",
"      )) has been studied in the adjuvant setting in two trials:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The multicenter PETACC-3 trial randomly assigned 3278 patients with resected colon cancer (71 percent stage III) to short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 every 14 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/67\">",
"       67",
"      </a>",
"      ]. In a report that covered the 2094 patients with stage III disease, the addition of irinotecan did not significantly improve either five-year DFS (57 versus 54 percent) or overall survival (74 versus 71 percent).",
"     </li>",
"     <li>",
"      The similarly designed ACCORD trial randomly assigned 400 patients with stage III or",
"      <span class=\"nowrap\">",
"       obstructed/perforated",
"      </span>",
"      stage II colon cancer to the same two treatment arms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/68\">",
"       68",
"      </a>",
"      ]. Three-year DFS and overall survival were not significantly better with FOLFIRI. However, there were significant imbalances between the groups for important prognostic factors which may have contributed to a worse outcome in the group receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BEVACIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    (Avastin&reg;) is a humanized monoclonal antibody targeting the vascular endothelial growth factor (VEGF), which is a dominant factor controlling tumor-associated angiogenesis. Adding bevacizumab to regimens containing 5-FU, LV, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    improves outcomes among patients with metastatic colorectal cancer, albeit at the cost of treatment-related side effects (bleeding, hypertension, bowel perforation, and thromboembolic events). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H44#H44\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Agents targeting VEGF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H26#H26\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing chemotherapy cannot be considered a standard approach for patients requiring adjuvant chemotherapy for colon cancer. The benefit of adding bevacizumab to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy was tested in NSABP C-08, which enrolled 2672 patients with stage II (25 percent) or III colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/69\">",
"     69",
"    </a>",
"    ]. The experimental arm received bevacizumab (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) concurrent with FOLFOX for six months, and then as monotherapy for an additional six months; the control arm was six months of FOLFOX alone.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    group had significantly higher rates of hypertension, wound complications, pain, proteinuria, and hand-foot syndrome, but not gastrointestinal perforation, hemorrhage, arterial or venous thrombotic events, or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/70\">",
"     70",
"    </a>",
"    ]. Unfortunately, there was no significant benefit for the addition of bevacizumab in terms of DFS (three-year DFS 78 versus 75 percent, HR for progression 0.93, 95% CI 0.81 to 1.08) or overall survival (five-year overall survival 83 versus 81 percent, HR for death 0.95, 95% CI 0.79-1.13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was also no evidence to suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -treated patients had a worse outcome (eg, higher rate of metastatic disease, multiple metastatic sites, poorer survival after recurrence). This finding refutes preclinical data raising the possibility that inhibition of angiogenesis might accelerate metastatic behavior. However, follow-up in this trial was relatively short. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Potential resistance to anti-angiogenic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second multicenter trial, the European AVANT trial (a randomized comparison of FOLFOX4 alone versus FOLFOX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or XELOX plus bevacizumab), also failed to show a disease-free or overall survival benefit from the addition of bevacizumab to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/71\">",
"     71",
"    </a>",
"    ]. In fact, the overall survival data suggested a possible detrimental impact of adding bevacizumab to oxaliplatin-containing adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CETUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a",
"    <span class=\"nowrap\">",
"     mouse/human",
"    </span>",
"    chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR); the benefit of this drug in metastatic colorectal cancer is limited to patients whose tumors express wild-type K-ras. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H21096055#H21096055\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'K-ras'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in the adjuvant setting is not indicated in any group of patients with resected colon cancer. A lack of benefit from cetuximab in the adjuvant setting was shown in the N0147 trial, in which patients with resected, stage III colon cancer (1760 of whom had wild-type K-ras, and 658 K-ras mutant tumors) were randomly assigned to FOLFOX with or without cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/72\">",
"     72",
"    </a>",
"    ]. The trial was closed prematurely after it was determined in an interim analysis that no group of patients benefited from cetuximab. A lack of benefit from adjuvant cetuximab added to FOLFOX in patients with K-ras wild type stage III colon cancer was also noted in a preliminary report of the European PETACC8 trial, reported at the 2012 meeting of the European Society of Medical Oncology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97815843\">",
"    <span class=\"h1\">",
"     TOOLS TO AID IN DECISION MAKING FOR ADJUVANT THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16290235\">",
"    <span class=\"h2\">",
"     Web-based tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two web-based tools are available to assist in risk stratification and counseling about adjuvant therapy by permitting the clinician to calculate the relative risk of disease recurrence and mortality based upon clinicopathologic features and the relative benefit to be gained by adjuvant chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant! Online [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/74\">",
"       74",
"      </a>",
"      ] was developed using prognostic estimates derived from US SEER tumor registry-reported outcomes for patients with colon cancer in the general population and estimates of adjuvant therapy efficacy derived from proportional risk reductions published in the literature.",
"     </li>",
"     <li>",
"      Numeracy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/75\">",
"       75",
"      </a>",
"      ] was developed at the Mayo Clinic and derived from a pooled individual patient data meta-analysis of seven randomized clinical trials of adjuvant therapy, including 3341 trial participants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both tools are used widely by clinicians, but the validity of the assumptions inherent in the estimates provided by these prognostic tools has not been tested extensively. One independent validation study of both tools that used a population-based dataset from the British Columbia Colorectal Cancer Outcomes unit concluded that both had similar predictive performance and acceptable reliability for stage III colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these programs can assist in estimating the potential benefit of FU-based versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing adjuvant therapy, the decision to pursue treatment requires careful consideration of all aspects of the individual patient by the clinician, including those that are not contained in Adjuvant! Online or Numeracy (eg, perforation). In our opinion, these tools are best used as a rough guide to explain the degree of absolute benefit that may be achieved by receipt of different adjuvant chemotherapy regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97816023\">",
"    <span class=\"h2\">",
"     Molecular markers and genomic profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts are underway to improve prognostication in stage III colon cancer beyond that achieved by the TNM staging system. As an example, early data suggest that analysis of molecular and clinical prognostic factors might permit the identification of patients with stage III disease whose outcomes are more similar to those of patients with stage II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/78\">",
"     78",
"    </a>",
"    ]. Whether such patients can safely forego adjuvant chemotherapy, however, is a hypothesis that has not been tested.",
"   </p>",
"   <p>",
"    In addition, a preliminary report based upon data from NSABP C-07 suggests that genomic profiling through use of the Oncotype DX Colon Cancer Assay may improve risk prognostication in stage III disease and better pinpoint the absolute level of benefit achieved by the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/79\">",
"     79",
"    </a>",
"    ]. However, the difference in absolute DFS benefit of oxaliplatin seen in the low-risk (3 percent benefit from oxaliplatin) versus high-risk patients (5 percent benefit from oxaliplatin) was small and may not be clinically meaningful. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     REGIONAL LIVER-DIRECTED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the dominant site of recurrence in half of patients undergoing potentially curative colon cancer resection. Several trials have studied prophylactic portal vein infusional (PVI) therapy or hepatic intraarterial infusion of fluoropyrimidines following resection of localized colon cancer, with most showing no benefit from this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/80-84\">",
"     80-84",
"    </a>",
"    ]. A meta-analysis concluded that, compared to no adjuvant treatment, the absolute survival benefit associated with PVI chemotherapy was 5 percent and not statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the benefit of these procedures is unproven, and they are not recommended in any setting outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     ADJUVANT RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative RT is not usually considered a routine component of care for completely resected colon cancer. This is in contrast to patients with rectal cancer, in whom effective adjuvant therapy for both transmural and node-positive disease includes RT. Local recurrence is more frequent with rectal cancer due to the local anatomy and the difficulty in obtaining adequate resection margins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in colon cancer, increasing TNM stage (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) predicts for local failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/85-87\">",
"     85-87",
"    </a>",
"    ], as does anatomic location:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ascending and descending colon are considered anatomically \"immobile\" structures. The anatomic constraints caused by the close proximity of these bowel segments to retroperitoneal tissues may preclude wide resection, increasing the risk of residual disease and local failure.",
"     </li>",
"     <li>",
"      The mid-sigmoid and mid-transverse colon are not fixed structures, and a wide margin in the mesentery is usually achievable. In the absence of adherence to local organs, local failure at these sites is uncommon.",
"     </li>",
"     <li>",
"      Local failure rates for tumors arising in the cecum, hepatic and splenic flexure, or proximal and distal sigmoid vary, depending on the amount of mesentery present, the extent of primary disease, and the adequacy of the radial margins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following data suggest that selected patients with colon cancer who are at high risk for local recurrence (ie, ascending or descending colon primary, positive resection margins, or T4 disease, (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    )) might potentially benefit from adjuvant RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Uncontrolled series",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective single-institution series suggest that failure rates within the operative bed for high-risk patients after resection alone are at least 30 percent and that this risk can be reduced substantially by RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/86,88-90\">",
"     86,88-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest report, 171 patients underwent RT for high-risk completely resected colon cancer (T4 tumors, T3N+ disease at sites other than the midsigmoid, midtransverse colon and cecum, and selected patients with high-risk T3N0 disease and a &lt;1 cm radial margin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/89\">",
"     89",
"    </a>",
"    ]. Concurrent chemoradiotherapy (mostly 5-FU on days 1 to 3 during the first and last week of RT) was administered to 68 patients. The outcomes of this irradiated group were compared to a historical cohort of 395 patients of similar T- and N-stage who underwent surgery alone at the same institution.",
"   </p>",
"   <p>",
"    Local failure rates in patients treated with RT for T4N0 and T4N+ disease were 7 and 28 percent, respectively; the corresponding values for patients undergoing surgery alone were 31 and 53 percent. DFS rates for T4N0 and T4N+ tumors in the irradiated group were 79 and 53 percent, versus 63 and 38 percent, respectively, with surgery alone.",
"   </p>",
"   <p>",
"    No significant outcome differences could be shown with RT in patients with T3N0 or T3N+ disease without perforation or fistula formation. However, many of these patients were referred for RT because of concerns about adequacy of resection, raising the possibility of selection bias. Nevertheless, the authors concluded that patients with T4 tumors,",
"    <span class=\"nowrap\">",
"     perforation/abscess",
"    </span>",
"    formation, a fistula at the tumor site, or positive resection margins all benefited from postoperative RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Intergroup trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only available trial, US Intergroup (INT) 0130, randomly assigned 222 patients with adherence to or invasion of adjacent structures or T3 N1-2 tumors of the ascending or descending colon (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) to",
"    <span class=\"nowrap\">",
"     5-FU/levamisole",
"    </span>",
"    with or without adjuvant RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/91\">",
"     91",
"    </a>",
"    ]. The trial was closed prior to the planned goal of 700 patients because of poor accrual.",
"   </p>",
"   <p>",
"    There was no significant difference in five-year overall survival (62 versus 58 percent for chemotherapy versus chemoradiotherapy) between the two groups. There were 18 local recurrences in each arm. Because of the limited statistical power, no definitive conclusions can be drawn regarding the efficacy of postoperative RT from this trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant RT in patients with resected colon cancer remains poorly defined. Nevertheless, current treatment recommendations suggest that adjuvant RT be offered to the following subgroups of patients who have an estimated risk of local recurrence that is 30 percent or higher: ascending or descending colon primary with T4 disease or a positive resection margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/86,92\">",
"     86,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY: DIET, EXERCISE, AND NSAIDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Diet and exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data suggest that dietary factors may influence outcomes in some patients with colorectal cancer. However, whether weight reduction or changes in diet would improve outcomes after treatment for colon cancer is not known. In addition, higher levels of physical activity may reduce the risk of colorectal cancer-specific and overall mortality, in addition to having a beneficial impact on fatigue, quality of life, and functional status. The roles of diet, physical activity, and body weight in cancer survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Aspirin and other NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous observational studies and randomized trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    against the development of colorectal adenomas and cancer through its actions as an inhibitor of the cyclooxygenase 2 (COX-2) pathway. This pathway is overexpressed in 80 to 85 percent of CRCs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies suggest that use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs may also improve survival among patients receiving treatment for early colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/93-97\">",
"     93-97",
"    </a>",
"    ]. As an example, in a report of patients with CRC who were participating in the Nurses' Health Study and the Health Professionals Follow-up Study, aspirin users had a significant 29 percent lower cancer-specific mortality and a 21 percent lower overall mortality than nonusers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/94\">",
"     94",
"    </a>",
"    ]. The reduction in mortality was even greater among patients who initiated aspirin use after cancer diagnosis than among patients who used it before, and benefit was limited to those whose tumors overexpressed COX-2. Benefits were similar in patients who received standard adjuvant chemotherapy and those who did not, and in patients with stage I, II and III disease at diagnosis.",
"   </p>",
"   <p>",
"    These data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may influence the biology of established colorectal cancers after potentially curative resection. However, these are observational data, and prospective confirmation of the benefit of aspirin in a randomized trial is needed before routine use of aspirin can be routinely recommended, given the potential for harm (eg, gastrointestinal bleeding). Furthermore, it is not clear that all patients benefit. In a study of 964 patients with colorectal cancer from the Nurses' Health Study and the Health Professionals Follow-up Study, post-cancer aspirin use in patients whose tumors harbored mutations in the PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide) gene (17 percent of the total) was associated with marked reduction in colorectal cancer specific death (HR 0.18, 95% CI 0.31-0.94) whereas in patients whose cancer was wild-type for PIK3CA, the HR colorectal cancer death was not influenced by aspirin use (HR 0.96, 0.69-1.32) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/98\">",
"     98",
"    </a>",
"    ]. Given that these data are observational and derived from subset analysis, it is premature to consider testing individual patients for mutations in the",
"    <em>",
"     PIK3CA",
"    </em>",
"    gene in order to make decisions about post-cancer aspirin use.",
"   </p>",
"   <p>",
"    A single placebo-controlled randomized trial of rofecoxib, a selective COX-2 inhibitor, in patients with resected stage II or III colon cancer failed to demonstrate a significant survival benefit for rofecoxib, but the trial was aborted early when rofecoxib was withdrawn from the market because of cardiovascular issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/99\">",
"     99",
"    </a>",
"    ]. Only 2327 of the planned 7000 patients were enrolled, and the median exposure time to the drug was only 7.4 months; just one-third of participants received the drug for at least one year. Thus, this trial cannot be interpreted as demonstrating a lack of benefit from NSAIDs. &nbsp;",
"   </p>",
"   <p>",
"    A US cooperative group placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , another selective COX-2 inhibitor, is open for patients with resected stage III colon cancer in the US; patients are randomly assigned to 3 versus 6 months of FOLFOX chemotherapy, with a second random assignment to celecoxib 200 mg twice daily or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/100\">",
"     100",
"    </a>",
"    ]. Several trials are also underway in Europe to address the optimal duration of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2948592\">",
"    <span class=\"h1\">",
"     ISSUES FOR SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for posttreatment cancer surveillance and issues for long-term survivors of colon cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=see_link\">",
"     \"Approach to the long-term survivor of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have undergone potentially curative resection of colon cancer, the goal of postoperative (adjuvant) therapy is to eradicate micrometastases, thereby reducing the likelihood of disease recurrence and increasing the cure rate. The benefits of adjuvant chemotherapy have been most clearly demonstrated in stage III (node-positive) disease (an approximately 30 percent reduction in the risk of disease recurrence and a 22 to 32 percent reduction in mortality), whereas benefit in stage II disease remains controversial. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend adjuvant systemic therapy after resection of stage III colon cancer (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If possible, chemotherapy should be initiated within six to eight weeks of surgery. (See",
"      <a class=\"local\" href=\"#H405297564\">",
"       'Timing of adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a six month course of an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen rather than bolus 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      <span class=\"nowrap\">",
"       (5-FU/LV)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      for patients who are likely to tolerate oxaliplatin (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Oxaliplatin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      When an oxaliplatin regimen is chosen, we prefer FOLFOX (oxaliplatin plus leucovorin (LV) and short-term infusional 5-FU). While FOLFOX4 was used in the adjuvant registration trials, many American oncologists use modified FOLFOX6 (mFOLFOX6) because it does not require the day 2 bolus of 5-FU and LV (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 4",
"      </a>",
"      ). Modified FOLFOX7 (mFOLFOX7, (",
"      <a class=\"graphic graphic_table graphicRef55829 \" href=\"mobipreview.htm?10/19/10558\">",
"       table 5",
"      </a>",
"      )), which eliminates bolus 5-FU completely, is significantly less myelosuppressive.",
"      <br/>",
"      <br/>",
"      Oxaliplatin plus oral capecitabine (XELOX, (",
"      <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"       table 6",
"      </a>",
"      )) is an acceptable, albeit potentially more toxic alternative to FOLFOX. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Capecitabine plus oxaliplatin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a contraindication to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (eg, preexisting neuropathy),",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      is an acceptable option, although outcomes may not be as favorable. Our preferred regimens are six to eight months of weekly bolus 5-FU plus high dose LV (each 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      weekly for six of each eight weeks for four cycles (the Roswell Park regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/44/34506/abstract/43\">",
"       43",
"      </a>",
"      ]), or short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Summary and choice of regimen'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An alternative is six months of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      or, outside of the US, oral UFT. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Oral fluoropyrimidines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), or an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) in the adjuvant setting. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Bevacizumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Cetuximab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Irinotecan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evidence is inconclusive as to the benefit of adding RT to chemotherapy for patients at high risk for a local recurrence. In keeping with guidelines from the NCCN, we suggest adjuvant RT for patients with T4 tumors and penetration to a fixed structure or positive resection margins (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Adjuvant RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the mounting evidence that diet and exercise can modify prognosis, patients should be encouraged to maintain a healthy weight and exercise regularly. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Diet and exercise'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      It is premature to routinely recommend the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or another NSAID to improve outcomes after a potentially curative resection of colon cancer; the data suggesting a survival benefit are still limited, and the competing risk benefit ratio is different than with diet and exercise. Although the evidence is intriguing, it is also premature to consider testing individual patients for mutations in the",
"      <em>",
"       PIK3CA",
"      </em>",
"      gene in order to make decisions about post-cancer aspirin use. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Aspirin and other NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, Greene FL, Page DL, Fleming ID, et al (Eds), Springer, New York 2002. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/3\">",
"      O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge, SB, Byrd, DR, Compton, CC, et al (Eds) (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/5\">",
"      Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988; 259:3571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/6\">",
"      Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/7\">",
"      Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/8\">",
"      Grem JL, Allegra CJ. Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst 1989; 81:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/9\">",
"      Smith RE, Colangelo L, Wieand HS, et al. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004; 96:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/10\">",
"      Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/11\">",
"      Porschen R, Bermann A, L&ouml;ffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001; 19:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/12\">",
"      Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/13\">",
"      Kimmel DW, Wijdicks EF, Rodriguez M. Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology 1995; 45:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/14\">",
"      Chen TC, Hinton DR, Leichman L, et al. Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report. Neurosurgery 1994; 35:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/15\">",
"      Savarese DM, Gordon J, Smith TW, et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. Cancer 1996; 77:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/16\">",
"      Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/17\">",
"      Punt CJ, Buyse M, K&ouml;hne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007; 99:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/18\">",
"      Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25:4569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/19\">",
"      de Gramont A, Hubbard J, Shi Q, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 2010; 28:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/20\">",
"      Sargent D, Shi Q, Yothers G, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011; 47:990.",
"     </a>",
"    </li>",
"    <li>",
"     Sargent DJ, Yothers G, Van Cutsem E, et al. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients frin MOSAIC, X-ACT, PETACC-3, NSABP C06 and C-07, and C89803 (abstract #4011). J Clin Oncol 2009; 27:170s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/22\">",
"      Bayraktar S, Bayraktar UD, Rocha-Lima CM. Timing of adjuvant and neoadjuvant therapy in colorectal cancers. Clin Colorectal Cancer 2010; 9:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/23\">",
"      Gibbs P, Handolias D, McLaughlin S, et al. Single-institution experience of adjuvant 5-fluorouracil-based chemotherapy for stage III colon cancer. Intern Med J 2008; 38:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/24\">",
"      Hendren S, Birkmeyer JD, Yin H, et al. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum 2010; 53:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/25\">",
"      Lima IS, Yasui Y, Scarfe A, Winget M. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer 2011; 117:3833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/26\">",
"      Dahl O, Fluge &Oslash;, Carlsen E, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 2009; 48:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/27\">",
"      Czaykowski PM, Gill S, Kennecke HF, et al. Adjuvant chemotherapy for stage III colon cancer: does timing matter? Dis Colon Rectum 2011; 54:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/28\">",
"      Bayraktar UD, Chen E, Bayraktar S, et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/29\">",
"      Ahmed S, Ahmad I, Zhu T, et al. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum 2010; 53:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/30\">",
"      Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/31\">",
"      Andr&eacute; T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25:3732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/32\">",
"      Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/33\">",
"      Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010; 46:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/34\">",
"      Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011; 305:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/35\">",
"      Chambers P, Daniels SH, Thompson LC, Stephens RJ. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012; 23:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/36\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/37\">",
"      Zaniboni A, Labianca R, Marsoni S, et al. GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer 1998; 82:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/38\">",
"      Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/39\">",
"      Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/40\">",
"      O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/41\">",
"      O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/42\">",
"      Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/43\">",
"      Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23:8671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/44\">",
"      Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000; 355:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/45\">",
"      Dencausse Y, Hartung G, Sturm J, et al. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie 2002; 25:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/46\">",
"      Des Guetz G, Uzzan B, Morere JF, et al. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev 2010; :CD007046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/47\">",
"      Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23:1819.",
"     </a>",
"    </li>",
"    <li>",
"     Carrato A, Kohne C, Bedenne L, et al. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study (abstract). J Clin Oncol 2006; 24:161s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/49\">",
"      Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/50\">",
"      Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/51\">",
"      Sakamoto J, Ohashi Y, Hamada C, et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/52\">",
"      Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/53\">",
"      Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/54\">",
"      Hennig IM, Naik JD, Brown S, et al. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. J Clin Oncol 2008; 26:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/55\">",
"      Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/56\">",
"      Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008; 6 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/57\">",
"      Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/58\">",
"      Andr&eacute; T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/59\">",
"      Andr&eacute; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/60\">",
"      Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/61\">",
"      Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/62\">",
"      Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/63\">",
"      Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29:1465.",
"     </a>",
"    </li>",
"    <li>",
"     Schmoll HJ, Tabernero J, Maroun JA, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III  colon cancer: Survival follow-up of study NO16968 (XELOXA) (abstract). J Clin oncol 2012; 30 (suppl 4): abstract 388. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=88795 (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/65\">",
"      Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/66\">",
"      Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/67\">",
"      Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/68\">",
"      Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/69\">",
"      Allegra CJ, Yothers G, O'Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013; 31:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/70\">",
"      Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27:3385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/71\">",
"      de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/72\">",
"      Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307:1383.",
"     </a>",
"    </li>",
"    <li>",
"     Taieb J, Tabernero J, Mini E, et al. Adjuvant FOLFOX4 with or without cetuximab in patients with resected stage III coloncacancer: DFS and OS results and subgroup analysis of the PETACC8 Intergroup Phase III Trial (abstrat). Data presented at the 2012 ESMO Congress, Vienna, Austria, September 30, 2012. Abstract available online at file://abstracts.webges.com/myitinerary/title.html (Accessed on December 06, 2012).",
"    </li>",
"    <li>",
"     Adjuvant! Online program for colon cancer available online at www.adjuvantonline.com (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     Numeracy web-based model for colon cancer available online at www.mayoclinic.com/calcs (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/76\">",
"      Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/77\">",
"      Gill S, Loprinzi C, Kennecke H, et al. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer 2011; 117:4155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/78\">",
"      Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012; 104:1635.",
"     </a>",
"    </li>",
"    <li>",
"     O'Connell M, Lee M, Lopatin M, et al. et al. Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in statge II and III colon cancer patients treated with 5FU/LV (FU) +  5FU/LV oxaliplatin (abstract 3512). J Clin Oncol 30, 20121 (suppl; abstr 3512). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=99494 (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/80\">",
"      Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. J Natl Cancer Inst 1997; 89:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/81\">",
"      Sadahiro S, Suzuki T, Ishikawa K, et al. Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial. Cancer 2004; 100:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/82\">",
"      Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/83\">",
"      James RD, Donaldson D, Gray R, et al. Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). Br J Surg 2003; 90:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/84\">",
"      Labianca R, Fossati R, Zaniboni A, et al. Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst 2004; 96:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/85\">",
"      Mendenhall WM, Amos EH, Rout WR, et al. Adjuvant postoperative radiotherapy for colon carcinoma. Cancer 2004; 101:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/86\">",
"      Czito BG, Bendell J, Willett CG. Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era? Oncology (Williston Park) 2006; 20:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/87\">",
"      Gunderson LL, Sosin H, Levitt S. Extrapelvic colon--areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1985; 11:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/88\">",
"      Willett CG, Goldberg S, Shellito PC, et al. Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? Cancer J Sci Am 1999; 5:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/89\">",
"      Willett CG, Fung CY, Kaufman DS, et al. Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol 1993; 11:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/90\">",
"      Amos EH, Mendenhall WM, McCarty PJ, et al. Postoperative radiotherapy for locally advanced colon cancer. Ann Surg Oncol 1996; 3:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/91\">",
"      Martenson JA Jr, Willett CG, Sargent DJ, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol 2004; 22:3277.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/93\">",
"      Fuchs CS, Meyerhardt JA, Heseltine DS, et al. Infulence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. (abstract #3530). J Clin Oncol 2005; 23:253s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/94\">",
"      Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/95\">",
"      Zell JA, Ziogas A, Bernstein L, et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009; 115:5662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/96\">",
"      Coghill AE, Newcomb PA, Campbell PT, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011; 60:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/97\">",
"      Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012; 106:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/98\">",
"      Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/44/34506/abstract/99\">",
"      Midgley RS, McConkey CC, Johnstone EC, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 2010; 28:4575.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01150045?term=celecoxib&amp;cond=colon+cancer&amp;lead_ex=Y&amp;rank=3.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2471 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34506=[""].join("\n");
var outline_f33_44_34506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENDPOINTS TO DEFINE BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H405297564\">",
"      TIMING OF ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22984319\">",
"      CHEMOTHERAPY DOSING IN OBESE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      5-FU-BASED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bolus 5-FU plus LV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dose of LV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infusional versus bolus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Short-term infusional 5-FU/LV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - UFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Summary and choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OXALIPLATIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MOSAIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NSABP C-07 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Capecitabine plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IRINOTECAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BEVACIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CETUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97815843\">",
"      TOOLS TO AID IN DECISION MAKING FOR ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16290235\">",
"      Web-based tools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97816023\">",
"      Molecular markers and genomic profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      REGIONAL LIVER-DIRECTED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      ADJUVANT RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Uncontrolled series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Intergroup trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      ADJUNCTIVE THERAPY: DIET, EXERCISE, AND NSAIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Diet and exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Aspirin and other NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2948592\">",
"      ISSUES FOR SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2471|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/54/41824\" title=\"figure 1\">",
"      SEER surv adeno colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/42/30379\" title=\"table 2\">",
"      Adjuv Rx colon CA INT0089",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/17/37149\" title=\"table 3\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 4\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10558\" title=\"table 5\">",
"      Modified FOLFOX7 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/60/14286\" title=\"table 6\">",
"      XELOX regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/2/19502\" title=\"table 7\">",
"      FOLFIRI regimen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=related_link\">",
"      Adjuvant therapy for resected colon cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=related_link\">",
"      Approach to the long-term survivor of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_44_34507="Stages of hepatic encephalopathy in young children";
var content_f33_44_34507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stages of hepatic encephalopathy in infants and children from birth to 48 months of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reflexes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neurological signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No encephalopathy",
"        <br/>",
"        (stage 0)",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early",
"        <br/>",
"        (stage I and II)",
"       </td>",
"       <td>",
"        Inconsolable crying, sleep reversal, inattention to task, child is not acting like self to parents",
"       </td>",
"       <td>",
"        Unreliable/ normal or hyperreflexic",
"       </td>",
"       <td>",
"        Untestable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mid",
"        <br/>",
"        (stage III)",
"       </td>",
"       <td>",
"        Somnolence, stupor, combativeness",
"       </td>",
"       <td>",
"        Unreliable/ hyperreflexic",
"       </td>",
"       <td>",
"        Likely untestable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late",
"        <br/>",
"        (stage IV)",
"       </td>",
"       <td>",
"        Comatose, arouses with painful stimuli (stage IVa) or no response (stage IVb)",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Decerebrate or decorticate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34507=[""].join("\n");
var outline_f33_44_34507=null;
var title_f33_44_34508="Number needed to treat";
var content_f33_44_34508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Number needed to treat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 148px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depiction of the results of two hypothetical placebo controlled trials involving 100 patients. The number needed to treat (NNT) is sensitive to the control rate (ie, the frequency that events such as death occur at baseline). The NNT decreases as the number of events (such as deaths) in the control arm (placebo arm) increases. The relative risk in these studies (the death rate in those receiving drug divided by the death rate in those receiving placebo) is equal; both demonstrate a 50 percent reduction in the risk of death in patients who received the drug. However, the number needed to treat (the reciprocal of the death rate in the placebo minus the death rate in the drug group) is different (5 versus 2.5). This difference reflects the higher death rate (ie, the control rate) in the second study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34508=[""].join("\n");
var outline_f33_44_34508=null;
var title_f33_44_34509="Abdominal gunshot management algorithm";
var content_f33_44_34509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal gunshot wound management algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; DL: diagnostic laparoscopy; DPL: diagnostic peritoneal lavage.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isenhour JL, Marx J. Advances in abdominal trauma. Emergency Clinics of North America 2007; 25:713. Copyright &copy; 2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34509=[""].join("\n");
var outline_f33_44_34509=null;
var title_f33_44_34510="Paragard IUD folding arms";
var content_f33_44_34510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paragard IUD folding arms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tips of the horizontal arms are tucked into the tube and inserted just to the point where the device is stable in the tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: FEI Women's Health. Copyright &copy;FEI Women's Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34510=[""].join("\n");
var outline_f33_44_34510=null;
var title_f33_44_34511="Nonsusceptibility invasive pneumococcal isolates children";
var content_f33_44_34511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Rates of antibiotic nonsusceptible pneumococcal disease among children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NS: nonsusceptible.",
"     <br>",
"      * The old/oral meningitis penicillin breakpoints classify isolates as penicillin nonsusceptible at a MIC &ge;0.12 mcg/mL.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Not susceptible to 3 or more of the antibiotic classes tested.",
"       <br>",
"        &Delta; The new parenteral penicillin breakpoints classify isolates as penicillin nonsusceptible at an MIC &ge;4 mcg/mL for nonmeningitis disease and &ge;0.12 mcg/mL for meningitis.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_44_34511=[""].join("\n");
var outline_f33_44_34511=null;
